Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Spring 5-15-2020

Transcription Factor-Mediated Epigenetic Regulation in the
Healthy Brain and Neurological Disease
Alexander J. Cammack
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Genetics Commons, and the Neuroscience and Neurobiology Commons

Recommended Citation
Cammack, Alexander J., "Transcription Factor-Mediated Epigenetic Regulation in the Healthy Brain and
Neurological Disease" (2020). Arts & Sciences Electronic Theses and Dissertations. 2170.
https://openscholarship.wustl.edu/art_sci_etds/2170

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Neurosciences

Dissertation Examination Committee:
Timothy M. Miller, Chairperson
Joseph D. Dougherty
Harrison W. Gabel
Robi D. Mitra
Erik S. Musiek
Conrad C. Weihl

Transcription Factor-Mediated Epigenetic Regulation
in the Healthy Brain and Neurological Disease
by
Alexander James Cammack

A dissertation presented to
The Graduate School
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2020
St. Louis, Missouri

© 2020, Alexander Cammack

Table of Contents
List of Figures ................................................................................................................................ iv
List of Tables .................................................................................................................................. v
Acknowledgements ........................................................................................................................ vi
Abstract of the Dissertation ......................................................................................................... xiii
CHAPTER 1 ................................................................................................................................... 1
Transcription factors and enhancers ........................................................................................... 2
Epilepsy and acute seizure: an epigenetics perspective .............................................................. 8
Epigenetic contributions to amyotrophic lateral sclerosis ........................................................ 11
Summary of the dissertation ..................................................................................................... 18
Bibliography ............................................................................................................................. 22
CHAPTER 2 ................................................................................................................................. 38
Preface....................................................................................................................................... 39
Abstract ..................................................................................................................................... 40
Introduction ............................................................................................................................... 41
Methods..................................................................................................................................... 45
Results ....................................................................................................................................... 60
Discussion ................................................................................................................................. 82
Acknowledgments..................................................................................................................... 86
Author contributions ................................................................................................................. 87
Declaration of interests ............................................................................................................. 87
Bibliography ............................................................................................................................. 88
Supplemental figures ................................................................................................................ 97
CHAPTER 3 ............................................................................................................................... 108
Preface..................................................................................................................................... 109
Abstract ................................................................................................................................... 110
Introduction ............................................................................................................................. 111
Methods................................................................................................................................... 113
Results ..................................................................................................................................... 117
Discussion ............................................................................................................................... 122
Acknowledgements ................................................................................................................. 124
Author contributions ............................................................................................................... 124

ii

Bibliography ........................................................................................................................... 125
CHAPTER 4 ............................................................................................................................... 130
Preface..................................................................................................................................... 131
Abstract ................................................................................................................................... 132
Introduction ............................................................................................................................. 133
Methods................................................................................................................................... 137
Results ..................................................................................................................................... 145
Discussion ............................................................................................................................... 155
Acknowledgements ................................................................................................................. 158
Author contributions ............................................................................................................... 158
Bibliography ........................................................................................................................... 159
CHAPTER 5 ............................................................................................................................... 165
Preface..................................................................................................................................... 166
Abstract ................................................................................................................................... 167
Introduction ............................................................................................................................. 169
Methods................................................................................................................................... 171
Results ..................................................................................................................................... 178
Discussion ............................................................................................................................... 187
Acknowledgements ................................................................................................................. 192
Author contributions ............................................................................................................... 193
Declaration of interests ........................................................................................................... 194
Bibliography ........................................................................................................................... 195
CHAPTER 6 ............................................................................................................................... 203
Summary of the dissertation ................................................................................................... 204
Advances, limitations, and future directions........................................................................... 206
Impact, innovation, and final thoughts ................................................................................... 220
Bibliography ........................................................................................................................... 221
Curriculum Vitae ........................................................................................................................ 230

iii

List of Figures
Chapter 2
Main figures
Figure 2.1 Co-AAV9 intracranial injection efficiently delivers calling cards to the cortex ................... 63
Figure 2.2 Unfused hypPB-directed calling cards insertions identify active enhancers and super
enhancers in the brain ...................................................................................................................... 67
Figure 2.3 FLEX calling cards system generates cell type-specific RE profiles ................................... 72
Figure 2.4 Fusion of SP1 to hypPB in FLEX calling cards system records SP1 occupancy .................. 74
Figure 2.5 Longitudinal SP1 profiling reports integrated record of SP1 binding .................................. 78
Figure 2.6 AAV::hypPB Frontflip reduces Cre-independent transposition in vitro and in vivo ............. 81
Supplemental figures
Figure 2.1S AAV9 intracranial injection induces hypPB expression in the cortex ............................... 97
Figure 2.2S Comparison of neonatal and adult AAV delivery of traditional DNA calling card and SRT
calling card systems ......................................................................................................................... 99
Figure 2.3S AAV SRT calling cards system does not induce excess degeneration or
behavioral/developmental deficits ................................................................................................... 100
Figure 2.4S In vitro and in vivo sensitivity of unfused hypPB calling card libraries for active REs ..... 101
Figure 2.5S Supplemental to: FLEX calling cards system generates cell type-specific RE profiles ..... 103
Figure 2.6S Functional validation of enhancer activity at P7 for GFAP::Cre enriched unfused hypPB
peaks ............................................................................................................................................ 104
Figure 2.7S Candidate astrocyte enhancers identified with FLEX calling cards direct cell type-specific
expression in astrocytes by P21 ...................................................................................................... 106
Figure 2.8S Gating procedure for flow cytometry in cells with BrokenHeart-derived TdTomato
fluorescence .................................................................................................................................. 107
Chapter 3
Figure 3.1 Seizure severity does not correlate with mouse sex, genotype, or weight .......................... 118
Figure 3.2 Retrospective analysis of longitudinally-recorded BRD4 occupancy identifies vulnerability
and resiliency loci that are predictive of seizure outcome ................................................................. 121
Chapter 4
Figure 4.1 Differentially expressed miRNAs in cervical spinal cord of C9orf72 transgenic mice ....... 146
Figure 4.2 BRD4-bound enhancer profiling in C9orf72 transgenic mice........................................... 148
Figure 4.3 H3K27ac ChIP-seq in postmortem C9ALS, sALS, and Con lumbar spinal cord ............... 150
Figure 4.4 ALS risk-associated genetic variants fall in active spinal cord enhancers.......................... 154
Chapter 5
Figure 5.1 C9ALS natural history: descriptive characteristics ......................................................... 180
Figure 5.2 C9ALS natural history: measures of disease progression ................................................. 182
Figure 5.3 Relationship of G4C2 repeat size and age........................................................................ 183
Figure 5.4 poly(GP) in C9ALS CSF and size in autopsy tissue ........................................................ 186

iv

List of Tables
Chapter 4
Table 4.1 List of epigenomic profiling assays used in C9ALS mice and humans ..................... 136
Table 4.2 Clinical and demographic information about C9ALS, sALS, and Con patient tissues
used in this study ......................................................................................................................... 144
Chapter 5
Table 5.1 Clinical and demographic information about prospective C9ALS cohort ................. 179

v

Acknowledgements
There are many people that deserve as much credit for this PhD as I. These are the people
that kept me grounded during the good times and supported me during the bad. I couldn’t have
made it here without them.
I’ll start with the ones who were my motivation for coming to graduate school to study
neurodegeneration in the first place: my grandparents. On my dad’s side, this includes Maggie
and Eugene Cammack (Grandmaggie and Granddad), and on my mom’s, Helen and Bill Orchid
(Mamaw and Papaw). Grandmaggie died when I was only 8 years old, yet I still have fond
memories of playing Scrabble and watching Wheel of Fortune with her. She was a bedrock for
our family. Granddad lived until 2014, though his last few years were beset with Alzheimer’s
disease. His Alzheimer’s symptoms began to appear near the time I was beginning college, so
while my family witnessed gradual declines in his memory, I saw noticeable, more drastic
changes when I would visit home over breaks and holidays. I always felt bad that I couldn’t be
there more often to support my family. So, when it came time to choose my next career steps, it
felt right to enter a neuroscience program and try to fight the disease for generations to come. By
this time, however, it was not only my paternal grandfather that was affected by dementia;
Papaw had it too. Papaw and Mamaw were married for 66 years before he died in 2018. When I
was born, I became a major focus of Papaw’s and Mamaw’s lives and continued to visit them
often throughout my middle and high school years. Seeing Papaw reach the end stages of his life
was really difficult for me and was compounded by my living far away from home. This further
cemented my intent to study neurodegenerative disease. Finally, I would be remiss if I failed to
mention Naomi Cammack, who married Granddad after Grandmaggie passed and really filled
the role of “grandmother” to me throughout my teenage years. Naomi passed away in 2018.

vi

In all of the places I have lived, I’ve been fortunate to have amazing friends that have
supported me and accompanied me through the best experiences of my life. My first “best
friend” that I can remember was Kenji Thompson, my neighbor on Barryknoll Lane from 1st
through 5th grades in Port Arthur, Texas. He taught me what friendship was like. My high school
buddies, Eric, Adrian, and Chad, we’ve stuck together through it all. I miss our high school days.
Playing in the band, hanging out at each other’s houses, playing Call of Duty and drinking
Mountain Dew until 5:00am, and maybe or maybe not partaking in some illicit activities
involving toilet paper...those were some good times! Even though we’ve split apart to follow our
own careers, we stay in close contact and visit each other often, for which I’m truly grateful. I
am also thankful for my friends at Wesley United Methodist Church in Nederland, Texas, where
I spent many of my formative years and thoroughly enjoyed playing in praise bands.
In college in New Orleans, I picked up another awesome set of lifelong friends - too
many to name individually (but I’ll try anyway, because this is my dissertation damn it, and
there’s no page limit to the acknowledgements section). I’d like to especially thank my TUMB
friends, Eleanor, Laura, Ari, Griff, Rachel, Ian, Zak, Olivia, Mendel, Mark, Barry, Ray, Pete,
Kyle, Brendan, Catherine, Martin, Richard, Matt VH, all of Green Wave Brass Band/Funky
Pelican Pleasure Club, and of course, the TUMB trombone section, Liz, JT, and Kate. Special
shout out to my beat bud Amy. And last but certainly not least, my best friend and lifetime
member of the TUMB, Chris “Cooch” Cuccio, who’s been by my side since day 1 and continues
to be to this day. While I miss our days of late-night Rally’s fries and South Park episodes, it’s
been even more fun to be your friend as we’ve grown older. I’m grateful that we are able to visit
each other at least a few times each year and look forward to continuing that tradition in the
future! Plus, who would have thought Lu’s best friend would be a scraggly, old, ugly-but-cute

vii

Elmo dog. Turns out, they are perfect for each other. Oh, and I guess there’s one other TUMB
member worth mentioning. But I’ll get to her later.
In my 6 years here in St. Louis, I’ve only further expanded this friend network. Of
course, I have to start with my first friend here, my roommate of 3 years, and one of my best
friends to this day, Ben Seitzman. It was so fortunate to find you during our interviews and
revisits and set up what turned out to be a great roommate situation. I always appreciated you
bringing me into your friend group with Adam and crew early on and making me feel at home in
this new city. And of course, Lu will always appreciate the playtime she was able to have with
lil’ Purrkinje. You’re destined for great things, and I’ll be proud to be watching when you
achieve them. Next, special shout outs to Jonathan and Steph. Jonathan, when we met for the
first time at Neuro retreat in 2014, I knew we’d be great friends. I was proven right when we
became first baggage buddies in SLUA leagues and eventually best friends beyond that. And
Steph, you’ve been awesome to hang out with too since we met and found out we lived in the
same apartment complex. So many great memories (and some memories that only exist because
pictures were taken to document them…coughcoughMardiGrascoughcough…). Wishing you
both the best in your next adventure in Boston. Krissy and Andrew, and of course, Zooey
“Beans” Hays, it was so fun hanging out with you two when you were still in St. Louis, and we
are really glad we were able to visit you in Raleigh-Durham last year! We can’t wait to make it
back out there for another visit soon (and finally meet Ramsey!). My cohort here in the Neuro
program has also been a huge support group for me, especially in the first couple of years Brian, Tom, Ben, Kael, and Katherine especially, thanks for your friendship through the years.
Kael and Manda, both of you have become best friends of mine and Melissa’s. I’m so glad we
were able to live down the street from you in the Grove. So many Harry Potter parties, U.R.B.

viii

tastings, O’Shay’s trivia nights, Handlebar evenings, cigars around the fire, hiking trips, and just
general awesome hang out sessions. I know Melissa and I both really appreciate your friendships
and the times we’ve had together. Speaking of trivia, how about that Dw/oB team though?! Ted,
Tirth, Ben, Kathleen, Andrew, Anna, Nicole, Jonathan, Steph, Kael, Manda, and the rest of you
champions, I salute you. But actually, weekly trivia with you all has been one of my longest
standing and most fun hobbies in St. Louis. Thanks for keeping me sane. Lastly, I want to thank
the entire Ultimate community in St. Louis. I’ve made a ton of friends playing frisbee, both in
leagues, and of course, through p’ArchD. I really feel like I was able to be a part of this tight knit
community while I was here, and I’ll miss playing with you all every day. Special shout outs to
Jonathan Lin, Jeff “BagelShoe” Hanson, Mitch Lindsey, Ciara Murphy, and Alex Holehouse,
with whom I’ve been fortunate to play on many teams and whose company I have truly enjoyed.
And finally, to end my friend acknowledgements, I’ll thank my labmates-turned-bestfriends from the Miller lab. Mariah, you were my rotation mentor and are probably the biggest
scientific influence in my life thus far. You’re one of the smartest people I know, and everyone
knows you’re going to be a famous P.I. one day. Even more frustrating is how freaking nice and
loving you are to your friends and family. And to top it off, you also have the world’s nicest,
funniest guy as a husband. Like geez dude, leave some good qualities for the rest of us! I’m
kidding of course

. Kelly, you really are probably the singular funniest person I’ve ever met

and such a genuine, caring human being. Mariah is lucky to have you, and Melissa and I are
fortunate to call you both our friends. Next up: Wade! Oh Wade, oh Wade. Where to start? Wade
was my Neuro program “buddy” that led me around to my interviews as a little prospective
graduate student. And I say little, because relative to Wade, I am quite small. I mean this both
literally (Wade was a linebacker in college) and figuratively (Wade has probably the biggest

ix

personality of anyone I know). I never would have thought he would end up as one of my best
friends, but alas, life presents itself in mysterious ways! Wade, you’ve always been a great
backboard off which to bounce ideas and have always been supportive of me and given me
advice, both in life and in science, when I’ve needed it. Melissa and I love getting to see you and
Zoe every chance we can. Finally, Kathleen and Andrew. Andrew, our time together has been a
blast. Thank you for teaching me your brewing and distilling ways, oh great master of ethanol.
Your smoked meats are tasty, and your friendship, even tastier. Or something like that. And then
there’s Kathleen. Your upward mobility in friendship rankings is astounding; from
administrative to executive friend in just a few short years!

You know you’re my best friend

in the world. There’s no way I could possibly recap what you mean to me in this section, so I’m
not going to try. I think you know anyway. You and Andrew have been integral in mine and
Melissa’s lives. I don’t think we would have made it through this journey without you. We will
miss you both so much when we move on.
Additionally, I’d like to thank all of those at Tulane, LSU, and Wash. U. that have
mentored me scientifically. Firstly, I’d like to thank Drs. Mimi Sammarco and Ed Grabczyk at
Tulane and LSU, respectively, for introducing me to science research as an undergraduate and
setting me on a path to success. I’d also like to thank my committee, Drs. Erik Musiek, Rob
Mitra, Joe Dougherty, Chris Weihl, and Harrison Gabel. Harrison, I appreciate you jumping in
last minute and providing your feedback for my defense. Erik, I really enjoyed rotating in your
lab as a first-year student and have always valued your input in committee meetings. Chris,
you’ve been a really supportive committee chair and collaborator these past few years, and I
have always appreciated your critical but fair views on my science. And Rob and Joe, both of
you have essentially been co-mentors to me. Your willingness to provide your time and energy to

x

a student that is in another lab is just an example of your selfless characters and fantastic
mentorship styles. I’ve benefitted greatly from your guidance throughout the years and will
always be grateful to both of you for your support. And finally, and most importantly, thank you
to Dr. Tim Miller, whose lab I have thoroughly enjoyed being a part, and whose scientific and
professional mentorship have shaped me as scientist. Tim, you’ve given me the freedom to
explore and the guidance to be successful. I am the researcher I am today because of your
mentorship.
I want to thank my family for being my most important support group throughout my life.
Their unconditional love and steady encouragement have allowed me to grow and become the
person I am today. First, the Myers’s, Marilyn, Gary, Jamie, and Chris. You four are like a
second family to me, and I think that’s been especially important while growing up as an only
child. In all of my best memories, you four are all there. Next, my mom. Mom, thank you for
raising me and supporting me throughout the years. You’ve always been there for me and made
sure I’ve had what I needed to be successful. As I’ve gotten older, our relationship has only
grown. Melissa and I will always be thankful for the fun times we’ve been able to spend every
year with you and Gary. And finally, my dad. Dad, you’re the best man I know, and I am so
thankful that you found Christina and are now truly happy again. You’ve raised me into the
person I am today, and I live my life trying to be the man you would want me to be. Everything I
know and every value I have comes from you. I am proud to be your son.
Now, some may say it’s silly to devote an entire paragraph to an animal. I agree. So I’ll
devote two. Lulu, my pup, you are seriously the best dog and best friend a guy could ask for.
You’ll never read this, but I know you know how much you mean to me.

xi

Paragraph number 2 for Lu. You are a beautiful puppy girl who has been there for me
through so much of my life. I know you won’t live forever. But I intend to cherish every single
day I have with you on this Earth. I love you pup.
Oh right, now about that other TUMB friend I mentioned earlier…okay maybe she’s
more than just a friend

. Melissa, you are my world. You’re the one that gets me through each

day. These past 6 years together have been the best 6 years of my life, and it’s all thanks to you.
Every memory we have made and continue to make together is a blessing. Thank you for
uprooting your life and coming to St. Louis to be with me. It’s not a sacrifice I will ever take for
granted. I am beyond excited to continue our journey together and experience life with you in the
future. I love you.
My time as a graduate student has now come full circle. I arrived as a bright-eyed and
bushy-tailed 22-year-old fresh out of undergrad, made it through the 3rd and 4th year doldrums
where no experiments were working and there was no light at the end of the tunnel, and have
now come out with even more ambition to continue to push forward our knowledge of
neurodegenerative disease. I look back at this time in my life, both the struggles and the
successes, and see how this experience has shaped me as scientist and as a person. I am sure now
that science research is the right path for me. But more importantly, I also now recognize the
power of a support group. Family, friends, labmates, pets, and even the friendly bartenders that
always knew my name - you have all played enormous roles in getting me to where I am today.
And for that, I am truly thankful.
Alexander J. Cammack
Washington University
May 2020

xii

Abstract of the Dissertation

Transcription factor-mediated epigenetic regulation
in the healthy brain and neurological disease

by
Alexander James Cammack
Doctor of Philosophy in Biology & Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2020
Professor Timothy M. Miller, M.D., Ph.D., Chairperson

Proper cellular development and function is a complex process established by elaborate
gene expression networks. These networks are regulated by epigenetic processes, which alter
chromatin states and coordinate the binding of transcription factors (TFs) to regulatory elements
(REs), such as enhancers, across the genome to facilitate gene expression. It follows then that a
major experimental effort is to profile and understand the binding patterns of TFs to REs in various
cellular types and contexts. Critically however, current TF profiling techniques are limited in their
abilities to profile TF occupancy in targeted cellular populations and temporal windows, hindering
investigations into epigenetic control in complex, multicellular systems, such as the brain. This
dissertation focuses on two related areas: firstly, the design of new tools for profiling TF genome
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occupancy in the mouse brain in specific cellular populations and time periods, and secondly,
investigating TF-mediated mechanisms of disease pathogenesis in animal models.
In Chapter 2, we describe the development of a novel, viral-mediated method, termed
adeno-associated virus (AAV) calling cards, for profiling binding sites of TFs across the genome
in the live mouse brain. The AAV calling cards approach allows unique access to TF occupancy
information that is inaccessible with other existing techniques, including cell type specificity
(through Cre-mediated conditional expression) and historical binding (through longitudinal
occupancy recording).
Then, in Chapters 3 and 4, we apply this new technique to mouse models to investigate
epigenetic misregulation in disease. Previous studies have demonstrated that a large portion of
genetic variation associated with cellular dysfunction or disease exists in TF-bound enhancers,
demonstrating the criticality of proper TF binding in maintaining cellular homeostasis. However,
whether these elements are misregulated more broadly in disease contexts is unclear. In Chapter
3, we apply AAV calling cards to a model of acute seizure and uncover aberrant epigenetic
regulation which is predictive of phenotypic outcomes. Particularly important in this study is the
ability of AAV calling cards to record and integrate historical TF binding information, allowing
linkage of antecedent epigenetic events to eventual seizure outcomes. Here, we longitudinally
recorded prodromal enhancer activity to identify loci which are predictive of seizure severity.
Next, in Chapter 4, we investigate epigenetic regulation in animal models and postmortem
tissues from individuals with amyotrophic lateral sclerosis (ALS). In this study, we focus on a
subset of ALS caused by a large hexanucleotide (G4C2) repeat expansion in the gene chromosome
9 open reading frame 72 (C9orf72), which is the most common genetic cause of ALS (C9ALS).
Utilizing AAV calling cards as well as other established epigenomic profiling techniques, we
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observe broad epigenetic misregulation both in C9ALS mouse models and human tissues at the
transcriptional and translational levels. Importantly, the C9ALS mouse models used in this study
do not develop motor neuron degeneration or ALS-like phenotypes and were profiled at an early
age, suggesting that these changes occur early in the disease process and are likely driven by
C9orf72-related pathologic species, such as dipeptide repeat proteins (DPRs).
Finally, in Chapter 5 we investigate the characteristic properties of C9orf72-specfic
pathologies, including DPRs, in human C9ALS. We probed size and abundance of DNA
expansions and DPRs in blood, cerebrospinal fluid, and postmortem tissues from C9ALS and
sporadic ALS (sALS) individuals and identified novel correlations of C9ALS patient pathologies
with clinical and demographic data. Moving forward, these data will facilitate mechanistic studies
and clinical trials aimed at reducing or altering C9ALS pathologies in the central nervous system
(CNS).
In summary, the body of work detailed here extends our knowledge of TFs in both the
healthy and diseased central nervous system (CNS), providing new insights into the role of
epigenetic regulation in disease pathogenesis. Further, the establishment of AAV calling cards as
a widely applicable epigenomic tool will empower innovative new studies in a variety of tissue
and model systems.
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CHAPTER 1

Introduction into epigenetics in the brain in health and disease

1

Transcription factors and enhancers
Transcription factors in the control of gene expression
The “central dogma of molecular biology,” first posited by Francis Crick over half a
century ago (Crick 1958, 1970), states that genetic information flows from the master template of
the cell, DNA; to a temporary, versatile copy, RNA; to the final workhorse, protein. While this
general concept continues to be a guiding principle in the fields of genetics, genomics, and
molecular biology, it is now clear that this process involves complex regulatory mechanisms by
which a cell determines which genes to express and not express, many of which act at the DNA
to RNA step (Chen et al. 2017). Indeed, of the estimated 20,000-25,000 protein coding genes in
the human genome (The ENCODE Project Consortium 2004), the average human cell expresses
only a 10,000-20,000 gene subset as RNA (Alberts, Johnson, and Lewis 2002), leading to the
vast cellular diversity that creates a complex organism. Collectively, we term these regulatory
processes “epigenetics,” and the genome-wide study of such mechanisms “epigenomics.”
Epigenetic mechanisms are multifaceted and include, but are likely not limited to: posttranslational modifications of the histone octamer, a set of proteins around which DNA is
wrapped and compacted; chemical changes to the DNA itself, namely methylation of CpG
dinucleotides; higher order changes to chromatin architecture, resulting in inter- and
intrachromosomal DNA–DNA interactions; and regulation of DNA or messenger RNAs
(mRNAs) by non-coding RNAs such as long noncoding RNAs (lncRNAs) or micro RNAs
(miRNAs) (Allis and Jenuwein 2016; Chen et al. 2017). Regardless of the mechanism, the
majority of these processes ultimately result in local changes to the structure of chromatin, which
in turn allows selective accessibility of transcription machinery such as transcription factors
(TFs) to DNA-based regulatory elements (REs) (Guertin and Lis 2010; John et al. 2011; Liu et
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al. 2006; Neph et al. 2012; Spitz and Furlong 2012). It is this critical step of TFs binding to REs
that ultimately determines the gene expression networks that will dictate the development,
function, and identity of a cell. Similarly, it is thought that altered TF-RE binding may disrupt
cellular function and may contribute to the pathogeneses of human diseases (Corradin and
Scacheri 2014; Ernst et al. 2011; Hnisz et al. 2013; Maurano et al. 2012).
TFs bind to a variety of types of REs, including gene promoters as well as cis-acting
elements in the non-coding space of the genome such as silencers, insulators, and enhancers
(Spitz and Furlong 2012). Of these, enhancers play a leading role in transcription initiation and
thus continue to be a major focus of epigenomic study. Enhancers are regions of non-coding
genomic space which harbor short (6-12 base pairs (bp) (Spitz and Furlong 2012)) canonical TF
binding motifs and thus act as platforms for TF occupancy. These elements are typically short in
length (50-1500 bp) (Blackwood and Kadonaga 1998; Ernst et al. 2011)), though more recently a
small population of large enhancers, termed super enhancers, has been identified and
characterized (Whyte et al. 2013). Super enhancers, which can reach lengths orders of magnitude
longer than typical enhancers, consist of multiple constitutive enhancers which act cooperatively
to drive high expression of a select group of critical cell identity genes (e.g. Yamanaka TFs in
embryonic stem cells (ESCs)) (Hnisz et al. 2013; Whyte et al. 2013). Accordingly, these
elements harbor a large portion of TF and co-factor occupancy. One such co-factor is the
bromodomain and extra-terminal domain (BET) protein, BRD4 (Hnisz et al. 2013), a “chromatin
reader” which binds to enhancer-associated acetylated lysine residues on histone tails (Jung et al.
2014; Kanno et al. 2004, 2014). This BRD4 binding regulates gene transcription through
recruitment of positive transcription elongation factor b (P-TEFb) to promoters of active genes in
order to promote phosphorylation of RNA polymerase II (RNAPII) (LeRoy, Rickards, and Flint
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2008; Mochizuki et al. 2008). Because BRD4 is constitutively expressed across the majority of
cell types, its occupancy is now a common and reliable proxy for super enhancer activation
(Hnisz et al. 2013).
It is estimated that there are hundreds of thousands of enhancer elements scattered
throughout the genome (Pennacchio et al. 2013), however only a small subset, on the order of
tens of thousands for typical enhancers and merely a few hundred for super enhancers
(Creyghton et al. 2010; Heintzman et al. 2009), are actively TF-bound and regulating gene
expression in any given cell. The mechanisms by which enhancer usage is governed are still
unclear and likely result from a combination of factors (Spitz and Furlong 2012), including
nucleosome density (Guertin and Lis 2010; John et al. 2011; Liu et al. 2006; Neph et al. 2012),
local sequence context (White et al. 2013; Yanez-Cuna et al. 2012), and parallel expression and
activity of co-factors and other TFs (Slattery et al. 2011). Further, despite often being located
tens or even hundreds of kilobases (kB) away, TF-bound enhancers are able to enact tight control
over expression of their associated genes. A variety of mechanisms have been proposed for this
long-range association, including chromatin looping (Amano et al. 2009; Shlyueva, Stampfel,
and Stark 2014) and, more recently, liquid-liquid phase separation (LLPS) of TFs and cofactors
(Boija et al. 2018; Hnisz et al. 2017; Sabari et al. 2018) and even chromatin itself (Gibson et al.
2019). In any case, it remains clear that the specificity with which TFs bind enhancers and
regulate gene expression is intentional and critical for the proper enactment of developmental
and homeostatic cellular programs. It follows then that a major focus of the epigenomics field is
to attempt to profile and understand the binding patterns of TFs to REs across the genome in
various cellular types and contexts.

4

Methods for genome-wide transcription factor and enhancer profiling
There exists a large and rapidly growing catalog of methods to profile TF binding and/or
RE activity across the genome, each providing unique insights into TF-mediated epigenetic
control. The most prominent and widely used method for profiling individual proteins is an
antibody-based technique called Chromatin Immunoprecipitation followed by sequencing (ChIPseq), which works by first crosslinking proteins to DNA and then isolating, sequencing, and
mapping protein-bound DNA, allowing for the genome-wide visualization of TF and/or posttranslationally modified histone occupancy. ChIP-seq, as well as its more recent successors such
as Cleavage Under Targets and Release Using Nuclease (CUT&RUN) (Skene, Henikoff, and
Henikoff 2018) and Tagmentation (CUT&Tag) (Kaya-Okur et al. 2019), have provided
numerous insights into the cellular functions of TFs and have been thoroughly used to illuminate
the diversity of TF binding amongst cell types (Ernst et al. 2011; Heintzman et al. 2009; Hnisz et
al. 2013). Alternatively, individual TFs or co-factors may be mapped using TF-tagging
techniques in which the protein of interest is fused to a DNA-modifying enzyme (Schmid,
Durussel, and Laemmli 2004; van Steensel and Henikoff 2000; Wang et al. 2012; Zentner et al.
2015). These can vary in which protein is chosen as the tagging enzyme, though the most
prominent among these are DamID (van Steensel and Henikoff 2000), in which the TF of interest
is fused to the E. coli Dam methylase and TF binding is marked via local adenine methylation,
and calling cards (Wang et al. 2011, 2012), which is a major focus of this dissertation and works
by fusing the TF to the hyperPiggyBac (hypPB) transposase and recording TF occupancy
through binding site-proximal transposon insertion. These methods require that the TF-tagging
enzyme fusion protein be exogenously expressed, a feature which allows for temporal and spatial
control of genome-wide TF profiling while negating the requirement for TF-specific antibodies
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that can burden and limit the scope of TF profiling when using ChIP-seq. However, the nature of
TF-tagging techniques does risk unintended modification or disruption of the local chromatin
landscape and thus may result in toxicity in some contexts (Southall et al. 2013). Finally, there
are a range of techniques for profiling chromatin state more generally, such as Assay for
Transposase-Accessible Chromatin followed by sequencing (ATAC-seq) (Buenrostro et al.
2013) and Formaldehyde-Assisted Isolation of Regulatory Elements followed by sequencing
(FAIRE-seq) (Giresi et al. 2007), which both profile accessibility and compaction, or “openness
and closedness,” of genomic regions at the nucleotide level, as well as chromatin capture
methods, such as high-throughput chromosome conformation capture (Hi-C) (Kempfer and
Pombo 2019), which are aimed at understanding higher order chromatin architecture. The
available options for profiling TFs and REs are numerous, and their unique abilities, when
combined, have led to the discovery of important insights into TF-mediated regulation.
Nonetheless, improvements and new approaches are being developed continually, each building
upon the last and opening doors for novel studies in the field of epigenomics.

Transcription factors and enhancers in the healthy brain and neurological disease
Regulation of TF binding and enhancer activity is highly varied and specific amongst cell
and tissue types. This is particularly true for super enhancers; one report which profiled super
enhancers with H3K27ac ChIP-seq across 86 different human tissues and cell lines found that
nearly half of all super enhancers were active only in one tissue and upwards of 70% in three or
fewer (Hnisz et al. 2013). This is perhaps unsurprising, given the strikingly variant gene
expression profiles observed between cells of different origin (The ENCODE Project
Consortium 2012) and the tendency for super enhancers to regulate cell type-specific cell
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identity genes (Hnisz et al. 2013; Whyte et al. 2013), but nonetheless highlights the criticality of
enhancer-mediated regulation in determining cell fate and maintaining proper cellular function.
This cell type-specific epigenetic regulation is also quite apparent in the brain, where a number
of studies have begun to elucidate profound cell type-specificity of enhancers within neuronal
and glial populations (Girdhar et al. 2018; Mo et al. 2015; Nott et al. 2019). Even subpopulations
of morphologically similar, yet transcriptionally separate neurons display many distinct and nonoverlapping patterns of TF binding and chromatin accessibility which have been shown to
regulate genes associated with known cell type-specific processes such as activity-dependent
transcription (Mo et al. 2015). Some of this variant enhancer activity may be driven by the
selective expression of cell type-specific TFs (Mo et al. 2015).
Perhaps the best evidence demonstrating the importance of proper TF binding and
enhancer activation for maintaining cellular homeostasis is the finding that active enhancers
harbor the vast majority of disease-associated genetic risk (Corradin and Scacheri 2014; Ernst et
al. 2011; Hnisz et al. 2013; Maurano et al. 2012). Critically, these risk-associated single
nucleotide polymorphisms (SNPs) most commonly fall within the cell type-specific enhancers of
the disease-associated cell or tissue type (Ernst et al. 2011; Hnisz et al. 2013). In the brain, it has
been shown that active enhancers and super enhancers harbor risk variants for Alzheimer’s
disease (Hnisz et al. 2013; Marzi et al. 2018; Nativio et al. 2018; Nott et al. 2019), schizophrenia
(Girdhar et al. 2017), and a host of other neurological disorders (Hannon et al. 2019). This result,
which has been well-replicated for a number of different diseases both in and out of the central
nervous system (CNS), strongly suggests that misregulation of enhancer-mediated epigenetic
control causes cellular dysfunction that could be a driver of disease pathogenesis.
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Epilepsy and acute seizure: an epigenetics perspective
Drug induced acute seizure as a model of epilepsy
Epilepsy is one of the most commonly observed neurological disorders, affecting millions
of individuals in the United States alone and costing billions of dollars in direct medical costs
(England et al. 2012). While a number of anti-epileptic drugs (AED) are commonly and
successfully used to control seizure susceptibility in some epileptic patients (Rogawski 2006), at
least one third of diagnosed individuals do not respond to treatment and continue to incur
uncontrolled epileptic seizures (Devinsky et al. 2018), emphasizing the need for the development
of new therapeutic strategies. And with a lifetime risk of 1 in 26 and an estimated 150,000 new
cases diagnosed annually (England et al. 2012), this need is important and urgent for the
treatment of this patient population.
The term epilepsy actually refers to a group of similar yet distinct clinical phenotypes
which can be diversified by their clinical features such as age at onset, co-morbidities, and
seizure type (Myers and Mefford 2015). However, the unifying feature of these variant disorders
is the recurrence of unprovoked epileptic seizures. While the underlying molecular mechanisms
for seizure are unclear and likely diverse, we now understand that this phenotype is due to an
imbalance in inhibitory and excitatory conductances in the brain (Staley 2015), which can be
modeled in animals by manipulating inhibitory or excitatory circuits to induce acute seizures
(Löscher 2011). One commonly used method of inducing acute seizures in mouse models is
through intraperitoneal (i.p.) injection of the GABA antagonist pentylenetetrazole (PTZ)
(Löscher 2011; Rogawski 2006). Upon injection of PTZ, animals undergo convulsive, clonic
seizures within minutes, although there is a high degree of variability in the severity of the
seizure induced, ranging from small spasms to full clonic activity and even death (DeVos et al.

8

2013). While models of more chronic seizure through genetic or kindling means are arguably
closer in phenotype to human epilepsy, a number of AEDs first found to be effective in acute
seizure models have been successfully translated to the clinic (Löscher 2011; Rogawski 2006),
supporting that these models are valid and important tools for understanding molecular
mechanisms underlying epileptic seizure.

Genetics and epigenetics of seizure
Genetic factors are thought to have a major role in the pathogenesis of epilepsy, or
epileptogenesis. Estimates of epilepsy cases with a genetic basis range from 70-80% of the total
(Hildebrand et al. 2013; Myers and Mefford 2015), a figure derived from twin studies in which
monozygotic twins have been found to have a much higher concordance rate with epilepsy than
do dizygotic pairs (Kjeldsen et al. 2003). A number of genes have been implicated in the
pathogenesis of epilepsy and/or epileptic seizure via human genetic studies, many of which
encode proteins affecting membrane potential, such as ion channels (Myers and Mefford 2015).
For this reason, many epileptic disorders are termed “channelopathies.” However, these epilepsycausing mutations are rare and do not explain the underlying mechanism for the majority of
epileptic cases.
Recent evidence suggests that epigenetic mechanisms may also play roles in
susceptibility to seizure. Previous studies in both rodent and human epilepsy have observed
changes in DNA methylation, histone acetylation, and miRNA expression upon seizure
(Devinsky et al. 2018; Kobow and Blümcke 2018). Further, a number of TFs and co-factors have
been shown to be sufficient to alter seizure severity when manipulated. Hippocampal expression
and activity of a TF called neuron-restrictive silencer factor (NRSF) has been found to be
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induced upon seizure, subsequently repressing a variety of target genes including ion channels
and receptors (McClelland et al. 2014), whereas blocking NRSF binding is sufficient to rescue
expression changes (McClelland et al. 2014) and attenuate the epileptic phenotype (McClelland
et al. 2011). Moreover, the BET family proteins have also been implicated in seizure
susceptibility, suggesting that enhancers may too be involved in epileptogenesis. Genetic
variants in Brd2 increase risk for juvenile myoclonic epilepsy (Pal et al. 2003), while Brd2 null
and heterozygous mice display lowered clonic seizure thresholds and disruptions in GABAergic
signaling pathways (Qureshi and Mehler 2014). Meanwhile, the super enhancer-associated
protein BRD4 has been shown to play a major role in the neuronal transcriptional response to
firing. Inhibition or genetic knockdown of BRD4 in primary mouse cortical neurons is sufficient
to block activity-dependent induction of immediate-early genes such as Arc and c-Fos, as well as
a host of other genes associated with synapses and membrane excitability. Further, BRD4
inhibition in vivo in prior to induction of acute seizure via PTZ injection results in a drastically
reduced peak seizure severity, suggesting that BRD4 is a mediator of genes critical to the
propagation of neuronal activity and necessary for the occurrence of seizure (Korb et al. 2015).
However, the target genes downstream of BRD4 regulation that are ultimately responsible for
this susceptibility are still yet to be deciphered.
In Chapter 3 of this dissertation, we utilize newly developed epigenomic tools to
elucidate the role of BRD4 in PTZ-induced seizure, in order to identify downstream vulnerability
and susceptibility loci.
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Epigenetic contributions to amyotrophic lateral sclerosis
Genetics and prevalence of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou
Gehrig’s disease, is a devastating neurodegenerative disorder characterized by the progressive
degeneration of upper and lower motor neurons (MNs) in the brain and spinal cord (Taylor,
Brown, and Cleveland 2016). This MN loss manifests clinically as a rapid deterioration of
muscle mass, inability to move, and ultimately death typically within 3-5 years after symptom
onset, often due to respiratory failure (Rowland and Shneider 2001). ALS is a relatively rare
disorder, with a prevalence of just 1-2 per 100,000, however, remarkably, the lifetime risk of
developing ALS is estimated to be as high as 1:400 (Johnston et al. 2006); notably, the rapidly
progressive nature of ALS prevents the accumulation of affected individuals in any given
population. Sadly, since the initial descriptions of the disease by Charcot in the mid 19th century
(Goetz 2000), relatively little progress has been made in terms of ALS therapy, with only two
drugs FDA-approved for the treatment of ALS, each with very modest effects on disease
progression (3-6 month survival extension) (Abe et al. 2014; Bensimon et al. 1994). Thus, the
need to develop new targeted therapies for ALS is critical, which will be enabled through first
understanding the biological mechanisms underlying MN death.
The majority (~90%) of ALS cases are singleton (sALS), however about 10% of
individuals with ALS do have a family history of disease and are thus collectively termed
“familial” ALS (fALS). Human genetic studies over the past 30 years have identified a number
of gene mutations causative for ALS, beginning in 1993 with mutations in the superoxide
dismutase 1 (SOD1) gene (Rosen et al. 1993). In total, these known mutations now account for
nearly two thirds of fALS and a small portion (~11%) of sALS cases as well (Renton, Chiò, and
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Traynor 2014). The majority of ALS-associated proteins fall within two categories: protein
quality control (e.g. VCP, TBK1, OPTN, UBQLN2) or RNA processing (e.g. TDP-43, FUS,
hnRNPA1/2B1) (Ghasemi and Brown 2018; Renton et al. 2014). However, more recently much
of the field has shifted its focus to a more unique mutation, a hexanucleotide (GGGGCC, or
G4C2) repeat expansion in the first intronic region of the chromosome 9 open reading frame 72,
or C9orf72, gene, which causes 38% and 6% of fALS and sALS, respectively, and is now the
most common genetic cause of ALS (abbreviated C9ALS) (DeJesus-Hernandez et al. 2011;
Majounie et al. 2012; Renton et al. 2011). Additionally, the same mutation causes 25% and 6%
of familial and sporadic frontotemporal dementia (C9FTD) (Majounie et al. 2012). This
expansion is typically small in non-ALS individuals (<30 repeats), however the disease
associated expansion ranges from hundreds to thousands of consecutive repeats (van Blitterswijk
et al. 2013; Dols-Icardo et al. 2014; Gijselinck et al. 2016; Nordin et al. 2015) which are
somatically unstable and can vary greatly in size even within individual (Nordin et al. 2015).

Molecular mechanisms of C9ALS
Because the C9orf72 mutation is a GC-rich expansion rather than a typical point
mutation, it was not initially identified by human genetic studies, and it was not until 2011 that
these mutations were discovered and subsequently published in landmark studies by two
independent groups (DeJesus-Hernandez et al. 2011; Renton et al. 2011). Since this time, a huge
amount of progress has been made in understanding the biological consequences of having this
large expansion (Gendron and Petrucelli 2017; Gitler and Tsuiji 2016). It is primarily
hypothesized that C9orf72 expansions induce toxicity through one or a combination of three
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distinct loss and gain of function mechanisms, each initially based on studies of related repeat
expansion disorders.
The first proposed mechanism is a loss of normal C9ORF72 function, due to repeatinduced transcription reduction of the C9orf72 gene. Indeed, presence of the expansion does
silence the repeat-containing allele, resulting in a ~50% reduction in total C9orf72 mRNA
(DeJesus-Hernandez et al. 2011; Renton et al. 2011). However, because loss of the C9ORF72
gene product does not result in neurodegeneration in mice (Burberry et al. 2016; O’Rourke et al.
2016) and no known coding mutations within C9orf72 have been found to associate with the
human disease (Harms et al. 2013), a solely loss of function mechanism is considered unlikely.
The remaining two proposed mechanisms are both based on gain of function toxicity. The
C9orf72 expansion is bidirectionally transcribed, and although the expansion is intronic, these
transcripts are stabilized and aggregated into formations called RNA foci inside the nuclei of
affected cellular populations (DeJesus-Hernandez et al. 2011). The presence of these foci causes
sequestration of critical RNA binding proteins (Donnelly et al. 2013; Lee et al. 2013), which is
the first of the two proposed gain of function toxicities. Moreover, these repetitive transcripts
make their way to the cytoplasm where they are translated into protein through repeat-associated
non-ATG (RAN) translation, a process wherein translation may initiate in the absence of a start
codon. This produces 5 separate species of dipeptide repeat proteins (DPRs): poly(GA) and
poly(GR) from the sense strand, poly(PA) and poly(PR) from the antisense, and poly(GP) from
both (Ash et al. 2013; Gendron et al. 2013; Mori et al. 2013; Zu et al. 2013). These DPRs are
specific to C9orf72 expansion carriers, and all five species have been shown to exist in patient
tissues, forming intracellular and intranuclear aggregates throughout the brain and spinal cord
(Ash et al. 2013; Gendron et al. 2013; Mackenzie et al. 2013, 2015; Mori et al. 2013; Zu et al.
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2013). Further, multiple separate studies have demonstrated that poly(GR) and poly(PR) are
sufficient for degeneration in isolated neurons (Wen et al. 2014), Drosophila (Mizielinska et al.
2014), and even mice (Hao et al. 2019; Zhang et al. 2019), while a number of poly(GA)mediated toxicities have also been demonstrated in vitro and in vivo (May et al. 2014; Nguyen et
al. 2019; Nihei et al. 2019; Schludi et al. 2017; Zhang et al. 2014), thus leading to the hypothesis
that the presence of these aberrant proteins could be a gain of function driver of disease.
Some studies have attempted to determine the relative contributions of DPRs versus RNA
foci to disease pathogenesis (Arzberger et al. 2018; Mizielinska et al. 2014; Moens et al. 2018;
Swinnen et al. 2018), however such studies are complicated by potential effects of
overexpression and lack of animals models accurately depicting C9ALS phenotypes. Intriguingly
however, while the relative toxicities driven by RNA foci and DPRs are still unclear, it has been
shown that downstream affected pathways driven by these two pathologies often converge (e.g.
disruptions in nucleocytoplasmic transport (Boeynaems et al. 2016; Freibaum et al. 2015; Jovičić
et al. 2015; Zhang et al. 2015)). Thus, while what ultimately drives pathogenesis in C9ALS is
still unclear, it is becoming increasingly accepted that these two pathologies are likely involved.

Evidence for epigenetic contributions to ALS
Emerging results suggest that epigenetic mechanisms may contribute to ALS
pathogenesis. In particular, recent studies have pointed to both transcriptional (chromatin
dynamics) and translational (miRNAs) components of epigenetic control as potentially
compromised in the disease state.
Firstly, a coalescence of evidence supports that chromatin dynamics and enhancer
activity may be altered in ALS. Using a targeted toxicity screen in Drosophila, one group
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identified the chromatin modifier CHD1 as being impaired by TDP-43, resulting in disrupted
nucleosomal dynamics, increased stress granule formation, and reduction of important stressinduced heat shock genes (Berson et al. 2017). Further, a recent study demonstrated that DPRs
co-localize to regions of heterochromatin in both mouse C9orf72 models and in C9ALS/FTD
postmortem cortical tissue and induce alterations in chromatin methylation, suggesting that
C9orf72-derived pathologies can directly alter the chromatin state (Zhang et al. 2019). In mutant
FUS transgenic mouse models, global histone hypoacetylation has been observed, while reversal
of these changes with pharmacological inhibitors of histone deacetylases (HDACs) has been
shown to slow disease progression and reverse aberrant metabolic changes (Rossaert et al. 2019).
Finally, one study observed an increase in ALS-associated genetic variation in active enhancers
profiled in postmortem entorhinal cortex samples, supporting that epigenetic misregulation may
increase ALS risk (Hannon et al. 2019).
While the mechanisms through which chromatin dynamics may be disrupted remain
unclear, indirect lines of evidence suggest that altered LLPS of chromatin-associated proteins
could be a factor. LLPS is a phenomenon which has been heavily implicated as a possible driver
of ALS-related pathologies. A number of ALS-associated proteins (e.g. TDP-43, FUS,
hnRNPA1) have been shown to undergo LLPS in vitro and in live cells, forming liquid-like
condensates that naturally transition between liquid, gel-like, and solid states (Boeynaems et al.
2017; Molliex et al. 2015; Patel et al. 2015). However, disease-linked mutations in these proteins
can drive these condensates more frequently into the solid state and ultimately into amyloid-like
aggregates reminiscent of those observed in patient tissues (Molliex et al. 2015; Patel et al.
2015). Moreover, poly(GR) and poly(PR) have also been shown to undergo LLPS (Boeynaems
et al. 2017), during which these aberrantly expressed DPRs associate with and re-localize to

15

other phase-separated subcellular bodies, such as nucleoli, and in turn alter their natural LLPS
dynamics (Lee et al. 2016). Interestingly, one recent study observed that poly(PR) disrupts the
LLPS dynamics of heterochromatin protein 1 (HP1), subsequently co-localizing to regions of
closed chromatin and inducing alterations in histone H3 methylation status, demonstrating that
DPRs can directly affect chromatin organization through alteration of phase separation (Zhang et
al. 2019). Extending this further, it is also now understood that TFs, nucleosomes, and co-factors
such as BRD4 also utilize LLPS to maintain or change chromatin architecture (Boija et al. 2018;
Gibson et al. 2019; Hnisz et al. 2017; Sabari et al. 2018); thus while no evidence has yet been
shown to suggest that DPRs directly affect TFs, it is possible that similar LLPS disruptions may
exist and affect enhancer activity in the context of C9ALS.
Epigenetic misregulation at the translational level through miRNA-mediated repression
may also contribute to ALS pathogenesis (Hoye et al. 2017, 2018; Koval et al. 2013;
Reichenstein et al. 2019; Varcianna et al. 2019). A number of studies, including from our group,
have shown that miRNA levels are altered in ALS mouse models (Hoye et al. 2017; Koval et al.
2013), patient-derived induced pluripotent stem cell (iPSC) models (Varcianna et al. 2019), and
patient tissues (Hoye et al. 2017; Reichenstein et al. 2019). These changes can result in neuronal
and glial dysfunction and have been linked to mechanisms involved in ALS pathogenesis (Amin
et al. 2015; Hoye et al. 2017, 2018; Koval et al. 2013; Reichenstein et al. 2019; Varcianna et al.
2019). However, whether miRNA-mediated regulation is similarly altered in C9ALS is unclear.
This dissertation explores and tests the concept that epigenetic disruption is an upstream
event in C9ALS pathogenesis. The work described in Chapter 4 details application of
epigenomic techniques to both mouse models and postmortem human CNS samples of C9ALS

16

to determine whether C9orf72-related pathologies induce alterations in miRNA and enhancer
activity.
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Summary of the dissertation
This dissertation focuses on the mapping of TF binding across the genome in the brain to
better understand TF-mediated epigenetic regulation in healthy and diseased conditions. The
work within first describes the development of a novel TF and enhancer profiling technique,
termed AAV calling cards, followed by its application to two models of neurological disease.
This method, the development of which is described in Chapter 2, allows access to unique TF
and co-factor occupancy information inaccessible with previously existing techniques such as
ChIP-seq or other antibody-based methodologies. These include cell type-specificity of TF
binding between neuronal and glial cell types, as well as integrated TF occupancy recording over
time, both of which are thoroughly tested and validated in the second half of Chapter 2. The
work describing AAV calling cards is part of a manuscript which, as of this writing, is currently
available as a pre-print on BioRxiv (Cammack, Moudgil, et al. 2019) and has been recently
accepted for publication at PNAS. Following this is the application of this technique to two
independent neurological disease models, both of which function as test cases of AAV calling
cards utilization for means of novel information gathering as well as elucidative studies into the
roles of TFs and enhancers in disease contexts.
Chapter 3 describes use of AAV calling cards to investigate the role of BRD4 in
susceptibility to or protection from acute seizure. In this study, BRD4 binding is recorded
genome wide in the mouse cortex across a 4-week period of time prior to induction of acute
seizure via PTZ injection. By subsequently comparing mice that incurred mild seizures to those
that progressed to a more severe phenotype, BRD4-bound vulnerability and susceptibility loci
are identified. Beyond elucidating a potential role for BRD4-mediated enhancer regulation in
acute seizure, this study also demonstrates the utility of longitudinal recording offered by AAV
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calling cards. Indeed, because BRD4 binding was recorded before rather than after seizure
induction, it can be interpreted that the observed differences between mild and severe seizurereceiving animals are present at seizure onset, rather than a resultant effect of the seizure itself.
In Chapter 4, we test the hypothesis that misregulated epigenetic control, including
miRNA and BRD4-bound enhancer activity, is a defining feature of C9ALS that may contribute
to pathogenesis. This work first details profiling of miRNAs and enhancers in spinal cord
samples from C9ALS mouse models carrying multiple copies of the human expansion mutation
(Liu et al. 2016; O’Rourke et al. 2015). These mice exhibit pathologic features reminiscent of the
human disease, however, in our colony, do not display weakness or other disease-related
phenotypes; thus, these mice represent “pre-onset” C9ALS and can be used to assess
pathologically-driven biology without the confounding variables of neuroinflammation or
neurodegeneration associated with end-stage ALS. By profiling global miRNA levels in the
spinal cords of these animals with microarray, we find a number of miRNAs to be
transcriptionally misregulated at an early timepoint. This is followed by application of BRD4directed AAV calling cards to the cortex of one of these models. Here, a number of differential
BRD4 binding sites are observed between C9ALS animals and their non-transgenic controls,
suggesting that C9orf72-related pathologies disrupt BRD4 binding. To extend this to the human
condition, enhancers are subsequently profiled with H3K27ac ChIP-seq in postmortem lumbar
spinal cord samples from C9ALS, sALS, and non-ALS control individuals. Again, differential
enhancer activity was observed between ALS and non-ALS samples which correlated between
C9ALS and sALS. Lastly, we demonstrate that these human spinal cord enhancers harbor known
ALS risk-associated SNPs, suggesting that misregulation of these regions may increase risk of
disease.
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Finally, in Chapter 5, we investigate further the properties of DNA expansions and DPRs
in human C9ALS. We first probed size of the G4C2 DNA repeat in blood samples from >100
C9ALS and non-ALS mutation carriers via Southern blotting and found that repeat size
correlates positively with age and age at disease onset. We extended this study to carriers of
large but non-expanded repeats (13-25 repeats), where a similar relationship with age was
observed. Together these results support that C9orf72 repeat expansions may be dynamic and
able to change size over time. We then asked whether size of the DNA expansion was related to
that of resultant DPRs. To do so, we probed DPR size in human autopsy CNS tissue via a novel
combination of size-exclusion chromatography and poly(GP) immunoassay and observed that
DPRs are generally quite large and often reach lengths similar to that of their DNA counterparts.
Interestingly, we also found that poly(GP) abundance in the cerebrospinal fluid (CSF) was
negatively correlated with DNA expansion size, suggesting that presence of larger expansions
reduces DPR load, possibly through reduced G4C2 RNA. This work is published in Neurology in
conjunction with a large, prospective natural history study of C9ALS in which clinical features
and biomarkers are thoroughly examined in this patient population (Cammack, Atassi, et al.
2019).
The body of work detailed here attempts to extend our knowledge of TFs and enhancers
in the brain, both in healthy and diseased conditions. Through the development of a new
epigenomic tool and its application to disease models, we have provided new insights into the
potential role of enhancer-mediated regulation in disease pathogenesis. Further, the unique
utilities offered by AAV calling cards will be equally relevant for the study of other neurological
conditions, as well as during neurodevelopment. While there remains much to do to fully
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understand the biology of TFs and enhancers in the brain, the contributions of this dissertation
will pave the way for new epigenetic insights and discoveries in the future.
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Abstract
Transcription factors (TFs) enact precise regulation of gene expression through sitespecific, genome-wide binding. Common methods for TF occupancy profiling, such as
chromatin immunoprecipitation, are limited by requirement of TF-specific antibodies and
provide only endpoint snapshots of TF binding. Alternatively, TF-tagging techniques, in which a
TF is fused to a DNA-modifying enzyme that marks TF binding events across the genome as
they occur, do not require TF-specific antibodies and offer the potential for unique applications,
such as recording of TF occupancy over time and cell type-specificity through conditional
expression of the TF-enzyme fusion. Here we create a viral toolkit for one such method, calling
cards, and demonstrate that these reagents can be delivered to the live mouse brain and used to
report TF occupancy. Further, we establish a Cre-dependent calling cards system and, in proofof-principle experiments, show utility in defining cell type-specific TF profiles and recording
and integrating TF binding events across time. This versatile approach will enable unique studies
of TF-mediated gene regulation in live animal models.
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Introduction
Proper cellular development and function is a complex process established by elaborate
gene expression networks. These networks are fundamentally regulated by transcription factors
(TF), which bind to regulatory elements (RE) across the genome and facilitate gene expression
through a variety of mechanisms, including recruitment of transcriptional co-factors and
modulation of chromatin state (Spitz and Furlong 2012). Extensive efforts to profile TF genome
occupancy and identify active REs across the genome have highlighted the profound diversity of
TF binding, providing important insights into TF-mediated gene regulation (Consortium 2012;
Ernst et al. 2011; Heintzman et al. 2009; Mo et al. 2015). Further, a large portion of genetic
variation associated with improper cellular function or disease has been shown to exist in TFbound REs (Corradin and Scacheri 2014; Ernst et al. 2011; Girdhar et al. 2018; Hnisz et al. 2013;
Maurano et al. 2012; Wells et al. 2015), demonstrating the criticality of proper TF binding in
maintaining cellular homeostasis.
Several methods exist for profiling TF occupancy across the genome. Antibody-based
techniques, such as chromatin immunoprecipitation followed by sequencing (ChIP-seq), and
more recently Cleavage Under Targets and Release Using Nuclease (CUT&RUN)(Skene,
Henikoff, and Henikoff 2018) or Tagmentation (CUT&Tag) (Kwon et al. 2017), are widely used
and have provided numerous insights into the cellular functions of TFs (Consortium 2012; Ernst
et al. 2011; Heintzman et al. 2009; Hnisz et al. 2013). Notably however, these methods require
the availability and individual optimization of TF-specific antibodies, limiting the throughput
and breadth of genome-wide TF profiling. Further, ChIP-seq provides only a snapshot of TF
activity at the moment of cell lysis and thus may be inefficient at detecting transient or infrequent
TF binding events. Finally, while robust for non-cell type-selective, tissue-level analyses, it is
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often challenging to interpret ChIP-seq data obtained from complex tissues such as the brain,
which is comprised of many different interconnected cell types. Because of this limitation,
efforts have recently been made to modify ChIP-seq for cell type-specific use, either through
physical nuclear sorting (Bonn et al. 2012; Girdhar et al. 2018), or conditional expression and
subsequent isolation of tagged nuclei (Deal and Henikoff 2010; Mo et al. 2015) or chromatinassociated enzymes (Zhou et al. 2017) prior to ChIP. However, these methods thus far have been
limited to highly abundant targets, such as histone modifications (Girdhar et al. 2018; Mo et al.
2015) and transcriptional coactivators (Zhou et al. 2017), and may be complicated by potential
disassociation-related artifacts (van den Brink et al. 2017). Therefore, it is unclear if ChIP-seq is
feasible from sorted or isolated nuclei for less abundant TFs.
An alternative approach is to record TF binding events by fusing the TF of interest to
DNA-modifying enzymes (Schmid, Durussel, and Laemmli 2004; van Steensel and Henikoff
2000; Wang et al. 2012; Zentner et al. 2015). Prominent among these are two techniques: DNA
adenine methylation identification (DamID) (van Steensel and Henikoff 2000), which records TF
binding through local adenine methylation by an E. coli Dam methylase fused to a TF of interest,
and calling cards (Wang et al. 2011, 2012), in which a TF is fused to a transposase enzyme and
binding events are recorded through transposon insertion proximal to the TF binding site.
Importantly, TF-tagging techniques do not require TF-specific antibodies and have the ability to
record and integrate occupancy information across time (Mitchell et al. 2016), while requiring
very little starting material (Southall et al. 2013). Further, these approaches offer the potential for
cell type-specificity through conditional expression of the TF-enzyme fusion protein. In this way,
DamID has been successfully implemented for cell type-specific profiling (van den Ameele,
Krautz, and Brand 2019), primarily in Drosophila (Southall et al. 2013) but also with some
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studies in cultured mammalian cells (Cheetham et al. 2018; Tosti et al. 2018; Vogel et al. 2006)
and embryos (Tosti et al. 2018). Meanwhile, calling cards has also been successfully applied to
yeast (Wang et al. 2008) and mammalian cell (Wang et al. 2012) model systems. However,
neither of these methodologies has to date been implemented for TF recording in postnatal
mammalian model systems, such as mice.
Here we adapt calling cards for in vivo use by delivering this system to the mouse brain
via adeno-associated virus (AAV). This method, in the mold of traditional calling card
technologies (Wang et al. 2012), works by first expressing the hyperPiggyBac (hypPB)
transposase within a cell and providing donor transposons. HypPB inserts donor transposons at
TTAA sites throughout the genome, leaving permanent marks, or calling cards, at these loci.
These transposons can later be sequenced and mapped to the genome to record the history of
hypPB localization across the genome. HypPB-mediated insertions can be used to assess TF
binding in two ways: 1) hypPB may be fused to a TF of interest, so that the TF directs the
insertion of transposons near its genomic binding sites (Wang et al. 2012), or 2) unfused hypPB
directly interacts with the bromodomain and extra-terminal domain (BET) protein, BRD4, and
directs transposon DNA into BRD4-associated genomic regions (Gogol-Doring et al. 2016;
Yoshida et al. 2017), most prominently active super enhancers (Hnisz et al. 2013). We establish
that calling card systems can be delivered to the mouse brain via AAV and that these
components successfully record TF occupancy without the need for a TF-specific antibody. We
then create a conditionally-expressed, Cre recombinase-dependent version of AAV calling cards,
termed Flip-Excision, or FLEX, calling cards and demonstrate, as a proof-of-principle, the ability
of this system to record cell type-specific TF occupancy profiles in the brain. Lastly, we provide
evidence that through continued transposon insertion, FLEX calling cards can record and
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integrate TF binding events over extended time periods following viral delivery, providing
insights into transient TF activity that would be otherwise missed with endpoint measures such
as ChIP-seq.
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Methods
Animals
All animal practices and procedures were approved by the Washington University in St.
Louis Institutional Animal Care and Use Committee (IACUC) in accordance with National
Institutes of Health (NIH) guidelines. Transgenic mouse strains used in this study include
Synapsin 1 (Syn1)::Cre (RRID:IMSR_JAX:003966) and glial fibrillary acidic protein
(GFAP)::Cre (RRID:IMSR_JAX:024098). All mice were bred to the C57BL/6J background,
with the exception of animals used for adult stereotactic injections, which were wild-type
animals of the FVB/N6 background (RRID:IMSR_JAX:001800). At indicated endpoints, mice
were anesthetized with isoflurane and perfused with 15ml of cold saline (PBS) prior to tissue
collection. Animals in the BRD4 Syn1::Cre, BRD4 GFAP::Cre, and P28 SP1 Syn1::Cre cohorts
received pentylenetrazole-induced seizures immediately prior to sacrifice. Unless otherwise
noted, brains were either dissected and flash frozen in liquid nitrogen (for molecular analyses) or
fixed in 4% paraformaldehyde 24-48 hours, exchanged into 30% sucrose, and either directly
frozen at -80C or cryoprotected in O.C.T. (for immunofluorescence).
To collect newborn litters, pregnant females were monitored daily until giving birth.
Newborn pups were injected within 24 hours of being found in the cage, i.e. 0-48 hours after
birth; thus, these injections are labeled “P0-1.” One exception is AAV::hypPB Frontflip in Fig
2.6, for which 1/3 of both the GFAP::Cre(+) and GFAP::Cre(-) animals were P3-4 when
injected.

Cell culture, transfections, and flow cytometry analysis
HEK293T and N2a cells used in this study were cultured in 1X DMEM with 10% fetal
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bovine serum (FBS) and grown under standard conditions (37°C; 5% CO2). Plasmid
transfections in HEK293T cells were carried out with Fugene® 6 Transfection Reagent
(Promega, Madison, WI, USA) with the manufacturer’s protocol. Calling cards constructs were
delivered to N2a cells via either Fugene 6 or Neon Electroporation (ThermoFisher #MPK10025)
with the following settings: 1050V, 30ms, 2 pulses.
For evaluation of SRT-tdTomato fluorescence in Fig 2.6B, HEK293T cells were
collected 96-hours post-transfection for flow cytometry analysis. The cells were lifted using
0.25% trypsin-EDTA (ThermoFisher 25200056) and washed once with PBS. Cell pellets were
resuspended at 1x106 cells/ml in PBS/0.5% BSA/2mM EDTA with 0.1μg/ml DAPI (SigmaAldrich D9542, St Louis, MO, USA) for 10 min for dead cell and debris exclusion from analysis.
Cells were washed once more with PBS/0.5% BSA/2mM EDTA and analyzed on a CytoFLEX S
(Beckman Coulter), with each sample being run at a low flow rate (10-30μl/min) for 3 min to
collect approximately 20,000 events per condition. A violet 405nm laser with 450/45 bandpass
filter was used to detect DAPI and a yellow-green 561nm laser with 585/42 bandpass filter was
used to collect tdTomato fluorescence. Flow cytometry data was analyzed with CytExpert
software (Beckman Coulter). The gating was performed as outlined in Fig 2.8SA.

Immunofluorescence and imaging
10µm-thick (for co-localization studies) or 40µm-thick (for imaging of
AAV::BrokenHeart) fixed-frozen sagittal or coronal brain sections were washed with PBS and
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA). Non-specific
binding was blocked with 5% normal donkey (Jackson ImmunoResearch, West Grove, PA,
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USA) or goat (Vector Laboratories, Burlingame, CA, USA) serum for 30-60 minutes at room
temperature. After blocking, slides were exposed to primary antibody overnight at 4°C, washed
three times with PBS, and then incubated with secondary antibodies for 1 hour at room
temperature. Nuclei were counterstained with DAPI (Sigma-Aldrich, St. Louis, MO, USA) and
coverslips were applied with ProLong Gold Antifade (ThermoFisher, Waltham, MA, USA) or
Fluoromount-G (SouthernBiotech, Birmingham, AL, USA) mounting media. Immunofluorescent
images of brain sections were acquired with a Nikon A1Rsi or Zeiss LSM 700 confocal
microscope and imported into ImageJ (v. 1.51s) for manual cell counts and quantification. For
analyses of hypPB expression in various cell types, 5 mice were used, and co-localization was
quantified in 2 cortical images from a single section per animal. Antibodies used for
immunostaining included chicken anti-GFP (Aves Labs GFP-1020) at 1:1000 dilution, mouse
rabbit anti-RFP at 1:400 or 1:500 dilution (Rockland 600-401-379), anti-NeuN at 1:100 dilution
(Millipore-Sigma MAB377), rabbit anti-cMyc at 1:250 dilution (Sigma C3956), and goat antiGFAP at 1:500 dilution (Abcam ab53554).
Cells transfected with AAV::hypPB FLEX for testing Cre-dependence were live imaged
for TdTomato on a Leica DMI 3000B tissue culture microscope. All images were acquired with
equal conditions and exposure times for direct comparison.

In situ hybridization and imaging
10μM-thick, 4% paraformaldehyde fixed-frozen sections were cut and slide-mounted.
mRNA encoding for hyperPiggyBac (VF1-20268-01) was detected using a custom probe-set
designed by Affymetrix (now ThermoFisher) using the Affymetrix ViewRNA ISH Tissue 1-Plex
kit (ThermoFisher, QVT0050) and chromogenic signal amplification kit (ThermoFisher
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VT0200) with the following modifications: Slides were immersed in 4% paraformaldehyde
overnight at 4C prior to in situ hybridization, then the baking, deparaffinization, and heat
pretreatment steps were omitted (steps 1-3, 5) because sections were not embedded in paraffin.
Slides were hybridized either with anti-hypPB or no-probe controls. Following the in situ
labeling protocol, sections were labeled for 5 minutes with DAPI (1:20,000, Sigma D9542),
washed with PBS, and a drop of prolong gold (ThermoFisher P36934) was added while applying
the coverslip. Slides were then imaged at 20x magnification on a Zeiss LSM 700 confocal
microscope using a Cy3 filterset to detect FastRed fluorescence.

Analysis of brain degeneration following viral injection
Mice were exposed to either the calling cards viruses (AAV::hypPB + AAV::SRT) or
RFP-only virus (as a control) via P0-1 injection and sacrificed 28 days later for silver staining (a
marker for cells irreversibly committed to cell death). Briefly, animals were heavily sedated and
perfused with TRIS fixative in 4% paraformaldehyde followed by vibratome sectioning of brains
at 75M in the coronal plane. Every eighth section across the rostrocaudal extent of the brain
was then silver stained as described previously (Noguchi, Nemmers, and Farber 2005). The
number of degenerating neurons was quantified for each animal by a rater blind to treatment who
counted the total number of silver positive neurons in the dorsal cortex of each section.

Mouse behavior, developmental milestones, and sensorimotor battery
Mouse behavior and development was monitored and compared between animals injected
calling cards AAV reagents (AAV::hypPB and AAV::SRT) or AAV::RFP only. In addition to
weight, which was measured at P8, P14, P25, tests were administered to assess attainment of
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developmental milestones (P14 righting from back), anxiety related behavior (P25 1 hour
behavior, recording time spent in the edge or center of cage), and balance/strength/coordination
(P25/26 sensorimotor battery). Procedures were done as previously described (Grady et al. 2006;
Wozniak et al. 2004), with two trials per animal. A break was allowed after the completion of the
first set of test trials to avoid exhaustion effects, and the test order was reversed for the second
trial for all animals. Walking initiation, ledge performance, platform performance, and pole
performance were all administered at P25, while 60° inclined screen test, 90° inclined screen
test, and inverted screen test were administered on P26. Prior to testing, mice were given a
routine health check, and from this, two animals were excluded; one for runtiness and one for
severe hydrocephaly likely derived from needle stick. Further, one litter of RFP-only animals
was not able to complete all timepoints (cage flooding) and was thus also excluded. In total, 21
animals were included in the calling card group (11M/10F) and 24 in the RFP-only group
(10M/14F), all of which were used for downstream analyses. Test administrators were blinded
from treatment group identity during all testing.

Virus generation and injections
Transposase and donor transposon constructs were cloned into Cre-dependent (FLEX) or
Cre-independent AAV transfer vectors and used for in vitro transfection or viral packaging.
Plasmids were packaged into AAV by the Hope Center Viral Vectors Core at Washington
University School of Medicine. For in vivo experiments involving P0-1 delivery, transposase and
donor transposon viruses (mixed equally by volume) or undiluted RFP-only virus were
intracranially injected into the cortex of postnatal day 0-1 (P0-1; 3 sites per hemisphere, 1l viral
mix per site). For adult injections, viruses were delivered to P107 animals intraparenchymally

49

with stereotactic surgery, as previously described(DeVos and Miller 2013). Two sites were
chosen for direct, unilateral cortical injection with coordinates relative to bregma of 1.25mm
rostral; 1.5mm lateral; 0.55mm depth; and 1.06mm caudal; 1.5mm lateral; 0.55mm depth. 2l of
viral mix was delivered at a rate of 0.2l/minute.
Viral titers (viral genomes per milliliter) were as follows:
AAV::hypPB

1.0x1013 - 1.1x1013 vg/ml

AAV::hypPB FLEX

8.0x1012 - 1.0x1013 vg/ml

AAV::SP1(621C)-hypPB FLEX

1.0x1013 vg/ml

AAV::SRT

1.6x1013 - 2.2x1013 vg/ml

AAV::BrokenHeart FLEX

1.4 x 1013 vg/ml

AAV::RFP only

1.6x1013 vg/ml

AAV::hypPB Frontflip

8.0x1013 vg/ml

SRT and BrokenHeart library preparation, sequencing, and mapping
SRT libraries were prepared from cortex RNA samples. Prior to library preparation,
cortex samples were dissected into 10 separate pieces, from which RNA was independently
isolated with the manufacturer’s protocol (Qiagen RNeasy kit, Germantown, MD, USA). This
allows for identification of up to 10 independent insertion events into any TTAA site, given that
these insertions occur in spatially separate samples. From these RNA samples, transposon
sequencing libraries were generated with our bulk SRT protocol (Moudgil et al. 2019). In brief,
RNA samples were first reverse transcribed, from which self-reporting transcripts, including
flanking genomic sequences, were amplified via PCR. These amplicons were then tagged with
universal Illumina sequencing overhangs, with separate indexes for libraries from each dissected
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piece, allowing for 10 ‘barcodes’ per sample and sequenced on Illumina HiSeq 2500, NextSeq
500, or MiniSeq platforms (Illumina, San Diego, CA, USA).
BrokenHeart libraries were prepared from cortical DNA samples, as previously described
(Wang et al. 2012). A set of 20 individually barcoded BrokenHeart transposons were pooled and
packaged into AAV. Thus, independent insertions into the same TTAA can be uniquely
identified via barcode, removing the need to dissect and process tissue samples in separate pools
as with SRT. Extracted DNA was self-ligated, amplified with inverse PCR, and sequenced with
the Illumina NextSeq 500 platform (Illumina, San Diego, CA, USA).
Sequencing reads obtained from SRT and BrokenHeart libraries were stringently filtered
for features of true insertion events (presence of piggyBac terminal repeat sequence; intact
sequencing adapters, barcodes, and indexes; and a TTAA site) and mapped to build version
mm10 of the mouse genome with Novoalign 3 (Novocraft Technologies) (for SRT) or Bowtie2
(Langmead et al. 2009) (for BrokenHeart). Reads aligning to the same TTAA with separate
barcodes were considered unique insertions, and all analyses in this report considered all unique
insertions equally, independent of read depth. We used BEDtools intersect to count the number
of insertions directed to introns, exons, 3'- and 5'-UTRs, and intergenic regions, using
annotations from the HOMER package (Heinz et al. 2010) (Fig 2.2SE).

Significant insertion peak calling and motif discovery
Significantly enriched insertion peaks were identified via a count-based statistical
comparison as previously described (Moudgil et al. 2019). In brief, this pipeline first segments
the genome into blocks of constant insertion density. For each block, it calculates the p-value of
insertion enrichment relative to a background model assuming uniformly distributed insertions.
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A user-defined significance threshold is defined, and all blocks surpassing this threshold are
considered “significantly enriched insertion peaks”. This “background-free” method for unbiased
identification of all significantly enriched genomic regions in a single experimental sample, used
here in Fig 2.2, is expected to identify all BRD4-bound regions within the parameters of the
calling cards system.
Alternatively, we can define differentially-bound regions between two experimental
samples, as was done in Fig 2.3, Fig 2.6, Fig 2.5S, and Fig 2.6S for astrocyte- or neuronspecific BRD4 peaks (using the combined insertion pools from three GFAP::Cre [n = 3,072,163
insertions] and three Syn1::Cre animals [n = 2,484,133 insertions]) and Fig 2.4 for SP1 peaks
over unfused hypPB. In this analysis, the pipeline again segments the genome into blocks, but
then assigns a p-value to each block based on the differential enrichment between the two
samples. As with the background-free pipeline, a user defined p-value threshold is chosen, below
which all blocks are considered significantly enriched. Because of the natural BRD4-bias of
hypPB, using this differential peak caller allows for identification of binding sites of specific TFs
by selecting genomic locations with re-directed insertion density in a TF-hypPB profile
compared to an unfused hypPB background.
TF motifs were identified with MEME-ChIP v4.11.2 motif discovery software(Bailey et
al. 2009; Machanick and Bailey 2011) with -zoops -meme-minw 6 -ccut 250.

Defining enhancers and super enhancers
Since H3K27ac is a known marker of active enhancers (Creyghton et al. 2010;
Heintzman et al. 2009) and super enhancers (Hnisz et al. 2013; Whyte et al. 2013), we utilized
published P14 mouse cortex (Stroud et al. 2017) and N2a (Kwon et al. 2017) H3K27ac ChIP-Seq
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datasets to define cortical and N2a enhancers super enhancers, respectively. As previously
described (Hnisz et al. 2013; Whyte et al. 2013), we used the rank ordering of super enhancers
(ROSE) v0.1 pipeline and the model-based analysis for ChIP-Seq (MACS) v1.4.1 peak finding
algorithm (Zhang et al. 2008) with a p-value enrichment threshold of 10-9 to define enhancers
and super enhancers. We then used the BEDtools suite (Quinlan and Hall 2010) to compare the
coincidence of enhancers and super enhancers with our unfused hypPB calling cards insertion
peaks (Fig 2.2 and Fig 2.4SC-D).
Additionally, for qualitative measures of histone modification enrichment at calling cards
BRD4 insertion peaks (Fig 2.2), we used publicly available P0 mouse forebrain ChIP-Seq
datasets from ENCODE (Quinlan and Hall 2010); specifically, H3K27ac (ENCSR094TTT),
H3K4me1 (ENCSR465PLB), and H3K27me3 (ENCSR070MOK).

Super enhancer in vitro sensitivity and specificity
Sensitivity and specificity of calling cards peaks were assessed for super enhancer
identification in N2a cells that were either transfected or electroporated with AAV::hypPB and
AAV::SRT plasmids (Fig 2.4S). RNA was separately isolated from a total of 33 wells (i.e.
barcodes) from 6-well plates, and SRTs were sequenced, generating 806,653 unique insertions,
though of note, the majority (651,631) were derived from 12 barcodes that received plasmids via
electroporation. 800,000 unique insertions were randomly selected from the total pool of 806,653
insertions, from which significantly enriched peaks were defined using our background-free peak
calling method at a range of significance thresholds. These peaks were intersected (with
BEDtools intersect) with known N2a super enhancers defined via a previously published N2a
H3K27ac ChIP-seq dataset (Kwon et al. 2017), and sensitivity was defined as the percentage of
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peaks intersecting super enhancers for each peak calling significance threshold. To then define
specificity, we identified the “true negative” space of the genome, and assessed the percentage of
true negative peaks intersected by calling cards peaks. To do this, we first identified any possible
active enhancer region of the genome with MACS peak finding using a low-stringency
significance threshold of 10-1 and subtracted these peaks from the mouse genome, creating a
“true negative” genome. We then sampled peaks (with BEDtools shuffle) within this true
negative genome of the same size distributions as the list of active super enhancers until we
collected an average of 1X coverage across the genome. With a true negative space of
2,616,503,093 basepairs and a total super enhancer size of 23,143,876 basepairs, this required
114 random samplings, resulting in 85,158 true negative peaks. Finally, we intersected our
calling card peaks with these true negative peaks, and specificity was defined as the percentage
of true negative peaks not intersected by a calling card peak. Of note, we expect that unfused
hypPB is driven to super enhancers via interaction with BRD4; thus, sensitivity and specificity
measurements may be higher if compared to BRD4 occupancy rather than H3K27ac.

Analysis of enhancer- and promoter-associated gene expression
Gene expression has been shown to be preferentially regulated by proximal enhancer
elements (Creyghton et al. 2010; Heintzman et al. 2009; Visel et al. 2009). Thus, since a cell
type-specific mapping of enhancers to the genes they regulate is not available, we used proximity
as an imperfect (Maurano et al. 2012) albeit widely used (Ernst et al. 2011) proxy. In our
analyses of cell type-specific expression of genes near cell type-enriched BRD4 calling cards
peaks (Fig 2.3, Fig 2.6, and Fig 2.5S), we first defined the nearest gene (or genes, if multiple
intersected a calling cards peak) to each significant calling cards peak. These gene sets were then

54

filtered and the remaining genes were used for subsequent analyses. Gene sets were filtered as
follows: 1) genes greater than 10,000 bases away from a differential insertion peak were
removed, to eliminate low confidence gene-enhancer pairs, 2) genes near or overlapping multiple
insertion peaks counted once, and 3) genes for which cell type-specific RNA expression data
were unavailable in our comparison dataset were removed.
Unbiased cell type identification was completed with the Cell-type Specific Expression
Analysis (CSEA) tool (Xu et al. 2014) (http://genetics.wustl.edu/jdlab/csea-tool-2/) using
candidate gene sets near either GFAP::Cre enriched or Syn1::Cre enriched insertion peaks. For
each set, we analyzed genes near the most enriched peaks for each cell type. For GFAP::Cre, this
included 131 genes (p<10-21 for associated insertion peaks), of which 114 were present in CSEA
reference sets and used for analysis. For Syn1:Cre, this included 123 genes (p<10-11), with 110
present in reference sets.
For comparison of SP1 binding and gene expression in Fig 2.5A-B, we utilized the
mm10_knownCanonical gene set and mm10_TSS coordinates from the UCSC genes table. We
defined promoter-proximal regions as +/-1000 bases from the TSS. We first filtered
mm10_knownCanonical gene set to remove duplicates (<3% of total genes) and then intersected
gene coordinates with promoter proximal regions. After manually filtering to assign true
promoters to each transcript (i.e. immediately upstream from TSS), we generated a list of unique
promoter/gene combinations (24,528 unique genes) and compared insertion density and gene
expression at these coordinates.
For comparison of P28 and P10 SP1 promoter insertions to RNA expression in Fig 2.5CG, we utilized a previously published RNA-seq dataset (Lister et al. 2013) with RNA expression
data available for week 1 (Wk1) and week 4 (Wk4), which correspond to ~P7 and ~P28,
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respectively. Before assessing P28 or P10 insertion density at promoters, insertion profiles were
downsampled such that each cohort had exactly 240,000 insertions per library (80,000 per mouse
for P10, 3 mice; 60,000 per mouse for P28, 4 mice); thus, insertion totals could be directly
compared without any normalization to library size. Further, this downsampling procedure
eliminates the possibility that any given observed increase in insertion density at P28 was due to
an overall increase in insertion total over time. We then calculated number of insertions at each
unique promoter (using the list of unique promoter/gene combinations generated above) and
removed any gene with no insertions at either timepoint (19,046 / 24,528 unique genes
remaining). A pseudocount of 1 was added to promoter insertion totals for each gene at each
timepoint prior to analysis. To eliminate noise due to low RNA expression and/or random lowfrequency insertion events, we next removed any gene with <6 insertions combined between the
P28 and P10 datasets (including the 2 pseudocounts) or <1 FPKM combined between Wk1 and
Wk4 RNA-seq expression, leaving a final total of 4991 unique gene/promoter combinations
which were used in subsequent analyses. This list of 4991 genes were divided into three
categories, based on their RNA expression at Wk1 and Wk4: (1) early genes; log(Wk4/Wk1
FPKM) < -0.5, (2) constitutive genes; -0.5 < log(Wk4/Wk1 FPKM) < 0.5, and (3) late genes;
log(Wk4/Wk1 FPKM > 0.5. Within these categories, SP1 occupancy was compared between the
P28 and P10 cohorts.

Validation of astrocyte enhancer candidates with PALE (Stogsdill et al. 2017)
Candidate astrocyte-enriched enhancers were selected from the list of GFAP::Creenriched insertion peaks in Fig 2.3 based on three criteria, which select for high-confidence
astrocyte enhancers: 1) enhancer size (smaller than 3kB, for cloning purposes), 2) significant
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GFAP::Cre enrichment (over Syn1::Cre), and 3) astrocyte-specific RNA expression of their
nearest genes. These candidates were PCR amplified with primers listed in the table below and
with an MluI overhang adapter (TGTAGGACGCGT) on either end, and cloned into the miniPdsRed plasmid with MluI, upstream of the hsp68 minimal promoter. As a positive control, the
canonical GFAP promoter (Sakers et al. 2017) was also cloned into this plasmid, in the same
location.
To test efficacy of the candidates for enhancing dsRed expression, each plasmid was
electroporated into lateral ventricle-proximal cells, along with a separate plasmid containing CFP
driven by the canonical GFAP promoter. P0-1 pups were placed on a wet towel on wet ice for 10
minutes to anesthetize. Then plasmids were delivered to the lateral ventricle via intraventricular
injection along with Fast Green FCF dye (Sigma, 2353-45-9), with coordinates approximately
equidistant from the lambdoid suture and the eye, 2mm lateral to the sagittal suture, and 2mm
depth to ensure lateral ventricle penetration. 1l of DNA was delivered into one hemisphere for
each mouse, at a concentration of 1g/l for GFAP::CFP and 0.5g/l for dsRed plasmids.
Electroporation was induced for 5 square pulses, 50ms per pulse at 100V and 950ms inter-pulse
intervals, sweeping the electrodes from the dorsal to lateral using ~25 angle intervals.
Pups were sacrificed at P7 or P21 and brains were collected and analyzed with
immunohistochemistry for CFP and dsRed (CFP and dsRed stained with GFP and RFP
antibodies, respectively, as indicated in methods). Individual astrocytes were imaged for
intensity analysis in Fig 2.3E-F, Fig 2.6SF,H, and Fig 2.7SA,C using equivalent exposure
settings. A region of interest (ROI) was defined around the astrocyte based on CFP only, and
dsRed and CFP fluorescence was quantified within the ROI using ImageJ (v. 1.51s). This was
done from 3 brains (34-42 cells) per condition at P7 and from 2 brains (28-32 cells) per condition
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at P28 (except pGFAP, which only had 1 brain and 17 cells used in quantification at P28, as this
was a positive control sample). The ratio of CFP:dsRed was calculated for each cell and
averaged and compared across conditions for final assessment of dsRed enhancement. For P7 colocalization quantifications in Fig 2.6SG, dsRed(+) cells were manually counted from 3 brains
(150 total cells) per condition, while P21 quantifications in Fig 2.7SB were taken from 2 brains
(287-769 total cells) per condition (again, the positive control, pGFAP had 1 brain, 67 total cells
used in quantifications).
eCandidate

Forward primer

Reverse primer

eRasa2

TTCATGAACTCTGTTACTAGTTTGT

TTTTAAACAGATGAGCTGGAGCC

eTaf4b

ATATTGGATCTCACTGGAGTTGC

TCAAAGTCTAGATTTAGGCATGAT

ePla2g7

ACAGAACAGACTCACATAAACTTGT

CCATTGTCACATCTAGTCATCAGT

eMms22l

GCTTATTTAAAATGAAAAGA

AAATTCCCTTAAACCCCCCTG

Statistical analyses
Statistical tests were done with GraphPad Prism v8.1.2 and are detailed in figure legends.
For box-and-whisker plots, central tendency line represents median, box represents 25th-75th
percentiles, and whiskers represent minimum and maximum values.

Data availability
All raw and processed data is available through GEO accession GSE128493
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128493) and the access token is
eroromaodhabzkz. Figures containing raw data include: 2.2, 2.3, 2.4, 2.5, 2.6, 2.2S, 2.4S, 2.5S,
and 2.6S. Supplemental tables containing information about significant peaks and figure-specific
analyses are also available upon request.
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Code availability
Calling card analysis software were developed previously (Moudgil et al. 2019) and are
available upon request.
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Results
Intracranial delivery of calling cards via AAV invokes widespread transposon insertion in the
mouse cortex.
In order to perform transposon calling cards in mammalian cells, two basic components
are required: the hypPB transposase (or a TF-hypPB fusion) and donor transposons (Wang et al.
2012). We sought to develop an in vivo method to efficiently deliver calling card components
throughout the mouse brain to identify TF-associated sites. We first tested AAV as a means for
calling card reagent delivery, as viral piggyBac delivery methods have been successful in other
organ systems previously (Cooney, Singh, and Sinn 2015; Smith et al. 2015). We packaged a
myc-tagged version of hypPB and donor transposons carrying TdTomato reporter genes into
separate AAV serotype 9 (AAV9) vectors, which efficiently transduce neuron and astrocyte
populations (Hammond et al. 2017), and intracranially injected these vectors into the cortices of
postnatal day 0-1 (P0-1) mice. Animals were sacrificed at P21 for analysis (Fig 2.1A). We
analyzed hypPB expression with in situ hybridization (Fig 2.1SA) and transposon-derived
TdTomato immunofluorescence (Fig 2.1B) across the brain and observed widespread viral
transduction in the neocortex, hippocampus, and inner brain structures. As expected with the
AAV9 serotype (Hammond et al. 2017), the vast majority of transduced cell types were neurons
and astrocytes (Fig 2.1C-D). These results demonstrate that calling card reagents can be
efficiently delivered to the mouse brain by AAV.
Earlier implementations of the calling cards method (e.g. BrokenHeart) mapped
transposon insertions by directly sequencing genomically-inserted transposon DNA (Wang et al.
2011, 2012) (Fig 2.2SA-B). However, our group recently developed a specialized calling cards
donor transposon, termed a “self-reporting transposon” (SRT), which allows for amplification of
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each insertion via RNA transcription and highly efficient mapping of transposition events
through deep sequencing of transposon-derived RNA (Moudgil et al. 2019) (Fig 2.2SA,C). We
first sought to directly compare traditional DNA calling cards (BrokenHeart) to RNA calling
cards (SRT) in AAV systems. To do this, we intracranially injected P0-1 mice with AAV::hypPB
and either AAV::BrokenHeart or AAV::SRT. At P21, we isolated DNA or RNA from cortex
samples and generated and sequenced calling cards libraries (Fig 2.2SB-C). We found that SRT
reads mapped much more consistently to the mouse genome than BrokenHeart, where the
majority of alignment was to the original AAV episomal sequence. We then mapped transposon
insertions from these reads. While insertions from the two methods reliably mapped to similar
genomic locations, we were able recover an order of magnitude greater total number of
insertions from animals receiving AAV::SRT compared to those receiving AAV::BrokenHeart
(Fig 2.2SE-F). In summary, we found that SRTs provide a much greater sensitivity for
recovering insertion events from AAV than traditional DNA methods. Finally, we tested whether
SRT calling cards could also be delivered efficiently via adult intraparenchymal stereotactical
cortical injection to precise coordinates, as this is more standard for AAV delivery than P0-1
injection. Indeed, after delivery of AAV::hypPB and AAV::SRT to three P107 adult mice
(euthanized one month later, at P136), we observed a near-equivalent read mapping rate (Fig.
2.2SD), insertion total (Fig. 2.2SE), and insertion localization (Fig. 2.2SF) as in P0-1 SRT
delivery. Thus, AAV calling cards systems are functional in vivo and can be delivered to the
mouse brain at various timepoints and to targeted locations.
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AAV calling cards delivery to the mouse brain does not induce excess degeneration, weight loss,
or behavioral/developmental defects.
An important question with all calling card technologies is whether continued transposon
insertion is deleterious, particularly after long-term delivery to a living mammalian system such
as the mouse brain. To address this question empirically, we intracranially delivered either
calling card viruses (AAV::hypPB/AAV::SRT) or control viruses (RFP only) to P0-1 mouse
pups, and then assessed neuronal degeneration, attainment of developmental milestones, anxiety
related behavior, and balance/strength/coordination during the first 4 weeks of life. Four weeks
after viral delivery, a small population of degenerating cells were found in the cortex, near the
injection site, however there was no significant difference between calling card and RFP-only
injected animals, suggesting that the observed degeneration was likely due to needle injury (Fig
2.1E-F). Likewise, no significant differences were observed in weight, righting from back, or
edge/center dwelling, indicating that calling cards-injected animals develop normally and display
no overt anxiety-like behavior (Fig 2.1G and Fig 2.3SA-C). Finally, in a sensorimotor battery,
calling cards-injected animals displayed a largely normal phenotype, with only one test (60
inclined screen climbing) having a significant reduction compared to RFP-only controls. Further,
these animals performed normally on the 90 inclined screen and inverted screen tests, which are
even more difficult tests of balance and strength than the 60 inclined screen (Fig 2.1H and Fig
2.3SD-I). In summary, AAV calling card reagents did not result in excess degeneration, weight
loss, or behavioral/developmental defects, suggesting that genomic transposon insertion does not
introduce significant toxicity or deleterious effects to the animal.
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Figure 2.1. Co-AAV9 intracranial injection efficiently delivers calling cards to the cortex.
Figure
(A) Experimental
1
paradigm and AAV constructs. Arrows represent approximate AAV injection sites. (B) Coronal

section of brain injected unilaterally at P0-1 with AAV::hypPB and AAV::SRT, displaying widespread expression
of SRT-derived TdTomato fluorescence throughout the brain (C,D) Co-immunofluorescence showing hypPB
expression in neurons and astrocytes. (C) Representative images display co-localization of hypPB with neuronal
(NeuN) and astrocyte (GFAP) markers in the cortex and hippocampus. HypPB is myc-tagged allowing for
visualization with myc-specific antibodies. Arrowheads show examples of hypPB-positive astrocytes. (D) Majority
of hypPB(+) cells transduced with AAV9 are NeuN(+) neurons and GFAP(+) astrocytes (n=1005 myc(+) cells,
counted across cortical image fields from 5 mice). (E) Representative images of silver staining in dorsal cortex to
screen for degenerating cells (black arrows) in mice intracranially injected at P0-1 with (top) red fluorescent protein
(AAV::RFP only) or (bottom) calling cards viruses (AAV::hypPB and AAV::SRT) and sacrificed at P28. (F)
Quantification of silver-positive cells in dorsal cortex revealed injection with either virus produces limited
neurotoxicity that did not significantly differ between groups (two-tailed, unpaired Student’s t-test, p > 0.05). (GH) Mice injected at P0-1 with AAV calling cards (n=21) or control, RFP only (n=24) viruses displayed no significant
differences in anxiety related behavior (center/edge dwelling; G) or motor skills (inclined screen test; H) relative to
control. See Fig 2.3S for further behavioral and developmental assessments of these groups. All group comparisons
were done with two-tailed, unpaired Student’s t-test, with Bonferroni corrected =0.05 as a significance threshold
(including all tests in Fig 3S).
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Unfused hypPB delivered with AAV profiles active REs in the brain.
BRD4 acts as a “chromatin reader” by binding to acetylated lysine residues on histones
(Jung et al. 2014; Kanno et al. 2004, 2014) and regulating gene transcription (LeRoy, Rickards,
and Flint 2008; Mochizuki et al. 2008). Accordingly, BRD4 is strongly associated with active,
TF-bound REs, most prominently super enhancers (Hnisz et al. 2013; Whyte et al. 2013).
Importantly, BRD4 has a known affinity for the unfused hypPB protein (Gogol-Doring et al.
2016), and consequently unfused hypPB insertions are greatly enriched at known BRD4 binding
sites (Gogol-Doring et al. 2016) such as super enhancers (Yoshida et al. 2017). Thus, we aimed
to test the hypothesis that unfused hypPB transposon insertion can be used to identify active REs
in the brain (Fig 2.2A).
We first analyzed the sensitivity and specificity of unfused hypPB insertions for
identification of active super enhancers in vitro in neuroblastoma (N2a) cells. While N2a’s do
not represent epigenetic regulation in vivo (only 20.9% of super enhancers are shared between
N2a cells and P14 mouse cortex), this pure population allows for assessment of sensitivity and
specificity without complex cellularity or serotype/transduction variability. To do this, we
transfected these cells with hypPB and SRT plasmids, from which we collected a total of
806,653 insertions. We then downsampled this library into randomly selected pools of various
insertion totals and used peak calling to identify regions of significantly enriched insertion
density in each pool, at a range of significance thresholds. Using a previously published N2a
H3K27ac ChIP-seq dataset (Kwon et al. 2017) to independently define active super enhancers in
this population, we assayed sensitivity and specificity of calling card insertion peaks for
identifying these regions. From this, we observed that calling card peaks are highly specific for
active super enhancers across a range of sensitivities, with a high area under the receiver-
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operator characteristic curve (0.82; Fig 2.4SA). Further, we observed a high sensitivity for super
enhancer identification, even at low insertion totals (e.g. sensitivity of up to 0.8 from only 10,000
insertions), that increases steadily with increasing number of insertions (Fig 2.4SB). Thus,
unfused hypPB calling card profiles can be used to identify active super enhancers in vitro.
We next asked whether AAV::hypPB could identify active REs, including super
enhancers, in the brain. To do this, we combined all 3,732,694 insertions collected from two
mice injected with AAV::hypPB and AAV::SRT at P0-1 and defined significantly enriched
insertion peaks (7,031 peaks; p<10-30), which we predict to be BRD4-bound REs. We observed
that insertion density at these peaks was highly correlated between the two animal replicates,
indicating a high reproducibility of this method (Fig 2.2B). To assess whether insertion peaks
represented active REs, we compared our calling card data to ENCODE ChIP-seq datasets
(Hammond et al. 2017) of enhancer-associated histone modifications (Heintzman et al. 2009) in
the developing mouse cortex. At the 7,031 significantly enriched insertion peaks, we observed a
strong enrichment of active enhancer-associated histone modifications H3K27ac and H3K4me1
and a de-enrichment of the repressive mark H3K27me3 (Fig 2.2C-F). We then used a previously
published (Stroud et al. 2017) H3K27ac ChIP-seq data from P14 mouse cortex to independently
define active enhancers and super enhancers and asked whether calling card peaks significantly
overlapped these regions. We observed that the majority of insertion peaks intersected with
H3K27ac-defined enhancers, significantly higher than when insertion peak coordinates are
randomized (Fig 2.2G). Similarly, calling card peak intersection with super enhancers is also
significantly higher than chance (Fig 2.2H). As expected for a BRD4-mediated mechanism,
unfused hypPB calling card profiles identify only a subset of all enhancers, but do intersect the
majority of super enhancers (Fig 2.2I-J). Of note, the reference ChIP-seq dataset used for
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enhancer and super enhancer identification encompasses REs from all cortical cell types, while
calling card peaks are derived only from transduced cells (i.e. neurons and astrocytes), thus
likely underrepresenting RE sensitivity. Further, this overlap analysis was performed using our
standard, highly rigorous significance threshold for peak calling (p=10-30), however we have also
performed these analyses at a range of p-value thresholds to confirm the finding is robust to this
parameter (Fig 2.4SC-D). Together, these data support that AAV calling card insertion profiles
of unfused hypPB can be used to identify putative REs in the brain.
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Figure 2.2. Unfused hypPB-directed calling cards insertions identify active enhancers and super enhancers in
the brain.
(A) Unfused hypPB endogenously interacts with BRD4 and is redirected toward sites of BRD4 occupancy, i.e.
enhancers and super enhancers. (B) Normalized insertion totals in two littermate C57BL/6J mice (Rep1 and Rep2) at
7031 significantly-enriched insertion peaks (p<10-30) displaying high correlation between replicates (R=0.994). (C-F)
Unfused hypPB-directed insertions are highly enriched for the active enhancer marks H3K27ac and H3K4me1 and
depleted for suppressive mark H3K27me3. Representative image (C), heatmaps, and enrichment plots (D-F) of
H3K27ac, H3K4me1, and H3K27me3 density at 7031 significantly-enriched insertion peaks in two littermate mice.
In (C), top track of each insertion replicate displays unique insertions, where each circle = 1 unique insertion and yaxis represents number of reads supporting each insertion on a log10 scale, and bottom track displays normalized local
insertion density across the genome (insertions per million per kB). Y-axis of ChIP-seq data represents read depth with
smoothing filter applied. Heatmaps and enrichment plots are centered on insertion peaks and extend 10kB in either
direction. Relative enrichment quantifications displayed in log2(fold-change over ChIP-seq input). (G,H) Percentage
of 7031 significantly-enriched insertion peaks with at least 1 basepair (bp) intersection with a H3K27ac-marked
enhancer or super enhancer. Gray bar represents intersections after randomizing genomic coordinates of insertion
peaks. 2 test with Yates correction: p<0.0001. (I,J) Percentage of H3K27ac-marked enhancers and super enhancers
with at least 1 bp intersection with a significantly-enriched insertion peak. 2 test with Yates correction: p<0.0001.

Figure 2
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FLEX calling cards system allows for cell type-specific profiling of REs in the brain.
Gene-based TF-tagging systems such as calling cards offer the potential for cell typespecific profiling through conditional expression of the TF-enzyme fusion. Thus, we generated a
Cre-dependent calling cards system, termed FLEX calling cards, and tested the ability of this
system to record cell type-specific RE activity or TF binding in complex tissues without isolation
of the cell population of interest. In the FLEX system, the reverse complement of the hypPB or
TF-hypPB gene is positioned downstream of a strong, ubiquitous promoter and is flanked by two
sets of loxP sites. In the presence of Cre, the transposase gene is flipped to the correct orientation
and is expressed. To confirm Cre-dependence of the FLEX system, we co-transfected the Credependent hypPB plasmid, hypPB FLEX, into HEK293T cells along with the BrokenHeart
reporter plasmid (Fig 2.5SA), which expresses TdTomato only after genomic transposon
insertion (Qi, Michael Nathaniel Wilkinson, et al. 2017). 24-hours post-transfection, we observed
BrokenHeart-derived TdTomato fluorescence only in cells that received both the FLEX calling
card constructs and a Cre expression plasmid, demonstrating that this system is Cre-dependent
(Fig 2.5SA).
As a proof of principle, we focused on two prominent and well-studied Cre-driver mouse
lines, Syn1::Cre and GFAP::Cre, which direct expression to neurons and astrocytes, respectively.
We packaged the hypPB FLEX plasmid into the AAV9 vector and intracranially co-injected it
along with AAV::SRT into P0-1 mouse pups of either the Syn1::Cre or GFAP::Cre genotype,
along with Cre(-) littermates as controls. We euthanized the animals at P28, isolated cortical
RNA, and sequenced and mapped insertions across the genome (Fig 2.3A). Immediately
apparent upon sacrifice was that brains of Syn1::Cre positive animals were noticeably more red
than their negative littermates, even to the naked eye (Fig 2.5SB), a result of the transposition-
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enhanced TdTomato reporter expression derived from AAV::SRT. This change in color was
striking for Syn1::Cre brains, but not as apparent in GFAP::Cre animals, an observation that is
consistent with the relative abundances of transduced neurons and astrocytes (Fig 2.1C-D). In
Syn1::Cre brains, we analyzed TdTomato expression with immunofluorescence and noted a
marked increase in neurons of Cre(+) animals but not Cre(-) littermates (Fig 2.5SC). We then
sequenced insertions in Cre(+) and Cre(-) littermates from each line and observed a significant
increase in insertion events in positive animals as compared to their negative littermates (Fig
2.5SD).
We next sought to test whether FLEX calling cards with unfused hypPB could identify
cell type-specific REs. To do this, we identified insertion peaks that were differentially enriched
in either Syn1::Cre over GFAP::Cre or GFAP::Cre over Syn1::Cre by a count-based statistical
comparison (Fig 2.3B). We then asked whether genes near these differentially enriched peaks are
more likely to be expressed in neurons or astrocytes, using a previously published and widely
used cell type-specific RNA-seq dataset (Zhang et al. 2014). As predicted, we found that as our
significance threshold for defining differentially enriched insertion peaks became more stringent,
the RNA expression of proximal gene sets became more cell type-specific (Fig 2.5SE-F). At a
stringent significance threshold of p=10-7, we compared all nearest genes to Syn1::Cre or
GFAP::Cre enriched insertion peaks, and found significant differences in astrocyte versus neuron
expression in the expected directionalities (Fig 2.3B and Fig 2.5SG). Of note, these neuron and
astrocyte RNA enrichments were observed despite using proximity as a means for enhancer-gene
pairing, which while widely used for analyses such as these (Ernst et al. 2011), is likely only
identifying the correct gene of interest in a subset of pairs (Maurano et al. 2012). Lastly, we
inputted these gene sets into an unbiased cell type-identification tool (CSEA (Xu et al. 2014))
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and successfully identified cortical astrocyte and neuron populations for genes near GFAP::Cre
and Syn1::Cre enriched insertion peaks, respectively (Fig 2.5SH-I). Together, these data indicate
that peaks derived from FLEX calling cards insertion profiles recorded by unfused hypPB
represent cell type-specific REs responsible for driving expression of cell type-enriched genes.
Lastly, we sought to functionally validate the enhancer activity of a subset of the novel
astrocyte-enriched REs by testing whether these regions could enhance the expression of a dsRed
reporter gene in astrocytes in vivo. We chose 4 candidate astrocyte-enriched REs, based on their
size, cell type-specific activity, and astrocyte/neuron RNA expression of their nearest genes (Fig
2.6SA-E). We then cloned these candidate REs upstream of the hsp68 minimal promoter driving
a dsRed reporter gene. As a positive control, we also cloned the canonical GFAP promoter
(pGFAP) (Sakers et al. 2017) into the same location upstream of hsp68::dsRed (Fig 2.3C). To
test the functional enhancer activity of these REs in vivo, we delivered these plasmids, along
with a separate plasmid carrying a CFP reporter under the GFAP promoter for astrocyte
identification, via postnatal astrocyte labeling electroporation (PALE) (Stogsdill et al. 2017). At
P7, mice were euthanized and brains were collected for immunohistochemistry. This method
specifically targeted astrocytes in the cerebral cortex, noting that >96% of dsRed(+) cells in this
region were also GFAP::CFP(+) (Fig 2.6SF-G). As expected, the positive control (pGFAP
hsp68::dsRed) plasmid exhibited enhanced dsRed fluorescence in astrocytes, relative to a
negative control plasmid carrying only hsp68::dsRed, that approached statistical significance
(p=0.055; Fig 2.3D-E and Fig 2.6SF,H). We then quantified enhancer activity of our candidate
REs and observed a significant enhancement of dsRed fluorescence for three of the four
candidates (Fig 2.3D-E and Fig 2.6SF,H). Thus, these astrocyte-enriched REs display functional
enhancer activity in astrocytes in the mouse brain at P7. Next, we repeated this experiment
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allowing mice to age to P21 to allow further astrocyte maturation prior to euthanasia. To our
surprise, at this timepoint we observed a change in localization of dsRed expression in brains
receiving the minimal promoter hsp68::dsRed construct, with fewer GFAP::CFP(+) astrocytes
and a new population of NeuN(+) neurons labeled with dsRed in the cortex (Fig 2.7SA-B). This
suggests that the PALE method does deliver plasmids to neurons or neural progenitors in
addition to astrocyte progenitors, but that expression via the hsp68 promoter in neurons does not
arise until later in postnatal development. Strikingly however, in animals that received pGFAP
hsp68::dsRed or any of the RE candidate plasmids, dsRed expression was contained to
GFAP::CFP(+) astrocytes, suggesting that in addition to enhancing expression in astrocytes,
these RE sequences also repress activity of hsp68 in neurons (Fig 2.7SA-B). Additionally, as in
the P7 experiment, we observed increased dsRed expression within GFAP::CFP(+) astrocytes for
all RE constructs relative to hsp68::dsRed only, of which two reached statistical significance
(Fig 2.7SC). Indeed, even eMms22l, which was not yet active at P7, displays these functional
enhancer phenotypes at P21. Overall, these data demonstrate that cell type-specific REs derived
from FLEX calling cards functionally regulate cell type-specific gene expression in the brain.
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Figure
Figure
2.3.3 FLEX calling cards system generates cell type-specific RE profiles.
(A) AAV::hypPB FLEX construct and experimental design in Syn1::Cre and GFAP::Cre animals. (B) (bottom)
Examples of differentially enriched insertion peaks near genes preferentially expressed in neurons (right) or
astrocytes (left). (top) Quantifications of neuron and astrocyte specific expression of genes near (C) GFAP::Cre
[Neuronmedian = 4.16 FPKM, Astrocytemedian = 6.38 FPKM, n = 1180 genes] or (D) Syn1::Cre [Neuronmedian = 4.55
FPKM, Astrocytemedian = 0.78 FPKM, n = 540 genes] enriched insertion peaks at a stringent peak-calling
significance threshold (p=10-7) showing significant preferential expression in the expected cell type (two-tailed
Mann-Whitney U test: p<0.0001). (C) A GFAP::Cre enriched insertion peak proximal to the Pla2g7 gene
(ePla2g7; see Fig 2.6SE for peak coordinates) was cloned into a plasmid upstream of the hsp68 minimal promoter
and a dsRed reporter gene and co-delivered along with a GFAP::CFP plasmid to ventricle-proximal glia, including
astrocytes, with postnatal astrocyte labeling electroporation (PALE)(Stogsdill et al., 2017). (D) Expression of
dsRed is enhanced by both the canonical GFAP promoter (pGFAP; positive control) and ePla2g7. (E)
Quantification of dsRed expression enhancement in CFP(+) astrocytes by pGFAP and ePla2g7. n=34-42 CFP(+)
cells from 3 brains per condition (one-way ANOVA with Dunnett’s multiple comparisons test; ****p<0.0001).
pGFAPmean diff. = 0.66, 95% C.I.diff [0.01 : 1.33]. ePla2g7mean diff. = 1.22, 95% C.I.diff [0.58 : 1.86].
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Fusion of hypPB to the promoter-binding transcription factor SP1 records SP1 occupancy
A key feature of calling cards is the ability to record binding of a TF of interest using TFhypPB fusions. To demonstrate calling card in vivo TF recording with AAV calling cards, we
fused hypPB to a sequence-specific DNA-binding general TF, SP1, which binds to gene
promoters and is involved in transcription (Beishline and Azizkhan-Clifford 2015; Li et al.
2004), and cloned this fusion gene into the FLEX calling cards system for cell type-specific use
(Fig 2.4A). As full length SP1 is too large to be efficiently packaged into AAV, we instead used
a truncated version of SP1 containing the C-terminal 621 amino acids, which includes the DNAbinding domain and has been shown to be sufficient to replicate sequence-specific binding of full
length SP1 (Kadonaga et al. 1988). To test this system, we intracranially co-injected
AAV::SP1(621C)-hypPB FLEX along with AAV::SRT into P0-1 mice of the Syn1::Cre line,
sacrificed animals at P28, generated and sequenced SRT libraries from cortical RNA samples,
and compared insertion profiles to that of unfused hypPB. Consistent with the affinity of SP1 for
proximal promoters, we found that insertions were significantly enriched upstream of TSS, as
compared to unfused hypPB insertion profiles (Fig 2.4C). Next, we defined differentially
enriched insertion peaks in SP1(621C)-hypPB profiles over unfused hypPB (p<10-15) and found
that the majority of significant enrichments occur in gene promoters (Fig 2.4D-E). Finally, at
these SP1 peaks, we performed motif discovery and identified the canonical SP1 binding motif,
GGGCGGGG (Wang et al. 2012) (Fig 2.4F). Thus, fusion of SP1 to hypPB and delivery via
AAV identifies SP1 binding sites in the mouse brain.
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Figure 2.4. Fusion of SP1 to hypPB in AAV calling cards system records SP1 occupancy.
(A) Schematic of AAV::SP1(621C)-hypPB FLEX construct. (B) Fusion of the promoter-binding TF SP1 to
hypPB directs insertions to promoter-proximal TTAA sites. (C) Percentage of total insertions within 1000
4
basepairs (bp) of a transcription start site (TSS), Figure
displaying
increased promoter-directed insertions upon SP1
fusion as compared to unfused hypPB (n = 3-4 mice per group; two-tailed, unpaired Student’s t-test: p<0.001,
t=7.66, df=5, 95% C.I.diff [9.22 : 18.54]; unfused hypPBmean = 6.9%, SP1(621C)-hypPBmean = 20.8%). Error bars
represent SD. Total SP1(621C)-hypPB insertions: 1,083,099. Total unfused hypPB insertions: 2,484,133. (D)
Percentage of significant SP1 insertion peaks differentially enriched over unfused hypPB (p<10 -15; 1596
intersecting out of 2316 total peaks) intersecting promoter-proximal regions (1000bp on either side of TSS)
compared to randomized peak coordinates (78/2316). 2 test with Yates correction: p<0.0001. (E) Representative
insertion peak displaying significantly increased insertion density near the TSS of the Plrg1 gene. (F) Highest
information content motif in the sequences flanking the center of significantly enriched SP1(621C)-hypPB
insertion peaks (p<10-15) is the canonical SP1 binding motif (GGGCGGGG; p<10-42).
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FLEX calling cards provides historical TF binding information through longitudinal TF
recording
An intriguing potential use of calling card technologies is in the recording of TF binding
over an integrated period of time. Such a method, which is not possible with endpoint TF
profiling methods such as ChIP-seq or CUT&Tag, could empower novel studies in which
historical TF binding information would be useful, such as during cellular development or
differentiation. Further, by integrating signal over time, longitudinal calling cards may report
transient binding events which would be otherwise missed with endpoint-only measures.
To test whether FLEX calling cards could report integrated, historical TF occupancy, we
asked whether we could recover transient SP1 promoter binding events and successfully read
them out at a later date. Importantly, consistent with the known role of SP1 in regulating gene
expression (Beishline and Azizkhan-Clifford 2015; Li et al. 2004; Wang et al. 2012), we
observed that expression of genes genome-wide was on average correlated with the number of
SP1-directed promoter insertions (Fig 2.5A-B). Thus, we predicted that should a gene be
expressed early, but not late, in the lifetime of the animal, this transient event could be marked
by SP1 binding and be recoverable via SP1 calling cards at a later timepoint.
To test this hypothesis, we intracranially co-injected AAV::SP1(621C)-hypPB and
AAV::SRT into two separate cohorts of P0-1 mice. The first cohort was euthanized at P10, while
the second cohort was allowed to continue to record SP1 occupancy until P28 (Fig 2.5C). This
time period of postnatal brain development involves several key neurodevelopmental processes
(Semple et al. 2013), including substantial hippocampal neurogenesis (Khalaf-Nazzal and
Francis 2013) as well as glial and synaptic maturation (Semple et al. 2013), development of the
extracellular matrix (Semple et al. 2013), and closing of critical periods (Semple et al. 2013),
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which are accompanied by numerous changes in gene and protein expression (Laeremans et al.
2013). For these analyses, we utilized a previously-published cortical RNA-seq dataset (Lister et
al. 2013) with postnatal timepoints of 1 week (Wk1; ~P7) and 4 weeks (Wk4; ~P28). From these
expression data, we then derived and tested three separate predictions (Fig 2.5C). First, for genes
expressing at Wk1 but not Wk4, (i.e. “early genes”) we would observe near-equivalent SP1
binding at promoters in both cohorts. Second, for constitutive genes that express equally at Wk1
and Wk4, we would observe continued integration of SP1 binding in the P28 cohort, resulting in
increased SP1 insertion density at promoters. And third, for genes expressing only at Wk4 (i.e.
“late genes”), we would observe SP1 promoter binding only in the P28 cohort. We defined early
genes as having a log(Wk4/Wk1 FPKM) of less than -0.5 (n = 292), late genes as greater than
0.5 (n = 285), and all genes in the middle as constitutive (n = 4413; Fig 2.5D-E). Indeed, at the
promoters of these gene sets, we observed SP1 promoter occupancy to be consistent with our
three predictions (Fig 2.5E; example early and late genes, Idh1 and Gjb6, displayed in Fig 2.5F
and Fig 2.5G, respectively). Importantly, at the promoters of early genes, we observed nearequivalent binding in the P10 and P28 cohorts (mean P28:P10 SP1 promoter insertion ratio =
0.98), despite these genes only being transiently expressed; thus, this system is capable of
permanently recording transient TF binding events for retrospective read out at a later date.
Together, these data support that TF-hypPB fusions integrate signal over time and provide a
historical, integrated picture of TF occupancy.
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Figure 5

Figure 2.5. Longitudinal SP1 profiling reports integrated record of SP1 binding.
(A-B) Normalized number of SP1(621C)-hypPB directed insertions at promoter proximal regions after
subtraction of unfused hypPB insertions, versus neuron-specific gene expression for all genes, binned and
averaged into 100-gene bins. In (A), left y-axis represents number of promoter insertions normalized to 106 total
insertions in the sample and right y-axis displays neuron-specific RNA expression from Zhang et al., Journal of
Neuroscience, 2014. (B) displays strong correlation of SP1(621C)-hypPB promoter insertions with gene
expression after subtraction of unfused hypPB insertions (R=0.96, p<0.0001). (C) Experimental paradigm and
predicted temporal SP1 occupancy for early, constitutive, and late expressing genes. (D) Distribution of
Wk4/Wk1 expression ratios for all expressed and SP1-bound genes. (E) (top) Categorization of genes into “early”
(log(Wk4/Wk1 FPKM) < -0.5), “constitutive” (-0.5 < log(Wk4/Wk1 FPKM) < 0.5), and “late” (log(Wk4/Wk1
FPKM) > 0.5) gene sets. RNA-seq from Lister et al., Science, 2013. (bottom) SP1-derived promoter insertions
for early, constitutive, and late gene sets, demonstrating efficient capture of transient SP1 binding events at early
gene promoters and continued integration of constitutive and late gene promoters in the P28 cohort relative to the
P10 cohort (One-way ANOVA [F(2, 4987) = 16.92], p<0.0001). Early genes mean = 0.98, const. genesmean = 1.25,
late genesmean = 1.45. Red square = mean, line = median. (F-G) Example of an (F) early expressed gene (Idh1)
displaying equivalent SP1 binding in both cohorts and a (G) late expressed gene (Gjb6) displaying SP1 binding
only in the P28 cohort. Left bar graph displays reference RNA-seq read counts from Lister et al., Science, 2013,
while right bar graph displays our own confirmatory RT-qPCR from brains of C57bl6/J mice at P7 and P28.
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FLEX splicing variant, “AAV::hypPB Frontflip,” reduces Cre-independent transposition
During our analysis of FLEX calling cards in neurons and astrocytes we observed the
presence of some background transposition activity in Cre(-) animals (Fig 2.5SD), which could
impinge on our ability to apply FLEX calling cards to analyze more rare cell populations. We
hypothesized that this aberrant hypPB expression could be due to cryptic transcription of the
hypPB gene on the antisense strand of the AAV::hypPB FLEX sequence, which would result in
expression independent of Cre-mediated flip-excision. To overcome this, we designed a variant
FLEX construct in which only the N-terminus of hypPB is present within the FLEX cassette and
is flanked by the 5’ end of a synthetic intron(Younis et al. 2010), the 3’ end of which is located
upstream of the hypPB C-terminus. Thus, aberrant transcription in either direction would
produce only a non-functional, truncated hypPB protein. However, upon Cre recombination, the
N-terminal hypPB segment is flipped in frame with its C-terminus, split by the newlyreconstituted artificial intron which will then be spliced out of the nascent RNA, producing a full
length, functioning hypPB. We coined this FLEX variant “hypPB Frontflip” (Fig 2.6A).
We first tested the ability of hypPB Frontflip to reduce Cre(-) backround in vitro by cotransfecting it into HEK293T cells along with the BrokenHeart reporter transposon. Previously,
we had shown that the original hypPB FLEX construct produces no Cre-independent
transposition in vitro at 24-hours post-transfection (Fig 2.5SA). However, at 96-hours posttransfection, we began to observe some background transposition in the absence of Cre,
mimicking our in vivo results. In contrast, the hypPB Frontflip variant eliminated this Creindependent transposition in vitro (Fig 2.6B). We then packaged hypPB Frontflip into an AAV9
vector and intracranially co-injected it with AAV::SRT into GFAP::Cre animals at P0-1. At P28,
we observed a significant and dramatic reduction in Cre-independent insertions in Cre(-) animals
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accompanied by a >30-fold increase in Cre(+) littermates (Fig 2.6C). To confirm that these
insertions were indeed astrocyte-derived, as we had previously done with the original
AAV::hypPB FLEX, we identified differential BRD4 binding peaks compared to the Syn1:Cre
line and analyzed the cell type expression patterns of proximal genes. Indeed, we found that
genes near differential binding peaks again exhibited increased expression in astrocytes, as
expected (Fig 2.6D). In summary, AAV::hypPB Frontflip is a tightly Cre-controlled conditional
expression viral system, which will allow for the implementation of AAV calling cards in more
rare cell types in the future.
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Figure 2.6. AAV::hypPB Frontflip reduces Cre-independent
Figure 6 transposition in vitro and in vivo
(A) Schematic of AAV::hypPB Frontflip. Prior to Cre-mediated recombination, hypPB is split into its N- and Ctermini, with the N-terminus in reverse orientation and inside a FLEX cassette. On the 3’ end of the N-terminus
is the splice donor (SD) and 5’ end of an artificial intron. On the 5’ end of the C-terminus is the splice acceptor
(SA) and 3’ end of the intron. Upon recombination, the N-terminal fragment is flipped into frame and the artificial
intron is reconstituted. This sequence is then transcribed into mRNA, spliced, and translated into an uninterrupted,
functional hypPB protein. (B) hypPB FLEX or hypPB Frontflip plasmids were co-transfected into HEK293T
cells along with the BrokenHeart fluorescent transposition reporter. At 96-hours post-transfection, Cre(-)
background is observed from hypPB FLEX, but not hypPB Frontflip. For quantification of fluorescent imaging
(left graph): n=2 wells per condition, 3 images per well. For flow cytometry (right graph): n=2 wells per condition.
(C) AAV::hypPB Frontflip significantly reduced transposition in Cre(-) animals (<10,000 insertions per brain),
with a >30-fold increase in insertion total in Cre(+) animals (two-tailed, unpaired Student’s t-test: *** p<0.001).
GFAP::Cre (+) vs (-): p=0.00031, t=11.63, df=4, 95% C.I.diff [129,913 : 211,436]. (D) Quantifications of neuron
and astrocyte specific expression of genes near GFAP::Cre [Neuronmedian = 3.96 FPKM, Astrocytemedian = 9.10
FPKM, n = 615 genes] enriched insertion peaks, called via AAV::hypPB Frontflip data (p<10 -7), showing
significant preferential expression in astrocytes (two-tailed Mann-Whitney U test: p<0.0001).
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Discussion
In this report, we have successfully developed an in vivo, virally mediated calling cards
approach, for which we have demonstrated utility for TF and RE profiling in the live mouse
brain. This technology builds on previously developed in vitro calling card methodologies,
adapting this method for investigation of epigenetic regulation in the mammalian brain. Further,
in proof-of-principle experiments, we demonstrated effectiveness of this protocol for 1) profiling
TFs without an antibody, 2) cell type-specific RE profiling without cellular population
purification, and 3) integrative recording of TF binding events over time. Our use of SRTs in this
paradigm now also enable calling cards for single cell analyses (Moudgil et al. 2019), which
expands and highlights the versatility of this toolkit in future studies.
Calling cards technologies, as gene-based systems, have several unique features that
provide advantages over biochemical TF profiling methods such as ChIP-seq for certain
applications (Qi, Wilkinson, et al. 2017; Wang et al. 2011, 2012). One such property of the
FLEX version of the AAV calling card methodology is that there is no requirement for physical
isolation of cell types or nuclei for cell type-specific analyses. This allows for the same protocol
to be used for any cell type of interest, the identify of which is determined by the Cre-driver
mouse line used, and avoids potential disassociation-related artifacts (van den Brink et al. 2017).
Secondly, while not explored here, one could envision simple manipulations of the AAV calling
cards system to allow for temporal control of the system (Zhang et al. 2014). Such adaptations
could allow for innovative studies in which TF binding is recorded only during defined windows
of time (Mitchell et al. 2016). In a similar vein, we have demonstrated here the ability of AAV
calling cards to integrate TF binding information over time, which will allow for retrospective
analysis of historical TF activity in cells. By applying this unique utility to SP1, we identified
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promoter regions of genes with accumulating SP1 binding across postnatal development and
captured transient SP1 binding events at early-expressed genes. Finally, AAV calling cards does
not require a TF-specific antibody, allowing for TF profiling for, in theory, any packagable TF,
simply by fusing it to hypPB. This being a virally-mediated system allows for simple and rapid
application to animal models without the need for expensive and time-consuming breeding.
Intracranial injection for a standard size litter of mice can be completed in under an hour. Finally,
the non-Cre dependent versions of the system should be equally applicable in other species of
interest such as rats and primates. Reagents, cloning strategies, and user-friendly analysis
pipelines are available upon request, making AAV calling cards readily available for
neuroscience research.
Of course, there are caveats to be considered as well. Most notably, there is potential for
induced mutation, given the tendency for transposons to insert into or near critical gene
regulatory regions. Indeed, transposon technologies are often used in mutagenesis screens in
which transposon-mediated gene disruption can be deleterious (Rad et al. 2014). However, in
such studies, the transposons are specifically engineered with splice-site gene or enhancer traps,
while the SRT used in AAV calling cards only drives expression of a reporter gene and the
genomic sequence immediately downstream of its insertion site. Further, the transposition rate of
the piggyBac transposase is inherently low (<20-100 per cell (Kettlun et al. 2011; Yusa et al.
2011)), suggesting that it is highly unlikely for insertions to disrupt regulatory regions on both
alleles in the same cell. Consistent with this, we observed no excess degeneration or
behavioral/developmental deficits in AAV calling card-injected animals beyond that induced by
needle injury, and in general, calling card technologies have not exhibited marked deleterious
effects in previous reports (Wang et al. 2011, 2012).
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The relatively low “per cell” transposition rate of hypPB also helps to alleviate concerns
of reduced insertion efficiency at specific loci due to saturation after long periods of calling cards
recording. Indeed, with millions of available TTAA sites and thousands of active REs across the
genome, the chances of two insertions falling in the same site in the same cell are on the order of
less than 10-6 to 10-12. Nevertheless, it remains possible that a small subset of calling cards
transposition events could perturb RE activity and nascent gene expression, which could, in
theory, alter the ability for hypPB to insert a second transposon into a nearby site. Further, while
we have demonstrated here the ability to record TF binding peaks across 28 days of FLEX
calling card expression, it should be noted that calling cards recording may be limited in some
cases by transposon availability, which could become exhausted after long periods of recording.
Our final experiment with SP1 at P10 and P28 demonstrates the acquisition of new peaks at late
gene promoters, despite early genes using many of the available transposons, suggesting that
such exhaustion effects are limited here.
Next, while useful for profiling enhancers and super enhancers more broadly, the natural
affinity of hypPB for BRD4 does necessitate that any experiment using a TF-hypPB be
accompanied by a control with unfused hypPB only, such that TF binding peaks can be identified
with differential peak calling, as was done for SP1 in this report. Future versions of AAV calling
cards systems may be improved by fusion of TFs to other, non-BRD4-biased transposases
(Yoshida et al. 2017), though the efficiency of transposon re-direction would need to be tested
empirically in each case.
Finally, while we do see a clear Cre-induction of AAV::hypPB FLEX, providing a proof
of principle for its use in cell type-specific profiling, we also observed some background
insertion events in the absence of Cre, which could be limiting for profiling of rare cell types in
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which signal is likely to be reduced. To directly address this, we designed and tested a variant
FLEX virus, AAV::hypPB Frontflip, and in doing so, substantially reduced the Cre(-)
background observed with the original FLEX construct both in vitro and in vivo. This major
improvement will now allow for the application of FLEX calling cards to more rare cell types,
where insertion number is likely to be diminished. Of note, “leaky” expression of sensitive
enzymes in FLEX cassettes in AAV vectors is a common issue in neuroscience, with a number
of other strategies also having been proposed to reduce Cre(-) background (e.g. start
codon/kozak outside of FLEX cassette (Wall et al. 2010), mutated loxp sites (Fischer, Collins,
and Callaway 2019), AAV titration (Lavin et al. 2019)), which may also be useful in reducing
FLEX calling cards background. Alternatively, simply changing the viral serotype (Hammond et
al. 2017) or promoter (Graybuck et al. 2019; Jüttner et al. 2019) could allow for similar analyses
in cell types not explored here without the need for Cre-dependent conditional expression.
In summary, we have introduced AAV calling cards as a viable method for recording TF
binding and active REs in vivo and demonstrated its effectiveness in profiling cell type-specific
and historical TF and RE activity in the brain. Future applications of this technology to animal
models of development and disease could unlock important insights into epigenetic gene
regulation in a variety of neuroscience disciplines.
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Supplemental figures

Figure 2.1S. AAV9 intracranial injection induces hypPB expression in the cortex.
Figure 7displaying widespread cortical expression of hypPB
(A) In situ hybridization of hypPB RNA and no probe control
after delivery of AAV::hypPB.
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Figure 8

Figure 2.2S. Comparison of neonatal and adult AAV delivery of traditional DNA calling card and SRT
calling card systems.
(A) Viral donor transposon constructs for DNA (AAV::BrokenHeart) and RNA (Self-Reporting Transposon;
SRT) calling cards. (B) DNA calling cards library preparations were carried out as previously described in Wang
et al., Genetics, 2012. TF-hypPB fusions insert BrokenHeart transposon DNA near TF binding sites. Genomic
DNA is then harvested and digested with restriction enzymes that cut near the end of the transposon and in
downstream genomic sequence. These fragments are subsequently self-ligated and circularized. From these,
transposons and their flanking genomic sequences are amplified with inverse PCR, using primers that contain
Illumina sequencing primers and adapters. Final products are sequenced and aligned to the mouse genome to map
transposons to genomic locations. (C) Schematic of RNA calling cards library preparation protocol. SRTs contain
a ubiquitous promoter that drives the transcription of a TdTomato reporter gene with no 3’ poly-A termination
signal. When the SRT gene is transcribed episomally in the context of the AAV genome (i.e. prior to
transposition), a downstream self-cleaving ribozyme is incorporated into the transcript, destabilizing it and
ultimately causing its degradation. However, once the transposon is inserted into the genome, the SRT is no longer
affiliated with the ribozyme, and the SRT transcript becomes stabilized and extends to include flanking genomic
sequence downstream of the TdTomato gene. RNA is then reverse transcribed and PCR amplified, and Illumina
adapters are added for sequencing. (D) Read mapping rates for BrokenHeart DNA calling cards and SRT RNA
calling cards libraries after P0-1 or adult cortical delivery, showing increased efficiency of recovery for genomemapping reads in SRT relative to BrokenHeart. (n=3 mice for P0-1 BrokenHeart [12.3% mapping to mm10]; n=2
mice for P0-1 SRT [80.7%]; n=3 mice for adult SRT [76.5%]) (E) Number of unique insertions observed from
BrokenHeart DNA calling cards and SRT RNA calling cards libraries (n=3 mice for P0-1 BrokenHeart [198,981
insertions were recovered at mean read coverage of 8.98 reads/insertion]; n=2 mice for P0-1 SRT [3,732,694
insertions at 3.84 reads/insertion]; n=3 mice for adult SRT [4,114,106 insertions at 5.92 reads/insertion]),
displaying greatly increased recovery with SRT. (F) Mapping locations of transposon insertions in various
genomic regions from BrokenHeart and SRT calling card libraries.
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Figure 9does not induce excess degeneration or
Figure 2.3S. AAV SRT calling cards system
behavioral/developmental deficits.
(A-I) Behavioral and developmental assessments of mice injected at P0-1 with SRT calling cards (n=21) or
control, RFP only (n=24) viruses revealed few or no developmental, sensorimotor, or anxiety-related deficits in
calling card animals relative to control. All group comparisons were done with two-tailed, unpaired Student’s ttest, with Bonferroni corrected =0.05 as a significance threshold (including all tests in Fig 1). **p<0.01
(Bonferroni corrected).

100

Figure
10 calling card libraries for active REs.
Figure 2.4S. In vitro and in vivo sensitivity of unfused
hypPB
(A-B) Sensitivity and specificity of super enhancer (SE) identification for unfused hypPB calling cards libraries
in N2a cells. (A) Receiver-operator characteristic (ROC) curve for identification of active super enhancers using
unfused hypPB peaks called from 800,000 unique insertions. Area under ROC curve: 0.82. (B) Super enhancer
sensitivity at various significance thresholds and insertion totals, demonstrating high super enhancer sensitivity
at even very low (104) insertion totals. (C-D) Intersections between significantly-enriched insertion peaks derived
from in vivo, cortical unfused hypPB calling cards libraries and H3K27ac-marked (C) enhancers or (D) super
enhancers at a range of insertion peak significance thresholds. Red line represents total number of significant
peaks at each p-value threshold. Quantifications in Fig. 2F-I represent intersections at p=10-30 significance
threshold.
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Figure 11

Figure 2.5S. Supplemental to: FLEX calling cards system generates cell type-specific RE profiles.
(A) Transfection of BrokenHeart transposons, hypPB FLEX plasmid, and Cre recombinase into HEK293T cells.
n=3 wells per condition, 5 image fields per well, representative images shown. No TdTomato reporter from
reconstituted BrokenHeart transposons observed in the absence of Cre or hypPB FLEX at 24-hours posttransfection. (B) Representative images of Syn1::Cre and GFAP::Cre positive and negative littermate brains,
displaying increased SRT-derived TdTomato reporter signal in Syn1::Cre positive animals. (C) Representative
images displaying preferential expression in Neu(+) neurons in CA3 hippocampal regions of Syn1:Cre(+) mice,
but not negative littermates. TdTomato images taken at equal exposure times for direct comparison. (D)
Quantifications of unique insertions in Syn1::Cre or GFAP::Cre positive and negative littermate mice (two-tailed,
unpaired Student’s t-test: * p<0.05, ** p<0.01). Syn1::Cre (+) vs (-): p=0.0032, t=3.86, df=10, 95% C.I.diff
[268,014 : 1,000,132]; GFAP::Cre (+) vs (-): p=0.015, t=2.92, df=10, 95% C.I.diff [103,883 : 771,416] (E) Number
of genes near differentially enriched insertion peaks in Syn1::Cre and GFAP::Cre animals at a range of
significance thresholds. (F) Normalized neuron-to-astrocyte expression ratio [Neuron FKPM/(Neuron FPKM +
Astrocyte FKPM] for genes near Syn1::Cre or GFAP::Cre enriched peaks at a range of significance thresholds
for defining differentially enriched insertion peaks. As significance threshold becomes more stringent, expression
of nearby genes becomes more cell type-specific. RNA-seq expression from Zhang et al., Journal of
Neuroscience, 2014. (G) Astrocyte versus neuron expression of all genes near Syn1::Cre or GFAP::Cre enriched
insertion peaks at a stringent peak-calling significance threshold (p=10-7). Percent of genes on either side of the
y=x midline shown. (H-I) Graphical representation of cortical cell type enrichment based on gene sets near either
(H) Syn1::Cre (p<10-11; top 123 genes) or (I) GFAP::Cre (p<10-21; top 131 genes) enriched insertion peaks.
Legend displays Benjamini-Hochberg corrected Fisher’s Exact Test p-value for overlap of reference cell typespecific gene sets and Syn1::Cre or GFAP::Cre candidate gene sets. Stringencies for enrichment for each predefined reference set are represented by size of each hexagon, with the outer ring being the least stringent set and
inner ring being the most stringent set.
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Figure 12
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Figure 2.6S. Functional validation of enhancer activity at P7 for GFAP::Cre enriched unfused hypPB
peaks.
(A-D) Candidate GFAP::Cre enriched insertion peaks that were chosen for functional enhancer validation based
on enhancer size, significant GFAP::Cre enrichment, and astrocyte-specific RNA expression of their nearest
genes. Each candidate RE (highlighted in blue) was separately cloned into a plasmid upstream of the hsp68
minimal promoter and a dsRed reporter gene for in vivo testing. (E) Chromosomal coordinates and lengths of
candidate REs. (F) Candidate RE reporter constructs were co-delivered along with a GFAP::CFP plasmid to
ventricle-proximal radial glia, including astrocytes, via PALE (Stogsdill et al., 2017). Expression of dsRed was
enhanced by both the canonical GFAP promoter (pGFAP; positive control) and three of the four candidate REs
(all but eMms22l). (G) Percentage of dsRed(+) cells in cortex co-labeled with GFAP::CFP, demonstrating that
>96% of labeled cells are glia at this timepoint in all conditions. n=150 dsRed(+) cells from 3 brains per condition.
(H) Quantification of dsRed expression enhancement in GFAP::CFP(+) astrocytes by pGFAP and candidate RE
constructs. n=34-42 GFAP::CFP(+) cells from 3 brains per condition (one-way ANOVA with Dunnett’s multiple
comparisons test; *p<0.05; **p<0.01; ****p<0.0001). pGFAPmean diff. = 0.66, 95% C.I.diff [0.01 : 1.33]. eRasa2mean
diff. = 0.67, 95% C.I.diff [0.03 : 1.32]. eTaf4bmean diff. = 0.84, 95% C.I.diff [0.21 : 1.48]. ePla2g7mean diff. = 1.22, 95%
C.I.diff [0.58 : 1.86]. eMms22lmean diff. = 0.002, 95% C.I.diff [-0.65 : 0.65].
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Figure 2.7S. Candidate astrocyte enhancers identified with FLEX calling cards direct cell type-specific
expression in astrocytes by P21.
Figure 13
(A-B) Candidate astrocyte enhancers derived from FLEX calling cards enrichment (see Fig 6S) were
electroporated into P0-1 mouse pups via PALE (Stogsdill et al., 2017) and animals were sacrificed at P21 for IF
analysis. In animals receiving a plasmid containing dsRed driven by a minimal promoter only (hsp68::dsRed),
dsRed expression in the cortex was evident in a population of NeuN(+) neurons (white arrows) that was not
observed at P7 (see Fig 6SF-G). In contrast, in animals receiving either the pGFAP-driven positive control
plasmid or plasmids containing the candidate enhancers, dsRed expression was significantly limited to
GFAP::CFP(+) cells, indicating that the enhancer candidates facilitate cell type-specificity of gene expression.
n=287-769 dsRed(+) cells from two brains per condition for RE candidates and n=67 dsRed(+) cells from one
brain for pGFAP (one-way ANOVA with Dunnett’s multiple comparisons test; ****p<0.0001). pGFAPmean diff. =
74.47%, 95% C.I.diff [69.66% : 79.28%]. eRasa2mean diff. = 73.57%, 95% C.I.diff [68.76% : 78.38%]. eTaf4bmean diff.
= 74.47%, 95% C.I.diff [69.66% : 79.28%]. ePla2g7mean diff. = 72.37%, 95% C.I.diff [67.56% : 77.18%]. eMms22lmean
diff. = 74.47%, 95% C.I.diff [69.66% : 79.28%]. (C) Quantification of dsRed expression enhancement in
GFAP::CFP(+) astrocytes by pGFAP and candidate RE constructs. n=28-32 GFAP::CFP(+) cells from 2 brains
per condition for RE candidates and n=17 GFAP::CFP(+) cells from one brain for pGFAP (one-way ANOVA
with Dunnett’s multiple comparisons test; *p<0.05). pGFAPmean diff. = 0.59, 95% C.I.diff [-0.03 : 1.21]. eRasa2mean
diff. = 0.58, 95% C.I.diff [0.04 : 1.13]. eTaf4bmean diff. = 0.42, 95% C.I.diff [-0.11 : 0.95]. ePla2g7mean diff. = 0.40, 95%
C.I.diff [-0.15 : 0.95]. eMms22lmean diff. = 0.62, 95% C.I.diff [0.10 : 1.15].
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Figure 2.8S. Gating procedure for flow cytometry
Figure 14 in cells with BrokenHeart-derived TdTomato
fluorescence.
(A) Cells were dissociated into suspension and spiked with 0.1g/ml DAPI as a viability dye, allowing
discrimination of intact from plasma membrane-compromised cells. Gates were drawn based on Cre(-) conditions.
The analyzed TdTomato(+) populations were selected from the parent cells/singlets/DAPI(-) subsets.
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CHAPTER 3

Retrospective BRD4 occupancy profiling reveals predictive vulnerability
and susceptibility loci in an acute seizure model
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Abstract
Epilepsy syndromes are characterized by the recurrence of acute seizures. Previous
evidence suggests that epigenetic mechanisms may be involved in epileptogenesis and/or
progression to severe seizure. One such mechanism is enhancer activation, which is mediated by
the chromatin reader, BRD4. BRD4 mediates activity-dependent expression of immediate-early
genes in neurons, and BRD4 inhibition has been shown to be protective from seizure. Here, we
profile BRD4 genome occupancy in a mouse model of acute seizure, prior to the induction of the
seizure itself, and in doing so, identify enhancers for which BRD4 binding predicts eventual
seizure severity outcomes. Many of these enhancers were proximal to genes with known roles in
seizure and epilepsy, and gene ontological analysis revealed enrichment of synaptic
transmission-related categories. These results suggest that BRD4 binding at specific loci may
predispose animals to severe seizures and support a role of BRD4 in mediating seizure
susceptibility pathways. Manipulation of BRD4 and/or its binding partners may be an effective
therapeutic strategy for seizure in the future.
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Introduction
Epilepsy is the fourth most common neurological disorder in the United States, with an
incidence of 68 per 100,000 persons (Fiest et al. 2017) and a lifetime risk of 1 in 26 (England et
al. 2012). The term epilepsy refers to an amalgam of neurological conditions, each affecting
various at-risk populations, however these disorders are all characterized by the unifying
phenotype of unprovoked, recurrent seizures (Myers and Mefford 2015). Perhaps the most
detrimental cases of seizures are status epilepticus (SE), in which a single seizure persists for a
sustained period of time (>30 min) without recovery of consciousness. The occurrence of SE can
cause severe neuronal damage and result in impairment of vital functions which can be fatal
(Betjemann and Lowenstein 2015). While a number of anti-epileptic drugs (AEDs) have been
identified and are now commonly used for the treatment of seizures (Löscher 2011; Rogawski
2006), there remains at least one third of the epileptic individuals for which their seizures are
unresponsive to treatment and continue uncontrolled (Devinsky et al. 2018).
Seizures are the result of imbalances in inhibitory and excitatory neural conductances,
which lead to massive, simultaneous propagations of neuronal activity (Staley 2015). These
imbalances are typically brief, however in instances of SE, they continue unchecked, resulting in
a sustained, severe seizure. Excessive excitation during the early stages of seizure and/or
ineffective recruitment of inhibitory, GABAergic signaling may both be involved in progression
from mild seizure to severe seizure in SE, though the underlying mechanisms are not yet fully
understood (Betjemann and Lowenstein 2015). In some cases, conductance imbalances are
caused by mutations in proteins directly involved in membrane potential and excitability, such as
ion channels, and are thus termed “channelopathies” (Myers and Mefford 2015). However, these
mutations do not account for the majority of epilepsy incidences (Helbig et al. 2008; Helbig and
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Lowenstein 2013). Thus, it is critical to understand the molecular mechanisms underlying both
onset and termination of seizure for the development of effective therapeutics.
Recent evidence suggests that transcription factor (TF)- and enhancer-mediated
epigenetic regulation may be involved in determining susceptibility to seizure. One such factor is
a chromatin reader called BRD4, a member of the bromo and extraterminal (BET) domain
family, which binds to acetylated histone tails in enhancer regions (Jung et al. 2014; Kanno et al.
2004, 2014) and facilitates initiation of transcription at associated gene promoters (LeRoy,
Rickards, and Flint 2008; Mochizuki et al. 2008). BRD4 is highly expressed in neurons, where it
regulates the expression of activity-dependent genes, such as immediate-early genes, and other
genes involved in synaptic transmission and membrane excitability (Korb et al. 2015). Critically,
pharmacological inhibition of BRD4 in mice prior to chemical induction of acute seizure (via the
GABA antagonist, pentylenetetrazole (PTZ)) is sufficient to reduce seizure severity (Korb et al.
2015), suggesting that BRD4 may regulate mechanisms underlying progression from mild to
severe and prolonged seizure. However, the downstream targets of BRD4 involved in this
process are not yet understood.
Here we identify BRD4-bound genomic loci that correlate with seizure severity in the
PTZ-induced acute seizure model in order to find factors that may underlie seizure vulnerability
and susceptibility. To do so, we utilize a newly developed epigenomic profiling technique, AAV
calling cards (Cammack et al. 2019), which allows for the recording of BRD4 genome
occupancy in the mouse cortex prior to seizure induction; thus these profiles represent the “preseizure” state which is unaltered by the seizure itself. In this study, we compare pre-seizure
BRD4 occupancy between mice incurring mild versus severe seizures and, in doing so, identify a
number of regulatory elements (REs) predictive of seizure severity outcomes in vivo.
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Methods
Animals
All animal procedures were approved by the Washington University in St. Louis
Institutional Animal Care and Use Committee (IACUC) in accordance with National Institutes of
Health (NIH) guidelines. All mice used in this study were of the Synapsin 1 (Syn1)::Cre
(RRID:IMSR_JAX:003966) transgenic mouse strain on a C57BL/6J background. Mice had
unlimited access to food and water and were housed in a facility with a 12-hour light/dark cycle.
For euthanasia and tissue collection, mice were anesthetized with isoflurane and perfused with
15ml of cold saline (PBS), after which brains were dissected and flash frozen in liquid nitrogen.
For P0-1 injections, pregnant females were monitored daily for litter delivery and pups were
injected with adeno-associated virus (AAV) within 24 hours of being found in the cage. As all
mice in this study were euthanized by P28, mice were not weaned prior to sacrifice.

PTZ-induced seizure induction and evaluation
PTZ was dissolved in sterile PBS at 5mg/mL prior to injection. For induction of acute
seizure, mice were injected intraperitoneally (i.p.) with PTZ at 65mg/mL and evaluated for 15
minutes post-injection while recording with a video camera. Immediately following the 15minute evaluation period, mice were euthanized as described above, and brains were dissected
and collected in liquid nitrogen.
Seizures were scored from the video recording based on previously published scales
(DeVos et al. 2013; Löscher and Nolting 1993; Racine 1972) with scores as follows: 0: normal;
1: immobility; 2: spasm, tremble, or twitch; 3: tail extension; 4: forelimb clonus; 5: generalized
clonic activity; 6: jumping or running seizures; 7: full tonic extension; and 8: death. For the
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purposes of this study, scores of 4 or less were considered “mild,” while 5 and above were
“severe.” After scoring, animals were selected for BRD4 calling cards analysis.

Virus generation and injections
A conditional expression, or “FLEX,” calling cards system was chosen for BRD4
profiling (Cammack et al. 2019). A Cre-dependent hypPB construct and a (self-reporting
transposon (SRT) construct were separately packaged into AAV serotype 9 (AAV9) vectors by
the Hope Center Viral Vectors Core at Washington University School of Medicine. For all
experiments, AAV9::hypPB FLEX and AAV9::SRT viruses were mixed equivolume at
maximum titer and co-injected into 3 cortical sites per hemisphere of P0-1 pups (1µl viral mix
per site), as previously described (Cammack et al. 2019).
Viral titers (viral genomes per milliliter) prior to mixing were as follows:
AAV9::hypPB FLEX = 8.0 x 1012 - 1.0 x 1013 vg/mL
AAV9::SRT = 1.6 x 1013 - 2.2 x 1013 vg/mL

Calling cards library preparation and sequencing
Self-reporting transposon (SRT) calling card libraries were prepared from cortical RNA
samples as previously described (Cammack et al. 2019; Moudgil et al. 2019). The cortex of each
animal was randomly separated into 10 pieces from which RNA samples were individually
prepped. Each RNA sample was subsequently reverse transcribed and prepared for sequencing,
as previously described (Cammack et al. 2019; Moudgil et al. 2019), resulting in 10 barcodes per
animals which were sequenced on Illumina HiSeq 2500, NextSeq 500, or MiniSeq platforms
(Illumina, San Diego, CA, USA). Raw reads were filtered for features of true insertion events
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and mapped to the mouse genome (mm10) with Novoalign 3 (Novocraft Technologies). Unique
insertions were defined as existing either in different TTAA’s in the same barcode or the same
TTAA but in different barcodes, and all insertions were all considered equal, regardless of read
depth.

Identification of differentially BRD4-bound loci in mild versus severe animals
Significantly enriched insertion peaks between mild and severe animals were identified
as previously described (Cammack et al. 2019; Moudgil et al. 2019). Prior to peak calling, each
animal’s library was individually downsampled to 440,000 unique insertions. Downsampled
libraries were then pooled into “severe” and “mild” groups (n=6 animals per group), to create
final pooled profiles of 2,640,000 insertions per group. After this, the genome was segmented
into blocks of constant insertion density and a p-value was assigned to each block based on the
differential enrichment between the two pooled profiles based on a count-based statistical
comparison. In these analyses, a significance threshold of p<10-7 was used, and all blocks
surpassing this threshold were considered peaks significantly enriched in mild over severe or
severe over mild profiles. All significant peaks past this cutoff reach statistical significance after
Bonferroni correction based on the total number of blocks in each final pooled library. To further
delineate predictive seizure outcome factors, BRD4-directed insertion depth at these loci was
then correlated with severity score via linear regression.

Gene-enhancer pairing and gene ontology
The nearest gene (or genes for direct intersections) to each differentially enriched BRD4
calling cards peak was defined and filtered out if greater than 10,000 bases away from the peak,
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as these are low confidence gene-peak pairings. Gene ontology (GO) enrichment analysis was
performed on resultant gene sets with the PANTHER v14 classification system (Mi et al. 2017).

Statistical analyses
Statistical tests were done with GraphPad Prism v8.1.2 assuming normal distributions.

Data and code availability
Raw and processed data will be made available through GEO following publication.
Calling card analysis software were previously published (Moudgil et al. 2019) and are available
upon request.
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Results
Recording pre-seizure BRD4 occupancy profiles in a chemically induced acute seizure model
We sought to identify BRD4-bound genomic loci predictive of seizure severity in the
PTZ-induced acute seizure model. We delivered BRD4-directed, conditionally expressed
(“FLEX”), AAV calling cards viral vectors to the cortices of a large cohort of P0-1 mouse pups
of the Syn1::Cre genotype, which enriches BRD4 signal in neurons while maintaining some
background in astrocytes (Cammack et al. 2019). At P28, after recording pre-seizure BRD4
occupancy profiles in each animal, mice were administered acute seizures through i.p. injection
of the GABA antagonist, PTZ, at 65mg/kg (Fig 3.1A). Mice were euthanized immediately
following seizure, and cortical tissues were collected for calling cards analyses. To determine the
degree of variability in seizure severity following PTZ injection, seizures were scored on a
standard severity scale (DeVos et al. 2013; Löscher and Nolting 1993; Racine 1972), ranging
from 1 (e.g. immobility) to 8 (e.g. death). Of the 27 total mice in the study, 14 scored with a
“mild” seizure (0-4) and 13 with a “severe” (5-8), which were determined by the absence or
presence, respectively, of generalized clonic seizure. Next, we asked whether this variability
could be explained by sex, genotype, or weight. We found no correlation between severity score
and any of these factors (Fig 3.1B-D).
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Figure 3.1: Seizure severity does not correlate
with15
mouse sex, genotype, or weight.
Figure
(A) Experimental paradigm for longitudinal, pre-seizure BRD4 recording. (B-D) Variability in seizure
severity is not explained by (B) sex, (C) Syn1::Cre genotype, or (D) animal weight.
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Identification of loci differentially BRD4-bound in mild versus severe seizures
To test whether BRD4 occupancy at specific loci might associate with seizure severity,
we compared BRD4 calling card profiles between mice incurring mild versus severe seizures.
We prepared and sequenced calling card libraries from a sex and littermate-matched subset of
animals with mild or severe seizures (n=6 per category) and called differential BRD4 peaks
between the combined mild and severe profiles. We observed 341 REs enriched for BRD4
binding in severe seizure animals and 226 enriched in mild at p<10-7. A number of these loci
exhibited a strong positive or negative correlation with peak seizure severity; thus, BRD4
occupancy at these peaks is predictive of seizure outcomes. Intriguingly, some of these peaks
were near to genes with known roles in membrane excitability and/or seizure susceptibility. For
example, one differential binding peak was within an intron of the CNTNAP2 gene, of which
mutations cause cortical dysplasiafocal epilepsy syndrome (Strauss et al. 2006) and knockout
mice display profound hyperactivity and epileptic seizures (Peñagarikano et al. 2011);
accordingly, we observed that BRD4 binding at this locus is negatively correlated with seizure
severity (Fig 3.2A-B). Two other peaks, which displayed positive correlations of BRD4
occupancy and seizure severity, were proximal to SYN2 (Fig 3.2D-E) and NBEA genes which
also harbor epilepsy- and neurodevelopmental disease-associated mutations (Cavalleri et al.
2007; Corradi et al. 2014; Mulhern et al. 2018) and have displayed epileptic phenotypes in
cellular and animal models (Etholm and Heggelund 2009; Feliciano, Andrade, and Bykhovskaia
2013).
To extend these observations genome-wide, we performed GO for gene sets proximal to
BRD4 calling card peaks enriched in severe or mild animals. Interestingly, we found that GO
terms for both gene sets were highly enriched for synaptic and neurodevelopmental genes (Fig
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3.2C,F), suggesting that BRD4 regulates pathways and processes critical to proper neuronal
development and function.
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Figure 16
Figure 3.2: Retrospective analysis of longitudinally-recorded
BRD4 occupancy identifies vulnerability and
resiliency loci that are predictive of seizure outcome.
(A,B,D,E) Example genes and (C,F) gene ontology terms of genes proximal to differentially enriched BRD4 binding
sites in mild over severe animals (A-C) or severe over mild animals (D-F). n = 6 mice per group. Peaks defined at
p<10-7; eCntnap2: R=0.85, p=0.0004; eSyn2: R=0.86, p=0.0003.
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Discussion
Epileptic seizures are caused by spontaneous neuronal overactivity. This overactivity
induces numerous changes in gene and protein expression, many of which occur immediately
following seizure onset. Indeed, within minutes of incurrence of seizure, a number of genes,
including immediate-early genes such as c-Fos, have been shown to be dramatically altered at
the mRNA and protein levels (Peng and Houser 2005), a process which is facilitated by BRD4
(Korb et al. 2015). Thus, we hypothesized that BRD4 binding at specific genomic loci would be
predictive of and may mechanistically underlie downstream seizure severity phenotypes.
However, activity-dependent changes induced by seizure may mask important, inherent
susceptibility factors present at seizure onset. To overcome these limitations, we longitudinally
recorded the prodromal genome occupancy of BRD4 with AAV calling cards in an acute seizure
model prior to seizure. Utilizing this novel approach, we identified a number of loci which are
predictive of seizure outcomes. Of these differentially BRD4-bound regulatory elements (REs),
we observed that many were located near to or within synaptic and excitability genes, perhaps
explaining why BRD4 inhibition protects from severe seizure. Moreover, for some of these
genes there is preceding evidence supporting their involvement in seizure susceptibility
(Cavalleri et al. 2007; Corradi et al. 2014; Etholm and Heggelund 2009; Feliciano et al. 2013;
Mulhern et al. 2018; Peñagarikano et al. 2011; Strauss et al. 2006). Critically, by recording
BRD4 binding before seizure induction, these profiles are largely unaltered by the seizure itself
and thus represent the pre-seizure state. This retrospective paradigm is particularly important
here, given the rapidity with which epigenetic and gene expression profiles can change in the
cellular context upon insult or stimulation (Stavreva et al. 2015).
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However, there are number of limitations to this study as well. Firstly, it remains unclear
whether these associations are correlative or causative in nature. Future studies in knockout or
overexpression models may help to delineate whether individual loci directly regulate seizure
susceptibility. Moreover, while pairing REs to specific genes via proximity is widely done (Ernst
et al. 2011) and is generally a valid proxy for RE-mediated gene identification (Creyghton et al.
2010; Heintzman et al. 2009; Visel et al. 2009), this method is inherently imperfect (Maurano et
al. 2012); thus, it is likely that some differentially BRD4-bound loci regulate genes other than
those analyzed here. Finally, while the four-week BRD4 recording period dwarfs the 15-minute
seizure observance period, it remains possible that BRD4 occupancy profiles may be altered in
some cases during the insult itself; however, given the length of time of BRD4 recording and the
previously-described permanent recording ability of AAV calling cards (Cammack et al. 2019),
we consider this unlikely to be a significant contributor to the profiles described here.
In summary, these results support that pre-seizure BRD4 genome occupancy is predictive
of seizure outcomes. This work delineates specific REs, genes, and pathways through which
BRD4 acts to functionally alter seizure susceptibility, providing potential mechanisms to explain
the previously demonstrated role for BRD4 in neuronal excitability (Korb et al. 2015). However,
perhaps most importantly, this study introduces a novel experimental paradigm to solve a
common biological conundrum: how to study pre-insult states while also observing post-insult
phenotypic outcomes. We feel similar retrospective analysis paradigms may be equally
applicable in the future in other neural contexts in which historical epigenetic information would
be useful, such as models of neurodevelopment or neurodegeneration.
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Brain and spinal cord enhancers are misregulated in C9orf72 ALS mouse models and
human tissues and harbor ALS risk-associated non-coding genetic variation
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Abstract
Large repeat expansion mutations in chromosome 9 open reading frame 72, or C9orf72,
are the largest genetic cause of amyotrophic lateral sclerosis (C9ALS). While the mechanisms
leading to C9ALS are unclear, recent evidence suggests that dysregulation of transcriptional and
translational epigenetic pathways may be involved. Firstly, microRNAs (miRNAs), which are
short regulatory RNAs that bind to and repress mRNAs, have been demonstrated to be
dysregulated in both human and mouse models of ALS and be involved in ALS-related
pathogenic mechanisms. Secondly, aberrant, C9orf72 repeat-derived peptides, called dipeptide
repeat proteins (DPRs) have been shown to disrupt chromatin dynamics, which could affect
activity of epigenetic transcriptional regulatory elements, such as enhancers and super enhancers.
Further, enhancers harbor a large portion of genetic variation associated with neurodegenerative
disease, suggesting that their misregulation leads to increased disease risk. However, whether
miRNAs or enhancers are disrupted in C9ALS remains undetermined. Here, we profiled miRNA
expression level and enhancer activity in both C9ALS mouse models and postmortem CNS
tissues and found broad patterns of dysregulation in both systems. These results implicate
C9ALS-associated pathologies, such as DPRs, in directly driving alterations in epigenetic
control.
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Introduction
A hexanucleotide (G4C2) repeat expansion in chromosome 9 open reading frame 72, or
C9orf72, causes 38% of familial and 6% of non-familial or singleton amyotrophic lateral
sclerosis (sALS), representing the largest genetically identified subgroup of ALS to date
(DeJesus-Hernandez et al. 2011; Majounie et al. 2012; Renton et al. 2011). Additionally, the
same expansion can cause frontotemporal lobar degeneration (FTLD) in isolation or comorbidly
with ALS (van Blitterswijk et al. 2013; Majounie et al. 2012; van der Zee et al. 2013). While this
locus typically has under 30 repeats, ALS individuals with C9orf72 expansion mutations
(C9ALS) have hundreds to thousands (van Blitterswijk et al. 2013; Dols-Icardo et al. 2014;
Gijselinck et al. 2016; Nordin et al. 2015). In addition to the common ALS pathology of TDP-43
aggregation (Mackenzie et al. 2013), presence of this large expansion leads to the accumulation
of two C9ALS-specific pathologies: nuclear RNA foci consisting of repeat-derived RNA, and
dipeptide repeat proteins (DPRs), which are translated through repeat associated, non-ATG
(RAN) translation (Ash et al. 2013; Gendron et al. 2013; Mori et al. 2013; Zu et al. 2013). For
C9ALS G4C2 repeats, RAN translation yields five distinct species of DPRs: poly(GP), poly(GA),
poly(PR), poly(GR), and poly(PA), each shown to aggregate in CNS tissues of C9ALS/FTLD
individuals (Ash et al. 2013; Gendron et al. 2013; Mackenzie et al. 2015; Mori et al. 2013; Zu et
al. 2013).
Mounting evidence in cellular and animal models suggests DPRs are toxic and may be
directly involved in disease pathogenesis (Gendron and Petrucelli 2017). While the proposed
mechanisms through which these aberrant peptides induce cellular dysfunction are diverse
(Freibaum and Taylor 2017), recent evidence suggests that epigenetic alteration may be a key
contributor. In one study, it was discovered that poly(PR) co-localizes to regions of
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heterochromatin in both a transgenic poly(PR)-expressing mouse model and in C9ALS/FTLD
postmortem cortical tissue and induces alterations in histone H3 posttranslational modifications
(Zhang et al. 2019). Poly(PR), along with the other arginine-containing DPR, poly(GR), has been
demonstrated to undergo LLPS, a dynamic process in which proteins demix from a homogenous
solution to form membraneless condensates (Boeynaems et al. 2017). In overexpression models,
these aberrant DPRs localize to biological condensates in the cell, such as nucleoli, and can
interfere with the dynamicity of these structures, promoting liquid-to-solid transitions (Lee et al.
2016). Interestingly, one possible explanation for the observations of poly(PR) at
heterochromatin is co-phase separation with hetereochromatin protein 1 (HP1), a direct interactor
with methylated histone tails which participates in gene silencing and has itself been shown to
undergo LLPS in biological contexts (Strom et al. 2017). Indeed, in in vitro droplet experiments,
it was found that poly(PR) induces aberrant phase transitions of HP1 to a solid, aggregated state,
suggesting that this DPR alters chromatin dynamics through LLPS (Zhang et al. 2019).
Extending this one step further, it has been recently recognized that a number of other
chromatin-associated proteins, such as transcription factors (TFs) and co-factors (Boija et al.
2018; Sabari et al. 2018), and even chromatin itself (Gibson et al. 2019), undergo natural phase
transitions which may underlie epigenetic regulation (Hnisz et al. 2017). It follows then that
presence of C9orf72 expansion-related pathologies may further influence the genome-wide
regulation of these factors as well. One such protein is the chromatin reader, BRD4, which binds
to enhancer-associated acetylations on histone tails (Jung et al. 2014; Kanno et al. 2004, 2014)
and is involved in the initiation of gene transcription (LeRoy, Rickards, and Flint 2008;
Mochizuki et al. 2008). BRD4 is highly associated with super enhancers (Hnisz et al. 2013) and
is critical for the transcriptional response to neuronal activation in the brain (Korb et al. 2015).
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Additionally, multiple studies, including those from our group, suggest that epigenetic
regulation at the translational level may also be altered in disease and contribute to ALS
pathogenesis (Hoye et al. 2017, 2018; Koval et al. 2013; Reichenstein et al. 2019; Varcianna et
al. 2019). microRNAs (miRNAs), which are short, regulatory RNAs that bind to and repress
mRNAs, display altered expression in ALS mouse models (Hoye et al. 2017; Koval et al. 2013),
patient-derived induced pluripotent stem cell (iPSC) models (Varcianna et al. 2019), and patient
tissues (Hoye et al. 2017; Reichenstein et al. 2019). These changes modulate neuronal and glial
function and have been implicated in ALS-related pathogenic mechanisms (Amin et al. 2015;
Hoye et al. 2017, 2018; Koval et al. 2013; Reichenstein et al. 2019; Varcianna et al. 2019).
However, whether similar alterations exist in C9ALS is unclear.
Here we profile multiple key epigenetic regulatory mechanisms in C9ALS mouse models
and human postmortem tissues to investigate potential contributions to disease pathogenesis
(Table 4.1). First, we profile miRNA levels in C9ALS transgenic mice compared to nonexpanded and non-transgenic controls. Then, using an AAV calling cards method (Cammack,
Moudgil, et al. 2019), we test whether C9orf72 expansions lead to altered BRD4 binding and
enhancer activity in a C9ALS mouse model. Finally, we profile genome-wide enhancer activity
with H3K27ac ChIP-seq in human postmortem C9ALS, sALS, and non-ALS control lumbar
spinal cord samples and test whether these human spinal cord enhancers harbor known ALS
genetic risk variants.
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Table 4.1
Table 1

Sample type

Assay

Target

Sample size

C9orf72 mouse line (O’Rourke et al., 2016)

Microarray

miRNA

C9orf72 mouse line (Liu et al., 2016)

AAV calling cards

BRD4

C9orf72 mouse line (Liu et al., 2016)

RNA-seq

mRNA

Human postmortem lumbar spinal cord

ChIP-seq

H3K27ac

n = 3 C9exp
n = 3 C9non-exp
n = 3 wt
n = 6 C9(+)
n = 6 C9(-)
n = 3 C9(+)
n = 3 C9(-)
n = 4 C9ALS
n = 4 sALS
n = 4 Con
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Methods
Animals and genotyping
All animal practices and procedures were approved by the Washington University in St.
Louis Institutional Animal Care and Use Committee (IACUC) in accordance with National
Institutes of Health (NIH) guidelines. Transgenic mouse strains used in this study include
Tg(C9orf72_3) line 112 (The Jackson Laboratory, 023099), hence referred to as “C9 exp” and
littermate controls as “wt”; Tg(C9orf72_2) line 8 (The Jackson Laboratory, 023088), hence
referred to as “C9non-exp”; and C9-500 (The Jackson Laboratory, 029099), hence referred to as
“C9(+)” and littermate controls as “C9(-).” The C9exp and C9non-exp lines were bred to
the C57BL/6J background, while the C9(+) line was bred to the FVB/N6 background. All
C9orf72 transgenic lines were genotyped with repeat-primed PCR (rpPCR) as previously
described (Cammack, Atassi, et al. 2019). At indicated endpoints, mice were anesthetized with
isoflurane and perfused with 15ml of cold saline (PBS). Afterwards, brains and spinal cords were
dissected and flash frozen in liquid nitrogen.

miRNA extraction and microarray/RT-qPCR expression analyses
miRNAs were extracted from cervical spinal cord samples from C9exp, C9non-exp, and wt
animals with miRNeasy kits (Qiagen), following manufacturer’s instructions. miRNAs were then
reverse transcribed (Megaplex™ Primer Pools, Rodent Pools Set v3.0, ThermoFisher) and run
(without preamplification) in low-density rodent miRNA A&B cards sets 3.0 (Life Technologies)
on a QuantStudio 12K Flex Real-Time PCR System for 40 cycles. Three animals (2F/1M) per
genotype were used for microarray assessments.
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For microarray analyses, miRNA with an average raw CT count of <34 across all 9
samples were discarded, leaving 263 for downstream analysis. Each CT was normalized to the
geomean of miR-24, miR-191, and miR-30c and then analyzed with the 2-ddCT method. These
three miRNAs were previously demonstrated to be consistently expressed across CNS cell types
in spinal cord (Hoye et al. 2017).

Virus generation and stereotactic injections
A constitutively expressed AAV calling cards system was chosen for BRD4 profiling
(Cammack, Moudgil, et al. 2019). An unfused hypPB construct and a self-reporting transposon
(SRT) construct were separately packaged into AAV serotype 9 (AAV9) vectors by the Hope
Center Viral Vectors Core at Washington University School of Medicine. For all experiments,
AAV9::hypPB and AAV9::SRT viruses were mixed equivolume at maximum titer and
unilaterally co-injected into 2 cortical sites per hemisphere with coordinates relative to bregma of
1.25mm rostral; 1.5mm lateral; 0.55mm depth; and 1.06mm caudal; 1.5mm lateral; 0.55mm
depth. 2l of viral mix was delivered at a rate of 0.2l/minute.
Viral titers (viral genomes per milliliter) prior to mixing were as follows:
AAV9::hypPB = 7.1 x 1012 - 1.0 x 1013 vg/mL
AAV9::SRT = 2.2 x 1013 vg/mL

SRT library preparation and sequencing
Prior to RNA extraction, cortex samples were randomly separated into 10 pieces. RNA
samples were then extracted from cortex samples using RNeasy kits (Qiagen) following the
manufacturer’s protocol. SRT calling card libraries were prepared from RNA samples as
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previously described (Cammack, Moudgil, et al. 2019; Moudgil et al. 2019) and sequenced
on the Illumina NextSeq 500 platform. After filtering and aligning reads to the mouse genome
(mm10), unique insertions were defined as existing either in different TTAA’s in the same RNA
sample or the same TTAA but in different samples. All insertions were considered equally
independent of read depth.

Significant BRD4 peak calling
BRD4 peaks significantly enriched in C9(+) over C9(-) animals (and visa versa) were
identified as previously described (Cammack, Moudgil, et al. 2019; Moudgil et al. 2019) based
on the differential insertion enrichment between the two profiles at genomic loci. Prior to peak
calling analyses, each mouse library was downsampled to exactly 740,000 insertions. Then, mice
were grouped by genotype (n=6 mice per genotype) and peaks were called based on the pooled
datasets (4,440,000 insertions per genotype). Here, the significance threshold was set at p<10-7 at
which significant peaks pass Bonferroni correction based on the number of genome blocks in
each dataset (130,000-135,000 per dataset). To eliminate peaks near background levels, we
filtered out any peaks with < 30 total insertions across all 12 animals assayed, with the remaining
peaks being utilized in subsequent analyses. Finally, to account for within-genotype variability,
unpaired Student’s t-tests were run on individual differential peaks to compare C9(+) to C9(-)
enrichment. As the peaks were initially defined with a Bonferroni-corrected p-value, these
resultant t-test p-values were used without further correction.
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Gene-enhancer pairing and gene ontology
Peak-proximal genes near each differentially enriched BRD4 calling cards peak were
defined and used for “cell component” gene ontology (GO) enrichment analysis with the
PANTHER v14 classification system (Mi et al. 2017). Prior to GO, genes were filtered out if
greater than 10kB away from the a differentially enriched BRD4 peak.

RNA sequencing (RNA-seq) and analysis
RNA-seq libraries were prepared, sequenced, and analyzed by the Genome Technology
Access Center (GTAC) at Washington University in St. Louis (St. Louis, MO, USA). The below
methods were provided by GTAC.
Samples were prepared according to library kit manufacturer’s protocol, indexed, pooled,
and sequenced on an Illumina HiSeq. Basecalls and demultiplexing were performed with
Illumina’s bcl2fastq software and a custom python demultiplexing program with a maximum of
one mismatch in the indexing read. RNA-seq reads were then aligned to the Ensembl release 76
primary assembly with STAR version 2.5.1a. Gene counts were derived from the number of
uniquely aligned unambiguous reads by Subread:featureCount version 1.4.6-p5. Sequencing
performance was assessed for the total number of aligned reads, total number of uniquely aligned
reads, and features detected. The ribosomal fraction, known junction saturation, and read
distribution over known gene models were quantified with RSeQC version 2.6.2.
All gene counts were then imported into the R/Bioconductor package EdgeR and TMM
normalization size factors were calculated to adjust for samples for differences in library size.
Ribosomal genes and genes not expressed in the smallest group size minus one sample greater
than one count-per-million were excluded from further analysis. The TMM size factors and the
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matrix of counts were then imported into the R/Bioconductor package Limma. Weighted
likelihoods based on the observed mean-variance relationship of every gene and sample were
then calculated for all samples with the voomWithQualityWeights. The performance of all genes
was assessed with plots of the residual standard deviation of every gene to their average logcount with a robustly fitted trend line of the residuals.

Chromatin Immunoprecipitation sequencing (ChIP-seq) and analysis
H3K27ac ChIP-seq libraries were prepared from fresh frozen autopsy lumbar spinal cord
samples were sent to ActiveMotif epigenetics services team (Carlsbad, CA, USA) for end-to-end
H3K27ac ChIP-seq services. Samples included patients with either C9ALS, sALS, or no ALS
(Con). Demographics and clinical information about these patients are provided in Table 4.2.
The below methods were modified from ActiveMotif’s description of their propriety analysis
steps.
75-nt single-end sequence reads were generated by Illumina sequencing (using the
NextSeq500 platform) and mapped to the genome using the BWA algorithm with default
settings. Only reads that passed Illumina’s purity filter, aligned with no more than 2 mismatches,
and mapped uniquely to the genome (hg38) were used in subsequent analyses. In addition,
duplicate reads (“PCR duplicates”) were removed. To identify the density of reads along the
genome, the genome was divided into 32-nt bins and the number of reads in each bin was
determined. Final libraries were downsampled to the level of the sample in the group with the
fewest usable number of reads. Peaks were called using either MACS with p-value cutoffs of 1-7
for narrow peaks and 1-1 for broad peaks; or SICER with a p-value cutoff of FDR 1-10 and gap
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parameter of 600 bp. Peak filtering was performed by removing false ChIP-Seq peaks as defined
within the ENCODE blacklist.
To compare peak metrics between samples, overlapping peaks were grouped into
“merged peaks”, which are defined by the start coordinate of the most upstream peak and the end
coordinate of the most downstream peak. Read density metrics at each merged peak were then
normalized within sample to the mean of read counts across all peaks; thus, the average read
density across all merged peaks was equivalent between samples. An unpaired Student’s test was
then used to identify enriched merged peaks in C9ALS or sALS over Con samples.
The identification of super enhancers was done with a proprietary algorithm that gives a
very similar result as the ROSE software. In a first step, MACS or SICER peaks generated by the
standard ChIP-Seq analysis were merged if their inner distance was equal or less than 12,500 bp.
Then, the merged peak regions with the strongest signals (top 5%) were identified as super
enhancers.
For subsequent analyses, all enhancers with low read counts (less than 15 in all samples)
were removed.

Analysis of ALS-associated risk variants in spinal cord enhancers
Nine non-coding single nucleotide polymorphisms (SNPs) were found to associated with
or suggestive of increased risk of ALS in a recent genome wide association study (GWAS)
(Nicolas et al. 2018). These SNP coordinates were converted from hg19 to hg38 with UCSC
liftOver and compared to merged region coordinates from H3K27ac ChIP-seq postmortem
lumbar spinal cord libraries (merged across all 12 samples) with BEDtools intersect.
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To compare ALS-associated SNP intersections in other tissue enhancers, BED files from
a publicly available dataset of H3K27ac ChIP-seq-defined enhancers from 86 different human
autopsy tissues and cell lines were utilized (Hnisz et al. 2013) and enhancer coordinates were
compared to SNP coordinates with BEDtools intersect. Prior to intersection analysis, enhancer
coordinates were also converted to hg38 with UCSC liftOver.

Statistical analyses
Statistical tests were done with GraphPad Prism v8.1.2 and Microsoft Excel v16.16.18.

Data and code availability
Raw and processed data will be made available through GEO following publication.
Calling card analysis software were previously published (Moudgil et al. 2019) and are available
upon request.
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Table 4.2
Table 2

Autopsy
ID

Genotype

AU-022
AU-060
AU-073
AU-038
AU-064
AU-065
AU-077
AU-075

C9ALS
C9ALS
C9ALS
C9ALS
sALS
sALS
sALS
sALS

Sex

Time to
autopsy

Age at
onset

Age at
death

F
F
M
M
F
F
M
M

18 hours
20 hours
33 hours
Unknown
20 hours
26 hours
64 hours
15 hours

67
63
62
75
76
75
Unknown
68

69
68
64
79
77
76
76
69

AU-020

Con

F

15 hours

N/A

73

AU-032

Con

F

20 hours

N/A

83

AU-078
AU-068

Con
Con

M
M

24 hours
23 hours

N/A
N/A

47
73
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Co-morbidities
FTD
FTD

Myotonic dystrophy type
II (ZFN9 mutation)
Renal cell disease,
pneumonia
Autonomic neuropathy,
alcoholism
Parkinsonism

Results
C9orf72 expansions induce differential miRNA expression in the mouse spinal cord
To investigate potential misregulation of miRNA expression due to C9orf72 mutations,
we profiled miRNA expression levels via microarray in cervical spinal cord samples from 14week old transgenic mice harboring multiple copies (ranging ~100-1000 repeats) of an expanded
C9orf72 mutation (“C9exp”), as well as two controls: the negative littermates of the C9 exp line
(“wt”) and a separate transgenic line carrying a normal repeat size allele (15 repeats; “C9 non-exp”)
(Fig 4.1A). In total, we examined expression levels of 381 miRNA species, of which 263 were
found to be reliably expressing above background in the mouse spinal cord. Normalized miRNA
expression levels were then compared between C9 exp animals and controls to identify
differentially expressing species.
Likely due to the low sample size in these arrays (n=3 per genotype), no miRNAs were
found to be significantly altered after Bonferroni multiple comparison correction. However, we
did find a significant correlation between the fold change in expression of all miRNAs when
comparing C9exp to either the C9non-exp or the wt control, suggesting that these global changes are
likely not artifactual (Fig 4.1B-D). Interestingly, these expression alterations generally appeared
to have a greater magnitude change when comparing C9exp to wt than to C9non-exp, suggesting that
presence of even a small repeat may induce mild changes in miRNA expression (Fig 4.1B-D).
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Figure 4.1: Differentially expressed miRNAs in cervical spinal cord of C9orf72 transgenic mice.
Figuredemonstrating
17
(A) rpPCR results from C9exp, C9non-exp, and wt animals,
their repeat expansion sizes. (B) Foldchanges in miRNA expression in C9exp are correlated when compared to either the C9non-exp or the wt controls
(R=0.51, p<0.0001). (C-D) Microarray expression levels of individual miRNAs either (C) upregulated or (D)
downregulated when compared to either the C9non-exp or the wt control. P-values generated with unpaired
Student’s t-tests, without multiple comparison corrections.
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BRD4 profiling in the cortex of C9orf72 transgenic mice reveals altered enhancer usage
We hypothesized that C9orf72 mutations would induce changes in enhancer activity at
specific loci, especially those bound by the chromatin reader, BRD4. To test this, we assayed
genome-wide occupancy of BRD4 with AAV calling cards across a month-long window from
7.5 to 8.5 months of age in the cortices of C9(+) and C9(-) transgenic animals. Briefly, this
technique assesses BRD4 occupancy by tagging binding events with a marker transposon,
allowing for quantification of BRD4 binding via transposon insertion density. Additionally, we
performed RNA sequencing (RNA-seq) on a subset of C9(+) and C9(-) mice to assess effect of
enhancer misregulation on gene expression.
By comparing insertion density between C9(+) and C9(-) littermates, we identified 61
peaks significantly enriched for BRD4 binding in C9(+) animals and 83 significantly de-enriched
(Fig 4.2A,E). At the mRNA level, while no genes were found to be significantly altered after
FDR multiple comparisons correction, we were nonetheless able to identify a number of genes
with trends toward altered expression in the same direction as a nearby significantly enriched or
de-enriched BRD4 peak, suggesting that misregulation of these peaks may have downstream
consequences for transcription (Fig 4.2B-D, F-H). Finally, to investigate potential downstream
pathways that could be affected by BRD4 misregulation, we performed gene ontology on gene
sets proximal to differentially bound BRD4 peaks and found that the most enriched categories
were involved in the synapse and synaptic membrane (Fig 4.2I). This is of particular interest,
given the known susceptibility of C9ALS iPSC-derived neurons to excitotoxicity (Donnelly et al.
2013).
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Figure 4.2: BRD4-bound enhancer profiling in C9orf72 transgenic mice.
Figure 18
(A) Heatmaps of peaks (A) upregulated or (E) downregulated
in C9orf72 transgenic mice compared to nontransgenic controls (Unpaired Student’s t-test, unadjusted p<0.05). Example (B-D) upregulated and (F-H)
downregulated REs with (B, F) quantifications of BRD4 calling card insertions within peak, (C, G) RNAseq counts per million (CPM) of proximal genes, and (D, H) genome browser screenshots. Unpaired
Student’s t-test, unadjusted *p<0.05, **p<0.01. (I) Gene ontology (cellular component) terms of genes
proximal to differentially enriched BRD4 binding sites (n = 6 mice per group).
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Differential enhancer activity in human spinal cord is correlated between C9ALS and sALS
Next, we sought to investigate potential misregulation of enhancer activity in human
ALS. To do so, we profiled genome-wide H3K27ac with ChIP-seq in postmortem lumbar spinal
cord samples from C9ALS, sALS, and non-ALS (Con) patients. We were able to identify a
number of enhancers with a pattern of up or downregulation in C9ALS compared to non-ALS
(Fig 4.3A-B). Interestingly, the fold-change between C9ALS and Con was highly correlated with
that between sALS and Con, suggesting that these changes may be representative of ALS more
broadly (Fig 4.3C-D). Of note, the magnitude of change was on average greater in C9ALS than
sALS. Finally, we separated out super enhancers, and found that these elements display a similar
pattern to all enhancers as a whole (Fig 4.3E-H). In sum, we found global misregulation of
enhancer activity in ALS spinal cords, supporting that aberrant epigenetic regulation extends to
the human disease condition.

149

Figure 19
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Figure 4.3: H3K27ac ChIP-seq in postmortem C9ALS, sALS, and Con lumbar spinal cord.
H3K27ac ChIP-seq enhancer activity of (A-D) all enhancers (each dot = separate enhancer; black dots: unadjusted
p<0.05; red dots: unadjusted p<0.01) or (E-H) super enhancers profiled in postmortem lumbar spinal cords of
C9ALS, sALS, and Con patients. (A, E) Volcano plots of enhancer activity at (A) all enhancers or (E) super
enhancers. Black and red dots are enhancers which reached unadjusted p<0.05 and p<0.01, respectively (unpaired
Student’s t-test). (B, F) Heatmaps displaying the fold-change (FC) of normalized H3K27ac density relative to the
average of the 4 Con samples across (B) all enhancers and (F) super enhancers which reached unadjusted p<0.05
(unpaired Student’s t-test). Heatmaps are sorted by average FC in C9ALS over Con. Rows above line break were
enriched in C9ALS while below are de-enriched. (C, G) FC in C9ALS relative to Con is highly correlated with
sALS over Con for (C) all enhancers (linear regression, R=0.68, p<0.0001) as well as (G) the super enhancer
subset (linear regression, R=0.78, p<0.0001). (D, H) Example (D) typical enhancers and (H) super enhancers
displaying (left) enrichment or (right) de-enrichment in C9ALS relative to Con. Y-axis represents normalized read
depth with smoothing filter applied.
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Spinal cord enhancers harbor ALS-associated non-coding genetic risk variants
Lastly, we sought to test the hypothesis that spinal cord enhancers may harbor ALS riskassociated genetic variation. To do this, we asked whether SNPs associated with increased ALS
risk via GWAS could be found in enhancer regions profiled above with H3K27ac ChIP-seq. The
most recent ALS GWAS found that 9 non-coding SNPs achieved or almost achieved genome
wide significance, indicating that these variant alleles confer increased risk of ALS (Nicolas et
al. 2018). Of note, 6/9 of these SNPs were proximal to genes which are known to cause ALS
when mutated, such as TBK1, C9orf72, and Kif5a, and thus may be simply “marker” SNPs of
disease-associated coding mutations. However, the remaining 3 SNPs do not appear near to any
ALS-associated gene and remain unclear as to why they cause increased disease risk.
In our analysis, we discovered that 2 out of 3 (rs10463311 and rs75087725) of these nonmarker SNPs fall within spinal cord enhancers (Fig 4.4A-B). The enhancer harboring
rs75087725 was within the super enhancer subset. We then asked whether these enhancers were
specific to the spinal cord or shared across other human tissues. To do so, we intersected these
two SNPs with enhancer coordinates from a previously published dataset of H3K27ac ChIP-seq
in 86 different human tissues and cell lines (Hnisz et al. 2013). Indeed, we found that these SNPs
fell within active enhancers in a subset of human tissues in addition to spinal cord (Fig 4.4C).
The super enhancer harboring rs75087725 was shared primarily with brain tissues, suggesting
that this super enhancer is neural-specific. In contrast, the typical enhancer harboring rs10463311
was shared with 19 other tissues/cell lines. Interestingly, the majority (14/19) of these shared
tissues were either muscle or muscle-containing tissues, but surprisingly not brain. Thus, this
enhancer appears to be specific to spinal cord and muscle. Of the 86 tissues in the dataset, only
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two other tissues (hippocampus and left ventricle) harbored more than 1/9 ALS risk SNPs and
none harbored more than 1/3 of the non-marker ALS risk SNPs as was seen in spinal cord.
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Figure
20
Figure 4.4: ALS risk-associated genetic variants fall
in active
spinal cord enhancers.
(A-B) Of the 9 non-coding SNPs found to significantly or nearly significantly increase risk of ALS in a recent
GWAS (Nicolas et al. 2018), 2 fell within spinal cord enhancers. (A) rs75087725 was found to reside in a super
enhancer, while (B) rs10463311 was within a typical enhancer. (C) The active enhancers harboring rs75087725
and rs10463311 were also found in other human tissues and cell lines. The tissues and cell lines with enhancers
harboring rs75087725 were largely neural, while those harboring rs10463311 were mostly either muscle or
muscle-containing tissues.
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Discussion
In this study, we profiled miRNA expression and enhancer activity in the brains and
spinal cords of C9ALS transgenic mice and postmortem C9ALS and sALS tissues and, in doing
so, found widespread epigenetic misregulation at both the transcriptional and translational levels
in both conditions. These results suggest that C9ALS-associated pathologies, such as DPRs,
drive alterations in epigenetic control. Further, as the transgenic models used here do not exhibit
overt neurodegeneration (and were studied at early timepoints), our findings support that these
changes may occur prior to disease onset and are likely driven by pathological species rather
than post-onset insults, such as neuroinflammation. Finally, we observed misregulated enhancer
activity in sALS as well, suggesting that these alterations may extend beyond just C9orf72mediated neurodegeneration.
Our finding that spinal cord enhancers harbor ALS risk-associated SNPs suggests that
misregulation of enhancer activity may contribute to increased risk of neurodegeneration.
Further, that enhancers of the spinal cord harbored 2/3 of the non-coding ALS SNPs not near
known ALS-associated genes (Nicolas et al. 2018), while no other human tissue (out 86 in our
reference dataset) harbored more than one, suggests that misregulated enhancer activity may
even contribute to the motor neuron-specific dysfunction associated with ALS. In support of this,
previous studies have shown that tissue-specific enhancers often harbor disease-associated
genetic variants of diseases uniquely associated with that tissue; for example, brain-specific
super enhancers harbor the majority of Alzheimer’s disease non-coding genetic risk, while, in
contrast, super enhancers specifically active in immune cell populations harbor the risk for the
autoimmune disorder, multiple sclerosis (Hnisz et al. 2013). It follows then that spinal cord
enhancers would harbor risk variation for a spinal cord disorder, such as ALS. Interestingly, the
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few tissues with which the ALS-associated SNP-harboring enhancers were shared were also
either neural (as was the case for rs75087725) or muscular (as in rs10463311). While these
observations are yet to be mechanistically understood, they add support to the idea that tissuespecific enhancer misregulation may delineate the cell or tissue type likely to experience
dysfunction.
However, there are number of aspects to this study which require further analysis. It is
important to note that the results described here are largely observational and correlative in
nature and require functional validation in future studies to elucidate their mechanistic
involvement in disease pathogenesis. Indeed, while profiling such as this is useful for uncovering
general trends and pathways, individual enhancers or miRNAs (which represent potential
therapeutic and mechanistic targets) cannot be confidently linked to pathogenesis without further
study, for example in knockout or overexpression models. Secondly, it would be interesting and
useful to directly compare RE activity between mouse and human to understand whether specific
differential loci are conserved between species. Here we were able to demonstrate that general
trends of epigenetic dysregulation observed in mice are recapitulated in human tissues. However,
specific loci were not compared, due to difficulty of properly matching sequences between
species in the less conserved, non-coding space. Our findings could be enhanced through
implementation of orthogonal methodologies, such as chromatin capture, which would allow for
functional pairing of REs to genes and may increase confidence that a given RE is properly
matched between mouse and human. Lastly, future studies will be necessary to understand the
mechanisms underlying the misregulated epigenetic control observed here. One possible
explanation for the observed changes in chromatin dynamics is altered LLPS of TFs, co-factors,
and/or chromatin itself induced by aberrant C9orf72-associated pathologies, such as DPRs.
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While such mechanisms have been demonstrated for some cellular proteins (Lee et al. 2016),
including the chromatin-associated enzyme, HP1 (Zhang et al. 2019), this has yet to be explored
for other TFs and co-factors, such as BRD4, which was directly assayed and found to be
misregulated in this study. Similarly, LLPS has been implicated as a critical mechanistic
component of miRNA biogenesis (Jiang et al. 2017; Sheu-Gruttadauria and MacRae 2018). In
either case, it is plausible that the presence of aberrant phase separating proteins such as DPRs
could interfere with natural biological LLPS and thus underlie the functional epigenetic
alterations observed here. Future biochemical and cell biological studies will help to elucidate
whether these or other mechanisms contribute the epigenetic dysregulation we observed in
C9ALS.
In summary, we have provided here a useful profile of epigenetic regulation in both
human and mouse models of C9ALS, providing a reference resource for future studies of
epigenetic control in motor neuron neurodegeneration. In doing so, we have uncovered a novel
pattern of epigenetic misregulation, both transcriptionally and translationally, associated with
presence of the C9orf72 mutation. Future studies will help to understand the functional
consequences of the changes observed here.
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Abstract
Objective:
To define the natural history of the C9orf72 amyotrophic lateral sclerosis (C9ALS) patient
population, develop disease biomarkers, and characterize patient pathologies.

Methods:
We prospectively collected clinical and demographic data from 116 symptomatic C9ALS and 12
non-ALS full expansion carriers across seven institutions in the United States and The
Netherlands. In addition, we collected blood samples for DNA repeat size assessment,
cerebrospinal fluid (CSF) samples for biomarker identification, and autopsy samples for
dipeptide repeat protein (DPR) size determination. Finally, we collected retrospective clinical
data via chart review from 208 C9ALS and 450 singleton ALS (SALS) individuals.

Results:
The mean age at onset in the symptomatic prospective cohort was 57.9 ± 8.3 years, and median
duration of survival after onset was 36.9 months. The monthly change was -1.8 ± 1.7 for
ALSFRS-R and -1.4% ± 3.24% of predicted for SVC. In blood DNA, we found that G4C2 repeat
size correlates positively with age. In CSF, we observed that concentrations of poly(GP)
negatively correlate with DNA expansion size but do not correlate with measures of disease
progression. Finally, we found that size of poly(GP) dipeptides in the brain can reach large sizes
similar to that of their DNA repeat derivatives.
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Conclusions:
We present a thorough investigation of C9ALS natural history, providing the basis for C9ALS
clinical trial design. We found that clinical features of this genetic subset are less variant than in
SALS. Additionally, we identified important correlations of C9ALS patient pathologies with
clinical and demographic data.
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Introduction
The C9orf72 repeat expansion mutation is the most common genetic cause of both
familial ALS (fALS) and sporadic, or singleton, ALS (sALS) (DeJesus-Hernandez et al. 2011;
Majounie et al. 2012; Renton et al. 2011). This mutation likely induces a gain of function
toxicity, either through one or a combination of two repeat-associated pathologies, each arising
following transcription of the repeat in both the sense and antisense directions: repeat-derived
RNA foci (Donnelly et al. 2013; Lee et al. 2013) and dipeptide repeat proteins (DPRs) formed
through repeat associated, non-ATG (RAN) translation (Ash et al. 2013; Gendron et al. 2013;
Mori et al. 2013; Zu et al. 2013). While the proposed molecular mechanisms by which RNA foci
and DPRs may disrupt cellular biology are numerous and diverse, it is widely accepted that, at
least in cellular and animal overexpression models, these pathologies can cause a remarkable
amount of neuronal toxicity (Freibaum and Taylor 2017).
However, despite the large amount of work demonstrating C9orf72 pathology-related
toxicities and mechanisms in model systems, there remains a lack of understanding of their
characteristics in vivo. Because DPRs can be translated without a traditional start codon, it is
unknown how large DPRs become in human ALS. Importantly, recent work in the C9ALS field
has demonstrated a direct relationship between DPR size and toxicity. One study showed that
survival of primary cortical neurons decreases as poly(GR) repeat length increases (Wen et al.
2014), while another demonstrated a similar survival decrease in Drosophila overexpressing
poly(GR) and poly(PR) with increasing size (Mizielinska et al. 2014). Further, using much larger
DPRs (>1000 repeats) in HeLa cells, one group found that electrophysiological deficits worsen
with increasing DPR size (Callister et al. 2016). However, largely due to difficulties in creating
and manipulating large repeats, the majority of studies focus on repeats much shorter than the
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thousands that are present in the human DNA expansion mutation. Thus, understanding DPR
size and its relationship to that of its DNA counterpart in the human context is critical for
understanding human disease.
In addition to investigating these pathological characteristics, it is important to facilitate
the transition of C9ALS-directed therapeutics from the bench to the clinic. Drugs targeted at
reducing or eliminating RNA foci and/or DPRs are in development, with multiple rapidly
approaching human trials (Donnelly et al. 2013; Jiang et al. 2016; Lagier-Tourenne et al. 2013;
Nguyen et al. 2019; Sareen et al. 2013; Zhou et al. 2017, 2019), the design of which will be
determined by the natural history of the C9ALS patient population. Thus, a detailed description
of the C9ALS population is necessary for the facilitation of C9ALS clinical trials.
Here we present a prospective natural history study of C9ALS individuals in the United
States and The Netherlands. We documented a wide array of demographic and clinical data in a
cohort of 116 symptomatic and 12 non-ALS full expansion carriers. Additionally, we collected
blood and cerebrospinal fluid (CSF) samples from these individuals for analysis of DNA repeat
size and C9ALS biomarkers, respectively. As the expansion in C9orf72 is somatically unstable
(Nordin et al. 2015), we examined potential relationships between repeat size and clinical and
demographic data. Previous studies suggest that CSF poly(GP) levels, while not strongly
correlated with disease characteristics, are steady over time and responsive to C9ALS
therapeutics, providing promise for use as a pharmacodynamics biomarker (Gendron et al. 2017;
Lehmer et al. 2017; Su et al. 2014). Thus, we examined poly(GP) levels in CSF and correlated
these measurements with DNA repeat expansion size and clinical characteristics. Finally, we
investigated the size of poly(GP) dipeptides in postmortem CNS tissues.
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Methods
Participant identification and enrollment
Participants for the prospective natural history study were enrolled at seven institutions:
Washington University (WU), Massachusetts General Hospital (MGH), University Medical
Center Utrecht (Utrecht), University of Massachusetts (UM), Columbia University Medical
Center (CUMC), Cedars-Sinai Medical Center (CSMC), and Johns Hopkins University (JHU).
Data management was handled by the Neurologic Clinical Research Institute (NCRI) at MGH.
The C9ALS subgroup (n = 116) required a minimum diagnosis of possible ALS based on the
most recent revision of the El-Escorial Criteria, while a separate “non-ALS” subgroup (n = 12)
included individuals without ALS-related motor symptoms. Of the 12 non-ALS participants, all
received cognitive assessment with the ALS Cognitive Behavioral Screen (ALS-CBS™).
C9orf72 expansions of greater than 50 repeats were confirmed for all participants via Clinical
Laboratory Improvement Amendments (CLIA)-approved testing provided by Prevention
Genetics (Marshfield, WI, USA).
A separate cohort of 208 C9ALS and 450 SALS individuals from WU and Utrecht was
assessed retrospectively for C9orf72 natural history, dating back to 2006. All individuals were
first delineated by the presence or absence of a C9orf72 expansion mutation, confirmed via inhouse genetic testing. Those without an expansion were then screened for the presence or
absence of a family history of ALS, and those with a family history were further excluded to
reduce potential presence of other ALS-causing mutations (Turner et al. 2017). The remaining
individuals were categorized as SALS.
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Standard protocol approvals, registrations, and patient consents
This study was approved by each recruiting center's Institutional Review Board and
written informed consent was provided by all participants.

Data and patient sample collection
Clinical data for the prospective study were collected in person or via telephone
interviews with individuals and/or caregivers, with the exception of slow vital capacity (SVC),
which was assessed via handheld electronic spirometer. Clinical assessments included the ALS
Functional Rating Scale-Revised (ALSFRS-R), ALS-CBS, and ALS Caregiver Behavioral
Questionnaire (ALSCBQ). Severe cognitive impairment consistent with a diagnosis of FTLD
was defined as an initial ALS-CBS score of 10 or less out of a total score of 20, and moderate
cognitive impairment as 11-15. Family history of ALS, dementia, or both was assessed with
criteria defined in Byrne et al. (Byrne et al. 2011) Additional data included family and personal
medical history, medication use, ALS-related history (onset site, onset date, timeline of symptom
progression), physical and neurological examination, vital signs, and demographics. Biological
specimens from prospective study participants were also collected, including whole blood,
serum, CSF, and urine. Participants were enrolled over a 44-month period and data were
collected until study closing. Additionally, participants were followed for survival outcomes
after study closing, up until the date of this report. Study site personnel were trained on good
clinical practices and study outcome measures. Data were collected by the sites and recorded on
source documents, then subsequently captured in the NeuroBANK™ patient-centric platform
(http://neurobank.org/) and monitored remotely for consistency and completeness.
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Longitudinal data were acquired through follow up visits or phone calls. In total, we were
able to acquire at least two longitudinal measures from 88 participants for ALSFRS-R, 53 for
SVC, 42 for ALS-CBS, and 29 for ALSCBQ. The average time (and range) between measures
was 2.6 months (0.6-14.5) for ALSFRS-R, 7.6 (0.7-26.6) for SVC, 7.8 (0.7-26.6) for ALS-CBS,
and 3.9 (0.6-18.1) for ALSCBQ. 21 participants in the prospective C9ALS subgroup reached
mortality within 6 months of study enrollment and 12 more between 6 and 12 months.
Additionally, 21 C9ALS participants enrolled less than 6 months before study closing. Of the 42
subjects enrolled in the study for 6 months or less, 16 were still able to provide longitudinal data
for ALSFRS-R, 12 for SVC, 10 for ALS-CBS, and 7 for ALSCBQ. Other reasons for lack of
follow up are mixed and include inability to perform tasks due to disease progression, time
constraints during clinic visits, and inability to travel to the study site.
In the non-ALS subgroup (n = 12 individuals), longitudinal ALS-CBS measures were
available for 7 individuals, with an average (and range) of 9.2 months (5.3-18.2) between
measures. No non-ALS individuals reached mortality during the study. 5 non-ALS participants
were enrolled within 9 months of study closure, the average time between measures in this
group, 4 of which did not provide longitudinal data. One other individual conducted their follow
up remotely via phone and thus was unable to provide a longitudinal ALS-CBS assessment.
Clinical data for the retrospective cohort were collected through chart review and
recorded to a central database.
Blood-derived DNA samples from unexpanded individuals were from the Knight
Alzheimer’s Disease Research Center (ADRC) at WU and the ADNI database
(www.loni.ucla.edu\ADNI; for up-to-date information see www.adni-info.org). As there is no
association between repeat size and dementia of the Alzheimer's type (DAT) status (Harms et al.
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2013), all individuals were grouped together for analysis. This study was approved by each
recruiting center's Institutional Review Board and was carried out in accordance with the
approved protocol.
Autopsy samples used in poly(GP) size assessments were from a separate cohort of
C9ALS individuals from WU. All samples were collected between 6-32 hours of death, flash
frozen in liquid nitrogen, and stored at -80°C until use.

DNA repeat size measurement
Presence or absence of an expanded repeat was assessed with repeat primed PCR
(rpPCR) as previously described(Harms et al. 2013) using published primer concentrations and
sequences (DeJesus-Hernandez et al. 2011). PCR products were analyzed with an ABI® 3130xl
Genetic Analyzer (Applied Biosystems) and GeneMapper® software. rpPCR was also used to
quantify repeat sizes in unexpanded individuals.
G4C2 repeat size assessment of full expansions was performed with Southern blot. DNA
was isolated from whole blood samples by a core facility at WU and sent to Dr. Robert H.
Brown’s lab for analysis. DNA was digested with AluI and DdeI, followed by gel electrophoresis
and probing with a (GGGGCC)5-DIG probe. Bands were visualized using an anti-DIG antibody
and a chemiluminescent protocol. For quantification, densitometry plots were generated for each
lane using GelEval software (FrogDance Software; ver. 1.37). Density peaks for each ladder
band were used to create a standard curve, from which sample density peak sizes were
interpolated (GraphPad Prism; ver. 7.0). Due to the upper limit of the ladder, this method could
not accurately distinguish expansion sizes greater than 3855 repeats. Sixteen samples were
measured twice, with a median difference of 318 repeats between measurements. All Southern
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blot size assessments were blinded to eliminate experimenter bias. Prior to unblinding, samples
with technical abnormalities (e.g. gel band too faint, presence of non-specific artifact, etc.) were
excluded. In total, samples from 100 C9ALS and non-ALS individuals were analyzed, with 11
being excluded, leaving 89 for further analysis.

Haplotype analysis
Unexpanded individuals were genotyped for a 24 single nucleotide polymorphism (SNP)
“at-risk” haplotype associated with expanded C9orf72 repeats (Mok et al. 2012) using an
Illumina 610 array. Stringent quality control criteria was applied to remove low-quality SNPs
(Wijsman et al. 2011). The SNPs reported previously as part of the risk haplotype for C9orf72
(Mok et al. 2012) were extracted and haplotype analysis was performed using PLINK. Haplotype
carrier status was defined as individuals with at least 21/24 matching SNPs.

Poly(GP) measurement and size assessment
Relative concentrations of poly(GP) were measured via immunoassay. A monoclonal
mouse anti-poly(GP) antibody (Biogen, Boston, MA, USA) was incubated on goat anti-mouse
plates (Meso Scale Diagnostics, Rockville, MD, USA) for capture. Consecutive incubations with
a polyclonal rabbit anti-poly(GP) antibody (Biogen, Boston, MA, USA) followed by a sulfotagged goat anti-rabbit antibody (Meso Scale Diagnostics, Rockville, MD, USA) were used for
detection. “Relative concentration” designations refer to the amount of poly(GP) signal present
in an equivalent amount of DPR-containing tissue or cell lysate. Thus, axes display ng/ml of total
standard lysate rather than absolute concentration of poly(GP).
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For assessment of poly(GP) in CSF, undiluted samples were measured in triplicate
(45µl/well). Any sample displaying less than twice the average signal in blank wells was
considered a zero value and all non-zero samples achieved a coefficient of variation of less than
15.
For poly(GP) size assessment, samples were first separated with size exclusion
chromatography (SEC) and then quantified with the poly(GP) immunoassay. Autopsy samples
were homogenized in TEN buffer (10mM Tris pH 8.0, 1mM EDTA, 100mM NaCl) with 2%
sodium dodecyl sulfate (SDS) and fresh protease inhibitors (Sigma Aldrich, St. Louis, MO,
USA), sonicated briefly, and centrifuged at 100,000g for 30 minutes at 4°C to remove insoluble
protein species. Resultant supernatants were normalized by volume, loaded into a Superdex 200
10/300 GL SEC column (GE Healthcare, Chicago, IL, USA), and separated into 1 mL fractions
at a flow rate of 0.75 mL/minute in TEN buffer + 0.5% SDS. SEC fractions were measured with
the poly(GP) immunoassay in triplicate.

Statistical analyses
Statistical analyses were performed in GraphPad Prism ver. 7.0. Central tendency
markers represent mean, while error bars represent standard deviation. All correlations were
analyzed with linear regression. All reported p-values were corrected for multiple comparisons
across the entire study (False discovery rate; FDR).
Survival analyses for the prospective C9ALS cohort included 88 individuals with
definitive survival endpoints, while the remaining 28 participants that were either alive or lost to
follow up were right-censored on last known date of contact. Censored datapoints are marked
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with tick marks in Fig 5.1A. Survival comparisons of retrospective C9ALS and SALS were done
with Long-rank (Mantel-Cox) test.

Data availability
All data from this study are stored in the NeuroBANK™ (http://neurobank.org/) data
repository at the MGH NCRI and are linked with biospecimen repositories. We will share
deidentified datasets with researchers who want to advance understanding of neurological
disease. A limited amount of deidentified biofluid samples (DNA, serum, PBMCs, urine and
CSF) collected from this study are stored at the Northeast ALS (NEALS) Biorepository
(https://www.neals.org/for-als-researchers/neals-sample-repository/) and are publicly available to
researchers around the world. All requests for data and biofluid samples will go through the
NEALS Sample Repository through an application request system for qualified researchers. All
biofluid samples will be available until they are depleted. Data will be made public one-year
post-publication.
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Results
C9ALS natural history: Prospective disease onset and survival
Data were collected prospectively from 116 symptomatic C9ALS and 12 non-ALS full
expansion carriers. Of the symptomatic individuals, 53 were male and 63 female. Average age at
disease onset was 57.9 ± 8.3 years (Fig 5.1A; Table 5.1). At the time of this report, 88
individuals had reached a survival endpoint (either mortality or initiation of invasive ventilation)
and 28 were either still alive or lost to follow up. Median survival in this population was 36.9
months after disease onset (Fig 5.1B; Table 5.1). Site of disease onset and patient-reported
family histories (following criteria defined by Byrne et al. (Byrne et al. 2011)) are described in
Fig 5.1C-D and Table 5.1.

C9ALS natural history: Retrospective disease onset and survival
In addition to the prospective study, we collected retrospective survival and age at onset
information from a separate cohort of 208 C9ALS and 450 SALS individuals. Mean age at onset
from the retrospective cohort was similar to the prospective cohort: 59.0 ± 9.3 years for C9ALS
and 59.3 ± 12.1 years for SALS (Fig 5.1E). Median survival was 29.9 and 30 months for C9ALS
and SALS, respectively; however, notably, C9ALS had a significantly smaller fraction of slowprogressing individuals (Fig 5.1F).

C9ALS natural history: Prospective ALSFRS-R, SVC, ALS-CBS, and ALSCBQ
Longitudinal data for C9ALS individuals were available for ALSFRS-R (n = 88), SVC (n
= 53), ALS-CBS (n = 42), and ALSCBQ (n = 29). Additionally, baseline ALS-CBS data were
collected from 101 C9ALS participants. We observed an average monthly decline in ALSFRS-R
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Table 5.1
Clinical values

Prospective cohort

Sex (% male)
Average age at onset
Median survival

45.7%
57.9 ± 8.3 years
36.9 months

Onset location
Limb
Bulbar
Respiratory
Cognitive
Multiple sites
Insufficient data

53.8% (63/116)
38.5% (45/116)
4.3% (5/116)
1.7% (2/116)
0.9% (1/116)
0.9% (1/116)

Family history (criteria from Byrne et al.)
“definite” ALS only
“probable” ALS only
“definite” dementia only
“probable” dementia only
“definite” ALS and dementia
“probable” ALS and dementia
No known family history

10.1% (13/128)
19.5% (25/128)
4.7% (6/128)
23.4% (30/128)
17.2% (22/128)
10.9% (14/128)
14.1% (18/128)

Cognitive impairment (ALS-CBS)
Cognitively normal (score = 16-20)
Moderate impairment (score = 11-15)
Severe impairment (score < 11)

47.5% (48/101)
32.7% (33/101)
19.8% (20/101)

Table 3
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Figure 5.1. C9ALS natural history: descriptive characteristics.
21 cohort (n = 116 individuals; mean age at onset =
(A) Distribution of ages at onset for the prospective Figure
C9ALS
57.9 ± 8.3 years). (B) Mortality in the prospective C9ALS cohort. (n = 88 individuals reaching survival
endpoint; n = 28 individuals alive or lost to follow up (right-censored on last known date of contact; marked
with tick marks); median survival = 36.9 months). (C) Distribution of onset locations in the prospective C9ALS
cohort. (D) Family history of ALS, dementia, or both in the prospective cohort (n = 128 individuals).
(E) Distribution of ages at onset for retrospective C9ALS (n = 208 individuals; mean age at onset = 59.0 ± 9.3
years) and SALS (n = 450 individuals; mean age at onset = 59.3 ± 12.1 years) cohorts. (F) Mortality in
retrospective C9ALS (n = 195 individuals; median survival = 29.9 months) and SALS cohorts (n = 214
individuals; median survival = 30 months). Upper quartile survival displays significantly decreased disease
duration in slow-progressing C9ALS individuals (n = 48 individuals; median survival = 55 months) as
compared to SALS individuals (n = 53 individuals; median survival = 73 months) (Long-rank (Mantel-Cox)
test: p < 0.001).
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of -1.8 ± 1.7 and SVC of -1.4% ± 3.24% (Fig 5.2A-B). At first visit, 47.5% (48/101) individuals
with available data presented as cognitively normal, 32.7% (33/101) as moderately impaired, and
19.8% (20/101) as severely impaired (Table 5.1). We observed little change in ALSCBS or
ALSCBQ total scores (Fig 5.2C-D) or individual subscores (Fig 5.2E-L) over time in this
cohort. Additionally, we obtained baseline ALS-CBS data for all 12 participants in the non-ALS
cohort. Of these, 6/12 presented as cognitively normal, 3/12 as moderately impaired, and 3/12 as
severely impaired. During the course of this study, no change in ALS-CBS impairment status
was observed in the 7 non-ALS individuals for whom longitudinal measures were available.

Relationship of expansion size and age in prospective cohort
We probed G4C2 repeat size in blood DNA from 89 individuals in the prospective C9ALS
and non-ALS cohorts. The average repeat size was 2789 ± 757 repeats, noting that 10
individuals’ repeat sizes were within 318 repeats of the upper limit of detection. We observed a
significant positive correlation of age at disease onset and repeat size (Fig 5.3A). As expected,
we also found a positive correlation between repeat size and age at sample collection (Fig 5.3BC). We observed no significant correlations between repeat size and survival after onset or
ALSFRS-R rate of decline (Fig 5.3D-E).

Relationship of expansion size and age in unexpanded individuals
We hypothesized that repeat size and age correlations we observed in the prospective
cohort may represent dynamic G4C2 expansion over time. We extended our analyses to bloodderived DNA samples from a large (n = 674) cohort of individuals with unexpanded repeat sizes
(<30 repeats) from WU and ADNI. Within this population, 36% (244/674) of individuals were
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Figureprogression.
22
Figure 5.2. C9ALS natural history: measures of disease
(A) ALS Functional Rating Scale (ALSFRS-R), (B) Slow vital capacity (SVC), (C) ALS Cognitive Behavioral
Screen (ALS-CBS), and (D) ALS Caregiver Behavioral Questionnaire (ALSCBQ) rates of decline for C9ALS
individuals with at least 2 longitudinal datapoints. (ALSFRS-R: n = 88; SVC: n = 53; ALS-CBS: n = 42; ALSCBQ:
n = 29). (E-H) ALSFRS-R (n = 88) and (I-L) ALS-CBS (n = 42) subscore rates of change.
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Figure 5.3. Relationship of G4C2 repeat size and age.
Figure 23
G4C2 repeat size in blood, as measured by Southern blot, a has a significant positive correlation with (A) age at
disease onset (n = 79; R = 0.254; p = 0.05) and (B) age at sample collection (n = 89; R = 0.281; p = 0.02). (C) When
individuals are separated by median repeat size, age at collection is significantly higher in the top half than the
bottom half (n = 89; Mann-Whitney U test: p < 0.01**). Repeat size does not correlate with (D) survival (n = 61;
R = 0.031; p = 0.91) after onset or (E) ALSFRS-R rates of decline (n = 66; R = 0.053; p = 0.90). (F) In an
unexpanded (<30 repeats) population, haplotype carrying individuals have a significantly larger average repeat size
in blood than non-carriers (n = 244 haplotype carriers, n = 430 non-carriers; Mann-Whitney U test: p < 0.0001).
(G) In non-ALS individuals carrying the C9orf72-associated risk haplotype with large, yet unexpanded repeat sizes
(upper quintile; 13-25 repeats) repeat size is significantly correlated with age at sample collection (n = 47; R =
.434; p < 0.01). (H) Repeat size is significantly higher in the top half of large, unexpanded repeat carriers than the
bottom half (n = 47; Mann-Whitney U test: p < 0.01**). All p-values are corrected for multiple comparisons (FDR).
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carriers of the C9orf72 risk haplotype. Mirroring previously described populations (Smith et al.
2012; van der Zee et al. 2013), haplotype carriers in this cohort have a significantly larger repeat
size than non-carriers, suggesting that this genetic background may be permissive to expansion
(Fig 5.3F).
Inherited repeat size is a known risk factor for active expansion in similar repeat
disorders (Fu et al. 1991). We hypothesized that repeat size would be age-dependent in
unexpanded individuals with large repeat sizes. We defined “large, unexpanded” repeats as the
upper quintile of repeat sizes in the haplotype carrier group (upper 47 of 244 individuals).
Indeed, within this group, we observed a significant positive correlation with age at sample
collection (Fig 5.3G-H).

poly(GP) dipeptides are large and CSF levels negatively correlate with DNA repeat size
We measured relative concentrations of poly(GP) in CSF of C9ALS and non-ALS
carriers from the prospective cohort, as well as SALS individuals from WU, confirming C9specificity of the immunoassay (Fig 5.4A). Next, we examined poly(GP) in longitudinal CSF
draws from a subset of individuals and observed that poly(GP) levels remain steady over time
(Fig 5.4B), consistent with previous reports (Gendron et al. 2017). We found no significant
correlations between poly(GP) CSF levels and ALS history measures, such as age at onset,
survival, and ALSFRS-R rate of change (Fig 5.4C-E). Interestingly, we observed a significant
negative correlation between DNA repeat size and poly(GP) levels (Fig 5.4F).
Finally, we investigated DPR size in human CNS autopsy tissue. We fractionated soluble
protein from C9ALS CNS autopsy tissues by size and measured relative poly(GP) concentration
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in various size ranges. This assay efficiently separated protein sizes covering the expected range
of DPR repeats (Fig 5.4G). We observed poly(GP) signal only in large fractions of both
cerebellum and frontal cortex (Fig 5.4H), indicative of full length repeat peptides.
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Figure 5.4. poly(GP) in C9ALS CSF and size in autopsy tissue.
Figure
(A) poly(GP) in CSF is highly C9-specific, with signal
only24
observed in full expansion carriers. (n = 32 C9ALS; n
= 4 SALS; n = 6 C9+ non-ALS carriers (AC)). (B) poly(GP) levels are consistent between draws for 9 out of 10
individuals with longitudinal CSF draws. (C-F) CSF poly(GP) correlations with (C) ALS age at onset (n = 30
individuals; R = 0.040; p = 0.91), (D) survival (n = 20 individuals; R = 0.023; p = 0.92), (E) ALSFRS-R average
monthly rate of change (n = 25 individuals; R = 0.111; p = 0.90), and (F) blood DNA repeat size, as measured by
Southern blot (n = 34 individuals; R = .371; p = 0.05). (G) SEC standard proteins (Bio-Rad, Hercules, CA, USA)
separated by a Superdex 10/300 GL SEC column used in poly(GP) size assessments, demonstrating efficient
separation of relevant protein sizes. (H) poly(GP) is observed in large SEC-separated C9ALS autopsy CNS
samples. All samples are normalized to fraction 9 (the largest SEC fraction after void volume). Dotted line
represents SEC standard proteins as shown in “G”. Matched patient autopsies were used for cerebellum and frontal
cortex analyses. All p-values are corrected for multiple comparisons (FDR).
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Discussion
Immense progress has been made in understanding the pathobiology of C9ALS since its
discovery in 2011. Of particular importance has been the discovery of RNA foci and DPR
pathologies, which numerous laboratory studies have now linked to toxicity in human and animal
models (Gendron and Petrucelli 2017). Correspondingly, much focus has been recently placed on
repeat RNA-lowering therapeutics such as antisense oligonucleotides (ASOs), which effectively
reduce both RNA foci and DPR pathologies and have been shown to alleviate defects in C9ALS
cell and animal models (Donnelly et al. 2013; Jiang et al. 2016; Lagier-Tourenne et al. 2013;
Sareen et al. 2013). These promising treatments are rapidly progressing toward clinical trials,
following the path of similar ASO therapies for spinal muscular atrophy (SMA) (Finkel et al.
2017) and SOD1 ALS (Miller et al. 2013). The data herein will help facilitate design of these
trials by providing an evidence-based description of the natural history and pathological features
of C9ALS and further supporting poly(GP) as a pharmacodynamic biomarker.
In our prospective analysis of C9ALS clinical characteristics, we found a mean age at
onset of 57.9 ± 8.3 years and a median survival of 36.9 months (Fig 5.1A-B). Interestingly, our
retrospective C9ALS cohort presented with similar onset (59.0 ± 9.3 years) but a shorter survival
(29.9 months) than the prospective cohort. While the reasons for these disparities are unclear,
this may reflect inherent differences in prospective and retrospective data collection. A number
of retrospectively-collected C9ALS natural history datasets have been previously reported,
however clinical characteristics in these studies have been notably variable, for reasons difficult
to pinpoint (van Blitterswijk et al. 2013; Boeve et al. 2012; Byrne et al. 2012; Irwin et al. 2013;
Majounie et al. 2012; Van Mossevelde et al. 2017; Stewart et al. 2012; van der Zee et al. 2013).
Additionally, one small prospective study has described C9ALS disease progression (Floeter et
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al. 2017), however, this study included only 21 symptomatic C9ALS individuals, of which only
9 reached a survival endpoint during the study period. By prospectively collecting clinical data
from a large, multi-center C9ALS population, this report definitively describes C9ALS natural
history, which will aid upcoming trials in accurately determining study length and other
parameters, such as power calculations, that are dependent on expectations of participants’
survival.
In our retrospective analysis, we identified less variance in age at onset and fewer very
slowly-progressing individuals in C9ALS compared to SALS (Fig 5.1E-F). In measures of
disease progression from prospective C9ALS individuals, we observed an ALSFRS-R rate of
decline of -1.8 ± 1.7 and SVC of -1.4% ± 3.24% of predicted (Fig 5.2A-B). In comparison, the
PRO-ACT dataset consisting of over 8600 ALS individuals compiled from 16 ALS clinical trials
demonstrated more variation in rates of decline, at -1.02 ± 2.3 and -2.3% ± 6.9% for ALSFRS-R
and forced vital capacity, respectively (Atassi et al. 2014), however why differences are observed
between the mean values of these measures between these two datasets is not yet understood. In
summary, the C9ALS population presented here displays a relatively more homogenous clinical
description than non-C9 ALS. Finally, we assessed utility of ALS-CBS and ALSCBQ in
evaluating longitudinal cognitive changes in the prospective C9ALS cohort. In either measure,
we were unable to observe changes over time (Fig 5.2C-D), though it is unclear whether these
results represent a true lack of decline or an inability of these measures to accurately assess
longitudinal cognitive function. With all measures of disease progression presented here, it is
important to consider possible ascertainment bias due to unavailability of follow up and
longitudinal data, which may be more likely to occur in quickly-progressing individuals.
Additionally, while rare, a small percentage of the C9ALS individuals may carry a second,
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unrelated disease-linked mutation, which may affect progression rates in an undetermined way.
This was not assessed in this population. Nevertheless, collectively these data provide a template
for C9ALS clinical trial design moving forward, and it is expected that the relative homogeneity
of the C9ALS population will decrease the number of participants required to observe a
treatment effect.
Importantly, during our prospective study, we collected C9ALS biofluids which are now
housed in the NEALS Biorepository and are available for C9orf72-related research
(https://www.neals.org/for-als-researchers/neals-sample-repository/). We analyzed blood DNA
repeat size in full expansion carriers, which we found to correlate with individuals’ ages of
sample collection (Fig 5.3B-C), a result that mirrors several previously published reports in
C9ALS populations (Beck et al. 2013; van Blitterswijk et al. 2013; Fournier et al. 2018; Hübers
et al. 2014; Nordin et al. 2015; Suh et al. 2015), including one recent report showing a similar
relationship in a large cohort of presymptomatic expansion carriers (Fournier et al. 2018).
Interestingly, we also observed a positive correlation of repeat size and age in a separate
population of unexpanded non-ALS individuals (Fig 5.3G-H). One possible interpretation of
these data is that the C9orf72 repeat is dynamic and able to expand over time. Similar genomic
instability has been demonstrated in other expansion disorders (Cossée et al. 1997; Ditch et al.
2009; Du et al. 2012; Fu et al. 1991; McMurray 2010; Møllersen et al. 2010). Further, an
abundance of SALS is attributed to C9orf72 expansions (Majounie et al. 2012) and somatic
mosaicism is commonly observed in C9ALS expansions (van Blitterswijk et al. 2013; DolsIcardo et al. 2014; Nordin et al. 2015), both suggesting dynamic expansion is possible.
Alternatively, it is possible that presence of larger repeats is in some way protective and is thus
over-represented in older populations. Indeed, we observed a positive correlation between repeat
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size and age at onset in the C9ALS prospective cohort (Fig 5.3A). In support of this, it is known
that presence of large repeats decreases RNA levels of C9orf72 (DeJesus-Hernandez et al. 2011;
Haeusler et al. 2014; Renton et al. 2011; Sareen et al. 2013), which could potentially provide a
protective effect by lowering levels of nascent RNA foci or DPRs. Additionally, sequestration of
larger repeat RNAs into RNA foci in the nucleus could result in less cytoplasmic RAN
translation, as supported by one study that found RNA foci and poly(GP) inclusions rarely
occurring in the same cells (Gendron et al. 2013). Consistent with this, in this study we observed
a negative correlation between DNA repeat size and poly(GP) levels in C9ALS individuals (Fig
5.4F), which could be attributed to these or other yet unexplored mechanisms. It should be noted
that these results were obtained from blood-derived DNA and may not accurately represent CNS
expansion characteristics. It is also important to note that one previous report found a
significantly older age at onset and lower methylation of an upstream CpG island in “short”
expansion carriers (55-100 repeats) than in full expansion carriers, supporting a possible inverse
relationship of repeat size and onset age (Gijselinck et al. 2016), while two other reports were
unable to find any relationship of repeat size with onset age (Chen et al. 2015; Dols-Icardo et al.
2014), albeit with smaller sample sizes than in this study. Future studies in cell culture and
animal models will help to refine the interpretation of these interesting correlations.
As C9ALS-targeted therapies begin to move toward clinical trials, it becomes
increasingly important to develop methods to measure drug target engagement. To this end,
C9ALS pharmacodynamic biomarkers have begun to be explored, such as poly(GP) (Gendron et
al. 2017). We sought to provide insight into the characteristics of poly(GP) in both CSF and
autopsy tissue to further investigate use of this DPR as a C9ALS biomarker. While we found no
correlations between CSF poly(GP) and ALS natural history measures (Fig 5.4C-E), we were
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able to confirm that CSF poly(GP) is C9-specific and its levels are consistent over time (Fig
5.4A-B), supporting its continued use as a pharmacodynamics biomarker for expansion-targeted
therapeutics. However, the lack of correlation between poly(GP) levels and clinical measures,
which is consistent with previous findings (Gendron et al. 2017), suggests that this measure
likely does not inform on disease status and perhaps other pathologies are involved in disease
pathogenesis, though these analyses could be confounded by low sample sizes in some cases.
Lastly, we sought to examine DPR size in C9ALS individuals. In human CNS samples, we
observed very large poly(GP) dipeptides, including those upwards of 2000 repeats (Fig 5.4H).
While we did not observe smaller poly(GP) species here, it is possible that these are below the
sensitivity limits of our immunoassay; as the epitope for poly(GP) antibodies is inherently
repetitive, this assay likely has greater sensitivity for larger species. Additionally, while we only
used soluble lysates in these analyses and ran this experiment under highly denaturing
conditions, we cannot rule out the possibility that these sizes could be obscured by some degree
of secondary structure or protein interactions. Nevertheless, this experiment highlights two
important findings: large DPRs are synthesized in human brains; and poly(GP) being measured
with immunoassays is likely only representing large species. Our results suggest that when
possible, large DPRs should be used in mechanistic studies.
In summary, we have presented a comprehensive clinical description of C9ALS and
provided a template for upcoming C9ALS clinical trials. Additionally, through collection of
longitudinal biofluid samples and comparison to our prospectively-collected clinical and
demographic datasets, we have highlighted important pathobiological correlations within this
population. Together, these results establish baseline clinical and pathological characteristics for
C9ALS and provide a reliable resource for future clinical and translational studies.
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CHAPTER 6

Conclusions and future directions
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Summary of the dissertation
This dissertation details four separate projects: Chapter 2: development of adenoassociated virus (AAV) calling cards for TF profiling in the brain; Chapter 3: investigation of
BRD4 binding patterns predictive of phenotypic outcomes in acute seizure; Chapter 4: enhancer
and miRNA profiling in C9orf72 ALS (C9ALS) mouse models and human tissues; Chapter 5:
defining the natural history, biomarkers, and pathobiology of C9ALS.
In Chapter 2, we described the development of AAV calling cards and demonstrated
proof-of-principle experiments showing utility of this technique in cell type-specific and
longitudinal TF recording. These advances allow for insights into TF-mediated epigenetic
regulation that could not be ascertained with previously available profiling techniques.
In Chapters 3 and 4, we utilized AAV calling cards as well as other established
epigenomic profiling methodologies to investigate epigenetic misregulation in neurological
disease models. In Chapter 3, we probed pre-insult BRD4 binding in an acute seizure model and
identified enhancers for which BRD4 occupancy predicts eventual phenotypic outcomes. Then,
in Chapter 4, we explored misregulation of transcriptional and translational epigenetic control
through enhancers and microRNAs (miRNAs), respectively, in C9ALS. We found a broad
pattern of disrupted epigenetic regulation in both mouse models and postmortem human tissues,
suggesting that C9orf72 mutations drive epigenetic aberrations which may be involved in disease
pathogenesis.
Finally, in Chapter 5, we detail our efforts to understand pathological and clinical
features of C9ALS patients. As part of a large natural history study of C9ALS, we probed size
and abundance of key C9orf72-related pathologies, including dipeptide repeat products (DPRs)
and DNA repeat expansions, in patient blood, cerebrospinal fluid (CSF), and postmortem CNS
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tissues. We found the presence of large DPRs in human brain and uncovered novel
pathobiological correlations between DNA repeat size and age, suggesting that such expansions
may increase in size over time.
Below, we discuss in detail the advances, limitations, and future directions associated
with each of these studies.
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Advances, limitations, and future directions
Development of AAV calling cards
AAV calling cards is a TF-tagging technique, in which binding events of a TF of interest
are marked by transposon insertion via a C-terminally-fused hyperPiggyBac (hypPB)
transposase. One innate advantage of this system over traditional TF profiling techniques, such
as ChIP-seq, is non-requirement of TF-specific antibodies, increasing the number of TFs that can
be potentially profiled with our method. Further, this advance eliminates individual assay
optimization for each TF and may potentially allow for the profiling of low-abundance TFs that
would not be accessible with ChIP-seq due to high input requirements (Aughey and Southall
2016; Southall et al. 2013). In future versions of the AAV calling cards technique, it may even be
possible to multiplex the profiling of multiple TFs at the same time using different transposase
species (Gogol-Doring et al. 2016), while AAV delivery of this system extends its potential
application to other AAV-tractable animal models (e.g. rats, primates). However, exogenous TF
expression also carries inherent risks that should be considered when contemplating which
methodology to choose for an experiment. It is possible that overexpression of the TF of interest
may induce artifactual binding patterns, or even transcriptional or phenotypic cellular changes in
some cases. However, in our experience, calling card and ChIP-seq data largely align
(Cammack, Moudgil, et al. 2019; Moudgil et al. 2019; Wang et al. 2012), suggesting that factors
other than TF expression level may regulate site-specific binding (e.g. surrounding chromatin
state (Guertin and Lis 2010; John et al. 2011; X. Liu et al. 2006; Neph et al. 2012), local
sequence context (White et al. 2013; Yanez-Cuna et al. 2012), co-expression of co-factors
(Slattery et al. 2011), etc.). Moreover, we have demonstrated here that even truncated TFs can
largely recapitulate binding profiles of full-length TFs; thus, some of these overexpression

206

concerns could be alleviated in future experiments by exclusion of active protein domains (other
than DNA-binding domains) when creating TF-hypPB fusions. Further, calling cards
applications are limited to live tissues, where TFs can be actively recorded; thus, profiling in
human tissues is not currently possible with our technique. Finally, until AAV calling cards
becomes more widely established, it remains important to validate functionality of each TF
fusion via orthogonal means, as not all TFs are likely to redirect hypPB insertions to the same
degree. This may be achieved by comparing calling cards datasets to reference ChIP-seq
datasets, which are often publicly available for in vitro cell lines, or alternatively, through motif
discovery analyses.
The Flip-Excision (FLEX) versions of AAV calling cards allow for the profiling of TFs
in targeted cellular populations via Cre-dependent conditional expression. While other TF
profiling techniques have also been modified for cell type-specific use, (Bonn et al. 2012; Deal
and Henikoff 2010; Girdhar et al. 2018; Mo et al. 2015; Zhou et al. 2017), these methods have
been limited to highly abundant targets and may be complicated by disassociation-related
artifacts (van den Brink et al. 2017). FLEX calling cards requires no physical sorting or breeding
to tagged-nuclei transgenic animals, negating these concerns and streamlining cell type-specific
profiling by utilizing the same library preparation protocol for all cell types. Further, this method
has the potential for use in rare cell populations for which starting material may be too little for
ChIP-seq and related analyses. However, while we have engineered a novel FLEX variant
(“Frontflip”) which dramatically reduces Cre(-) background in FLEX calling cards systems, it is
unclear whether the remaining signal from rarer Cre(+) populations would be sufficient for TF
profiling, and sensitivities of our system are likely to vary greatly between TFs. Further, FLEX
calling cards is inherently limited to cell populations for which Cre driver mouse lines exist,
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however this may be circumvented in some cases through the use of cell type-specific promoters
(Graybuck et al. 2019; Jüttner et al. 2019) in the TF-hypPB AAV construct. Alternatively, a
separate publication from our group details the adaptation of AAV calling cards for bimodal
single cell TF and RNA profiling (Moudgil et al. 2019). While the sensitivity of this method is
currently limited by transposon insertion rate, this technique may eventually allow for TF
profiling in many brain cell types in parallel as single cell technologies gradually improve.
Finally, we demonstrated the ability of AAV calling cards to record and integrate TF
binding information across time, and, in doing so, recovered transient TF binding events which
were available for readout weeks later. This advantage has the capability to link downstream
molecular or behavioral phenotypic outcomes with historical epigenetic information in a
uniquely powerful way. One can imagine future experiments wherein the underlying drivers of
cell fates can be retrospectively identified. Similarly, there are opportunities to link antecedent
TF binding patterns to behavioral outcomes, such as in neurological disease models. As one
direct biological example of this type of analysis, in Chapter 3 we described the use of pre-insult,
longitudinal recording to identify predictive susceptibility and vulnerability enhancers in an
acute seizure model. However, integrative recording comes with potential disadvantages as well.
Firstly, there is the possibility that some epigenetic changes could be overwritten or canceled out
by events occurring later in the recording period. Secondly, for differences that are observed
between two conditions, it would be difficult or impossible to determine the exact timepoint
during the recording period at which a TF binding event occurred, and similarly, one may not be
able to distinguish singular, high-magnitude events from integration of multiple small-magnitude
events at the same locus. Finally, there is the potential for loss of some transient events due to
transposon reintegration and/or missed recording of recent events due to transposon exhaustion,
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particularly after long periods of recording. Improvements in temporal control of AAV calling
cards could help mitigate many of these concerns. While not explored in this dissertation, one
could envision addition of drug-inducible mechanics to the AAV system, such as destabilization
domains or estrogen receptor fusions, both of which have been shown to confer temporal control
to calling cards systems in vitro (Qi et al. 2017). Alternatively, the construction of calling cards
transgenic mouse lines may allow for coordinated use with conventional doxycycline-inducible
systems.
Despite the drawbacks of AAV calling cards detailed above, we believe this system is
capable of uncovering new biology in previously inaccessible contexts. Further, we consider this
to be “version 1.0” of the system and expect that future improvements may allow its use in yet
even more settings. Nonetheless, it remains important to consider all advantages and caveats
when choosing a TF profiling system for future experiments.

Retrospective BRD4 profiling to identify pre-seizure susceptibility and vulnerability loci
In Chapter 3, we utilized longitudinal AAV calling cards to test whether BRD4 binding
patterns could predict eventual phenotypic outcomes in an acute seizure model. We hypothesized
that BRD4 may regulate seizure susceptibility, as previous work had demonstrated that BRD4
mediates transcriptional responses to neuronal activation, which in turn, influences mouse
behavior. Perhaps most critically, one study demonstrated that pharmacological BRD4 inhibition
in the week prior to induction of acute seizure is sufficient to reduce peak seizure severity in live
mice (Korb et al. 2015). We sought to identify specific loci through which BRD4 is acting to
mediate these phenotypes.
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In our work, we identified a number of loci for which pre-insult BRD4 binding is
predictive of seizure severity. Many of these loci were located near to genes with clear roles in
epilepsy and/or seizure, supporting that epigenetic mechanisms may have a role in conferring
vulnerability to severe seizure. Importantly, this study was made possible by the ability of AAV
calling cards to record prodromal epigenetic states and is an example of the power of
retrospective TF profiling in vivo. This is particularly important in the brain, where epigenetic
and transcriptional changes often occur immediately following neuronal stimulation (Stavreva et
al. 2015). In the context of seizures, it has been well established that immediate-early genes, such
as c-Fos, rapidly increase in mRNA and protein expression within minutes of seizure induction
(Peng and Houser 2005); thus, endpoint capture methods, such as ChIP-seq or RNA-seq would
likely not inform on pre-seizure states. In contrast, by permanently recording BRD4 binding preseizure, AAV calling cards allows for unique access to binding information that was present preinsult, which can then be linked to downstream phenotypic outcomes.
However, while these results generally support that BRD4 regulates seizure vulnerability,
individual loci require further validation. We demonstrated that many of the genes proximal to
differential BRD4-bound loci have known roles in seizure susceptibility, however the impact of
the nearby enhancers identified in our study remains undetermined. This could be investigated
through CRISPR-Cas9 mediated deletion of these regions, perhaps in primary or induced
pluripotent stem cell (iPSC)-derived neuronal models, followed by assaying of neuronal
stimulation responses. Similarly, selective activation, perhaps through dCas9-p300 fusion
enzymes (Hilton et al. 2015), may inform on the contributions of individual enhancers to seizure
phenotypes.
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Next, it possible that some of the observed loci were altered during the seizure itself
rather than being present pre-seizure. While we recorded BRD4 over a 28-day pre-seizure period
and induced seizures for only 15 minutes prior to euthanizing animals, we have not empirically
tested the transposition rate of hypPB in vivo and do not know how it may be altered during
states of intense neuronal activity, such as seizures. This should be tested in the future by
delivering AAV calling cards to multiple cohorts of mice, followed by sacrifice and transposon
sequencing at various timepoints to determine the rate of insertion. Further, one could also
compare the average insertion total between mice receiving pentylenetetrazole (PTZ) or saline
control injections to determine whether insertion rate increases during seizure. However,
ultimately this study would benefit the most from the implementation of temporal control, such
that AAV calling cards recording may be turned off entirely prior to seizure induction.
Lastly, this work was carried out exclusively in the PTZ acute seizure model, which may
not accurately represent human epilepsy. Follow up studies in human iPSC neuron models or in
other mouse seizure models would help to corroborate the results depicted here (Löscher 2011;
Rogawski 2006). However, it is worth noting that the PTZ model has been used previously in the
discovery and testing of antiepileptic drugs (AEDs), many of which have translated successfully
to the clinic and are currently used to treat epileptic patients (Löscher 2011; Rogawski 2006).
Thus, this model has been proven useful and relevant for mechanistic studies of seizures in the
past.

Epigenomic profiling in C9ALS
Chapter 4 explores epigenetic contributions to ALS caused by repeat expansion
mutations in C9orf72 (C9ALS). This work began by profiling miRNA expression levels in the
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cervical spinal cords of C9orf72 mutation-harboring transgenic mice (C9exp), which led to the
uncovering of a pattern of dysregulation amongst many miRNA species. One advantage of the
line we chose to use in this study is that it is accompanied by two separate control lines: its own
non-transgenic littermates (which we called “wt”) and a separate transgenic model harboring an
unexpanded (15-mer) repeat in C9orf72 (C9non-exp) (O’Rourke et al. 2015). As microarray
screens such as this are often underpowered for the identification of statistically significant
differences after multiple comparison correction, utilization of both controls adds another layer
of confidence when identifying hits for follow up study. We found a significant correlation
between the fold changes in miRNA expression levels when comparing C9exp to either control
line. Further, these differences appeared to be more pronounced when comparing C9exp to wt
than C9non-exp, suggesting even small expansions may induce changes in miRNA expression.
When selecting individual miRNAs for follow up study in the future, one could choose to focus
on miRNAs displaying pronounced up or downregulation when compared to either line, as we
reason these are more likely to be informative hits. Importantly, the mice used here were only 14
weeks of age, when C9orf72 pathologies, such as DPRs, are beginning to accumulate, and
further, while these transgenic lines do express human ALS-like pathologic features, they do not
develop motor neuron degeneration or ALS phenotypes, suggesting that the miRNA changes
observed here are not likely to be driven by inflammation or other insults associated with postonset ALS. However, it is important to recognize that screening assays such as this are
confounded by low sample sizes and large numbers of multiple comparisons, thus rendering all
miRNA changes observed here not significant after multiple comparison correcting. While valid
for identification of targets for further investigation and for uncovering broad trends, it will be
critical to continue to validate the interesting hits of this screen in mice and humans with larger
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sample sizes, as well as to investigate functional ramifications of altered miRNA expression for
motor neuron health in the future.
We were also interested in investigating enhancer activity in C9ALS, as these elements
have been shown to harbor genetic variants associated with increased risk of neurological disease
(Corradin and Scacheri 2014; Ernst et al. 2011; Girdhar et al. 2018; Hannon et al. 2019; Hnisz et
al. 2013; Maurano et al. 2012; Wells et al. 2015). We first quantified BRD4 binding across the
genome in the cerebral cortices of 7.5-8.5 month old C9orf72 transgenic mice (C9(+); a different
line than was used for miRNA profiling (Liu et al. 2016)) and their non-transgenic littermates
(C9(-)) with AAV calling cards. In doing so, we discovered hundreds of significantly altered
binding sites reaching statistical significance surpassing Bonferroni-corrected thresholds, the
majority of which were also significantly altered in post-hoc Student’s t-tests, suggesting that
variability within genotype was low. We also profiled mRNA levels with RNA-seq in a subset of
these animals to investigate consequences of this aberrant epigenetic regulation on gene
expression. While no mRNAs were significantly altered (false discovery rate (FDR)-corrected),
only 3 mice per group were assayed here, and some genes proximal to differential BRD4 peaks
did show trends toward up or downregulation consistent with nearby BRD4 occupancy. Further,
gene ontology (GO) of all proximal genes identified neuronal pathways known to be involved in
C9ALS, such as neuronal excitability (Donnelly et al. 2013). Similar to those used for our
miRNA profiling, these mice do not get motor neuron disease in our hands (despite previously
reported phenotypes (Liu et al. 2016)), and these mice were profiled at a later timepoint (7.5-8.5
months) where DPR pathology is abundant ((Liu et al. 2016) and in-house data not shown),
suggesting that these changes could be upstream of motor neuron dysfunction. However, it is
important to note that these results are limited by the serotype of AAV9, which was used in this
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study for AAV calling cards profiling and only transduces neurons and astrocytes (Cammack,
Moudgil, et al. 2019). While these two cell types are historically the most heavily implicated in
ALS pathogenic mechanisms (Boillee et al. 2006; Haidet-Phillips et al. 2011; Nagai et al. 2007;
Yamanaka et al. 2008), other glial types, such as microglia (Boillee et al. 2006) and
oligodendrocytes (Ferraiuolo et al. 2016; Kang et al. 2013), have also been shown to alter ALS
pathogenesis and progression in animal models. Future studies of BRD4 in C9ALS could be
improved through implementation of FLEX calling cards for cell type-specific profiling. It
would be exciting to observe, for example, motor neuron-specific epigenetic signatures in these
animals. Further, extending these studies to the spinal cord, perhaps through intrathecal AAV
delivery, would probe cell types directly affected in C9ALS (though it should be noted that
C9orf72 mutations also cause a significant portion of frontotemporal dementia (FTD) cases, and
are thus also worth exploring in cortical regions).
Given our findings in C9orf72 transgenic mice, we then sought to investigate enhancer
activation in human ALS postmortem tissues. To do so, we profiled enhancers and super
enhancers via H3K27ac ChIP-seq in lumbar spinal cord tissues from age and sex matched
autopsy samples from C9ALS, sALS, and non-ALS (Con) individuals. We found a broad pattern
of enhancer and super enhancer dysregulation in the spinal cord which correlated between
C9ALS and sALS, suggesting that these alterations may extend beyond just C9orf72-associated
disease. These results help to corroborate and extend the results we observed in the C9ALS
mouse model. We also found that spinal cord enhancers harbor known ALS risk-associated
genetic variants, suggesting that misregulation at these regions may be an upstream pathogenic
mechanism. Interestingly, in addition to the spinal cord, these enhancers were found to be active
nearly exclusively in brain and muscle/muscle-containing tissues (from a reference H3K27ac
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ChIP-seq dataset). While this is simply observational at this point, it will be interesting to
investigate these variants further in future studies to determine their roles in conferring
susceptibility to motor neuron disease.
It is important to note that the findings observed here are descriptive and somewhat
preliminary in nature. Whether these epigenetic aberrations contribute to C9ALS disease
mechanisms is yet unclear and requires further follow up study. This could be done through
selective disruption or activation of enhancer loci via CRISPR Cas9-related methodologies
(Hilton et al. 2015), as discussed above in our seizure study, or broad pharmacological or genetic
inhibition of epigenetic co-factors, including BRD4 in C9ALS cell and animal models. One
challenge with studies such as this is choosing a disease-relevant phenotypic outcome to assay.
Some studies have demonstrated that primary and patient-derived iPSC neurons can recapitulate
C9ALS disease survival phenotypes (Shi et al. 2018; Wen et al. 2014), suggesting they may be
useful in determining functional effects of targeting enhancers. A number of C9orf72 transgenic
and virally induced mouse models have been developed for the study of C9ALS in vivo (Chew et
al. 2015; Hao et al. 2019; Jiang et al. 2016; Liu et al. 2016; O’Rourke et al. 2015; Peters et al.
2015; Zhang et al. 2019), however only a select few display disease-relevant phenotypes (Jiang
et al. 2016; Liu et al. 2016; Zhang et al. 2019), with one having not yet been replicated outside of
the depositing laboratory (Liu et al. 2016). As we hypothesize that DPRs may be drivers of the
epigenetic aberrations, we have begun to develop our own cell models of DPR-mediated toxicity
and hope to utilize these systems in the future for functional investigation of enhancers in
C9ALS.
Finally, and perhaps most critically, we are interested in understanding the mechanisms
underlying the miRNA and enhancer activity changes we have observed here. One interesting

215

hypothesis is that miRNA and/or enhancer regulation could be impaired through altered liquidliquid phase separation (LLPS) of their enzymatic components. Indeed, evidence has been
demonstrated that all of these biological processes may involve LLPS. Enzymes involved in both
miRNA biogenesis as well as mRNA repression mechanisms naturally undergo LLPS (Jiang et
al. 2017; Sheu-Gruttadauria and MacRae 2018), while TFs (Boija et al. 2018), co-factors such as
BRD4 (Sabari et al. 2018), and even chromatin itself (Gibson et al. 2019) are thought to use
LLPS as a means for increasing their local concentrations at enhancers (Hnisz et al. 2017). LLPS
has recently become a major focus in the ALS field as well, as many ALS-linked genes have
been shown to undergo this process, while ALS-causing mutations disrupt the dynamicity of
phase separated bodies (Dao et al. 2019; Mann et al. 2019; Molliex et al. 2015; Patel et al. 2015).
In C9ALS, it has been shown that the arginine-containing DPRs, poly(GR) and poly(PR)
themselves phase separate (Boeynaems et al. 2017), co-localize to other phase separated
condensates (Lee et al. 2016), and disrupt natural condensate function (Boeynaems et al. 2017;
Lee et al. 2016). Interestingly, one recent study demonstrated the poly(PR) co-phase separates
with hetereochromatin protein 1 (HP1), an enzyme which interacts with methylated histone tails
and participates in gene silencing, and in turn, induces alterations in histone H3 posttranslational
modifications, both in the poly(PR)-expressing mouse model, as well as C9ALS/FTD
postmortem tissue (Zhang et al. 2019). However, whether similar LLPS changes are induced by
DPRs for miRNA or enhancer-associated proteins has not yet been explored. We have begun to
develop assays to test the hypothesis that presence of DPRs disrupts of LLPS of BRD4,
chromatin, and miRNA processing enzymes. These include “optodroplet”-like assays, as well as
in vitro experiments utilizing recombinant proteins, as has been done for similar proteins in the
past (Boija et al. 2018; Lee et al. 2016; Mann et al. 2019; Sabari et al. 2018; Zhang et al. 2019).
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However, this remains, at this point, a hypothesis; it is equally possible that other mechanisms
may be responsible for driving epigenetic aberrations in C9ALS. For example, TDP-43 has been
shown to impair nucleosomal dynamics through the chromatin modifier CHD1 (Berson et al.
2017). Further, global histone hypoacetylation has been observed in mutant FUS transgenic
mouse models which can be reversed with pharmacological inhibition of histone deacetylases
(HDACs) (Rossaert et al. 2019). Future studies will help to elucidate whether these, or other yet
unexplored mechanisms may be responsible the observations described here.

Investigation of pathological characteristics, biomarkers, and natural history of C9ALS
In the penultimate Chapter of this dissertation, we present our C9ALS natural history
study (Cammack, Atassi, et al. 2019), wherein we characterize the clinical and pathological
characteristics of the C9ALS patient population. This Chapter is the aggregate of years of effort
by clinical and basic science research staff and represents a substantial step forward in the path to
develop C9ALS-targeted therapeutics. By thoroughly and definitively describing the clinical
demographics of C9ALS patients, future clinical trials can now make evidence-based decisions
on treatment regiments and timelines.
However, for the purposes of this dissertation, perhaps the most relevant findings to come
from this work are from the investigations into DNA expansion and DPR size in human tissues.
Given that presence of DPRs is one of the few consistent pathological species between C9ALS
transgenic mice and humans, we believe they are a likely candidate for causing the epigenetic
aberrations seen in Chapter 4 (of note, this is yet unproven). However, despite intense interest in
DPRs in the C9ALS field, it was previously unknown known how large DPR peptides are in
human CNS tissues. Because DPRs form via repeat associated, non-ATG (RAN) translation
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mechanisms (Ash et al. 2013; Gendron et al. 2013; Mori et al. 2013; Zu et al. 2013), it is unclear
where translation begins for these protein species. In the majority of mechanistic studies, small
(<100-mer) DPRs are utilized, largely for convenience; indeed, the creation of large DPRs is
technically challenging, and short DPRs appear to confer similar toxicities as longer DPRs in
some contexts (Gendron and Petrucelli 2017). However, DPRs of different sizes may behave
differently in biological settings. In our study, we provided the first characterization of DPR size
in humans, and in doing so, identified the existence of large poly(GP) species which extend to
lengths similar to their DNA repeat derivatives. In addition, we quantified poly(GP) abundance
in human CSF samples, as well as size of DNA repeat expansions, both of which we later
compared with our prospectively collected clinical and demographic datasets. We found that
poly(GP) abundance in CSF was negatively correlated with DNA expansion size, suggesting that
large expansions may decrease RAN translation levels. Further, poly(GP) in CSF was specific to
C9ALS, helping to solidify its status as a pharmacodynamic biomarker in future clinical trials
(Gendron et al. 2017; Lehmer et al. 2017; Su et al. 2014). However, our investigations into DPR
characteristics were somewhat constrained in this study by technical limitations; because the
antibodies used in our poly(GP) quantification assay were targeted to repetitive epitopes, they
likely have increased sensitivity for large species. Thus, we could not eliminate the possibility
that small species exist as well but are below the sensitivity thresholds of our assay. Further, our
finding that poly(GP) in CSF was not correlated to clinical features of the C9ALS population
indicates that this DPR is likely not a valid biomarker of disease progression, which is consistent
with previously published findings (Gendron et al. 2017; Lehmer et al. 2017; Su et al. 2014).
For DNA expansions, we found positive correlations between repeat size and age in both
C9ALS and unexpanded control individuals, suggesting that these repeats may be unstable and
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grow over time. While this hypothesis is appealing and suggests the possibility of de novo
mutations which could account for the abundance of C9orf72 mutations described in sALS
(DeJesus-Hernandez et al. 2011; Majounie et al. 2012; Renton et al. 2011), our measurements of
DNA repeat size in this study were static and do not directly demonstrate change in repeat size
over time. Further, because DNA samples were collected near the same time as ALS disease
onset, we found that expansion size is also correlated with this measure. Thus, an alternative
explanation of these data is that large expansions could be protective and overrepresented in the
older onset population. Future mechanistic studies examining whether repeat size changes over
time in cell or animal models will be critical for the interpretation of these interesting
pathobiological correlations.
Finally, it should be noted that because this study was focused on C9ALS, it did not test
for possible double mutation carriers. Further, some patients in our survival analysis had not
reached a survival endpoint by study closing, and thus we may be underrepresenting survival
estimates in this patient population. Nonetheless however, the work presented here provides a
template for C9ALS clinical trials and highlights novel pathobiological correlations within this
population, providing new insights and a reliable resource for future translational and
mechanistic studies.

219

Impact, innovation, and final thoughts
In this dissertation, we have detailed here four studies which help to elucidate the
mechanistic underpinnings of epigenetic regulation in the brain. Each Chapter tells a unique
story of gene expression control, either in the healthy brain or in disease states.
Most importantly, what we have provided here is a set of resources that will lead to
innovative new studies in the future. AAV calling cards is a novel method that may unlock
original biology in a number of different contexts moving forward. Meanwhile, our epigenetic
profiling in disease models, beyond implicating these mechanisms as potentially involved in
disease pathogenesis, provide a catalog of specific regulatory processes displaying misregulation
in disease. Finally, our pathological and clinical characterization of the C9ALS population will
facilitate the design and implementation of future clinical trials.
It is my hope that the results presented here will continue to be a valuable resource to the
neuroscience community in the future, as we continue to strive to understand the human brain in
health and disease.
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